<chapter label="CHAPTER 7" id="ch0007">
<title><emphasis role="strong">Diseases of the Blood/Blood-Forming Organs</emphasis></title>
<sect1 id="ch0007s0224"><title><emphasis role="strong">ANEMIAS&mdash;IRON DEFICIENCY, ANEMIA OF CHRONIC DISEASE, PERNICIOUS, APLASTIC, HEMOLYTIC</emphasis></title>
<orderedlist numeration="upperroman" inheritnum="ignore" continuation="restarts">
<listitem><para><emphasis role="strong">Pathophysiology</emphasis>&mdash;decreased number of circulating red blood cells (RBCs), due to blood loss, increased destruction of RBCs (hemolysis), or decreased production of RBCs, resulting in diminished oxygen-carrying capacity of the blood (Maakaron et al, 2016)</para>
<orderedlist numeration="loweralpha" inheritnum="ignore" continuation="restarts">
<listitem><para>Iron deficiency anemia (ID): inadequate iron stores, which results in insufficient hemoglobin (Hgb) (key molecule in RBCs), causing cells to appear abnormal, unusually small (microcytic), and pale (hypochromic)</para></listitem>
<listitem><para>Anemia of chronic disease (ACD): Common conditions associated with ACD may include <emphasis>infections</emphasis> (e.g., human immunodeficiency virus [HIV], tuberculosis [TB], sepsis, osteomyelitis), <emphasis>inflammation</emphasis> (e.g., arthritis, inflammatory bowel disease), and <emphasis>malignancies</emphasis> (e.g., carcinomas, myeloma, lymphoma) (Betcher et al, 2015; Schrier &amp; Camaschella, 2016).</para></listitem>
<listitem><para>Pernicious anemia (PA): Lack of intrinsic factor in the stomach results in inability to absorb vitamin B<subscript>12</subscript>, causing abnormal RBC formation.</para></listitem>
<listitem><para>Aplastic anemia: failure of bone marrow to produce cells, including RBCs and white blood cells (WBCs) and platelets</para></listitem>
<listitem><para>Hemolytic anemia: premature destruction of RBCs</para>
</listitem></orderedlist></listitem>
<listitem><para><emphasis role="strong">Etiology (Maakaron et al, 2016; National Institutes of Health [NIH], 2012)</emphasis></para>
<orderedlist numeration="loweralpha" inheritnum="ignore" continuation="restarts">
<listitem><para>Three main causes of anemia exist. They are:</para>
<orderedlist numeration="lowerroman" inheritnum="ignore" continuation="restarts">
<listitem><para>Blood loss (acute or chronic)</para></listitem>
<listitem><para>Decreased RBC production as may occur with (1) defect in stem cells (e.g., aplastic anemia), defect in heme (see <link linkend="ch0007s0224note0566">Glossary</link>) production (e.g., iron deficiency, thalassemias), and (3) defective DNA production</para></listitem>
<listitem><para>Increased RBC destruction caused by (1) external factors, (2) hereditary internal factors, and (3) acquired defects</para></listitem>
<listitem><para>Within these causes, there are a number of specific etiologies. Some examples of these specifics include (1) genetics (e.g., thalassemias, Fanconi anemia); (2) nutritional (e.g., iron deficiency, vitamin B<subscript>12</subscript> and folate deficiency; starvation and malnutrition); (3) physical (e.g., trauma, burns, frostbite, prosthetic valves); (4) chronic disease and malignancies (e.g., kidney and liver disease, chronic infections, neoplasms); (5) infectious: viral (e.g., hepatitis), bacterial (e.g., gram-negative sepsis, <emphasis>Clostridia</emphasis>), and protozoal (e.g., malaria, toxoplasmosis); (6) drugs or chemicals (common cause of aplastic and hypoplastic disorders) and bone marrow suppression (e.g., antibiotics, anticonvulsants); and (7) active bleeding (e.g., trauma, ulcers, varices, use of mediations such as nonsteroidal anti-inflammatory drugs [NSAIDs] or warfarin).</para>
</listitem></orderedlist></listitem>
<listitem><para>Adult anemia is usually defined as an Hgb level lower than 11 g/dL, with severe anemia defined as an Hgb lower than 8 g/dL. Not all sources agree with these numbers. For example, Maakaron opines that anemia is defined by the lower limits set for the Hgb range and that &ldquo;the World Health Organization (WHO) chose 12.5 g/dL for both adult males and females. In the United States, limits of 13.5 g/dL for men and 12.5 g/dL for women are probably more realistic&rdquo; (Maakaron et al, 2016).</para></listitem>
<listitem><para>Anemia is a common condition, occurring in all age groups, both male and female (although incidence is twice as prevalent in females), and in all races and ethnic groups. Certain races and ethnic groups have an increased prevalence of genetic anemias (e.g., sickle cell anemia has greater morbidity and mortality in African Americans than in general population) (Maakaron et al, 2016).</para></listitem>
<listitem><para>Anemias are associated with many physiological complications, including dyspnea, fatigue, dizziness, decreased cognition, impaired sleep, sexual dysfunction, and significant debilitation. The most serious complications of severe anemia arise from tissue hypoxia such as may occur in shock or coronary and pulmonary insufficiency.</para></listitem>
<listitem><para>ID</para>
<orderedlist numeration="lowerroman" inheritnum="ignore" continuation="restarts">
<listitem><para>Most frequently occurring form of anemia</para></listitem>
<listitem><para>Lack of iron in the body due to a variety of causes (Nabili, 2016)</para>
<orderedlist numeration="arabic" inheritnum="ignore" continuation="restarts">
<listitem><para>Blood loss due to disease, such as gastric or duodenal ulcers, diverticula, hemorrhoids, ulcerative colitis; injury or trauma; or certain medications, including aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)</para></listitem>
<listitem><para>Inadequate nutrition, such as not eating enough foods that contain iron</para></listitem>
<listitem><para>Malabsorption syndromes, such as not utilizing iron from food that is eaten</para></listitem>
<listitem><para>Lead exposure</para>
</listitem></orderedlist></listitem></orderedlist></listitem>
<listitem><para>ACD</para>
<orderedlist numeration="lowerroman" inheritnum="ignore" continuation="restarts">
<listitem><para>Primarily due to slowed production of RBCs as a result of low reticulocyte production</para></listitem>
<listitem><para>Develops slowly and is only evident after time</para></listitem>
<listitem><para>Symptoms are usually associated with the disease causing the anemia rather than the anemia itself. Examples are the anemias associated with chronic kidney disease, chronic malnutrition, or cancers (Nabili, 2016).</para></listitem>
<listitem><para>Second most prevalent form of anemia.</para>
</listitem></orderedlist></listitem>
<listitem><para>PA&mdash;an autoimmune disorder</para>
<orderedlist numeration="lowerroman" inheritnum="ignore" continuation="restarts">
<listitem><para>Characterized by the production of autoantibodies to gastric parietal cells and their secretory product&mdash;intrinsic factor&mdash;which is needed for vitamin B<subscript>12</subscript> absorption</para></listitem>
<listitem><para>Conditions that interfere with the body&rsquo;s absorption and use of B<subscript>12</subscript> include Crohn&rsquo;s and Whipple&rsquo;s diseases, gastrectomy or gastric bypass, and the use of chemotherapeutic medications.</para>
</listitem></orderedlist></listitem>
<listitem><para>Aplastic anemia&mdash;bone marrow failure</para>
<orderedlist numeration="lowerroman" inheritnum="ignore" continuation="restarts">
<listitem><para>May be associated with conditions that affect erythropoietin production and secretion, such as certain cancers and cancer treatments and renal, hepatic, or endocrine disorders</para></listitem>
<listitem><para>Other known causes include exposure to chemicals, such as benzene, insecticides, solvents; certain drugs, such as chemotherapy, gold, seizure medications, some antibiotics; viruses, such as HIV, Epstein-Barr; immune conditions, such as systemic lupus erythematosus, rheumatoid arthritis; radiation; and certain inherited disorders, such as Fanconi&rsquo;s anemia.</para>
</listitem></orderedlist></listitem>
<listitem><para>Hemolytic anemia&mdash;marked by an accelerated destruction of RBCs</para>
<orderedlist numeration="lowerroman" inheritnum="ignore" continuation="restarts">
<listitem><para>Several types of hemolytic anemias, including sickle cell anemia (Maakaron &amp; Taher, 2017; Nabili, 2016). (See CP: <link linkend="ch0007s0229">Sickle Cell Crisis</link>.)</para></listitem>
<listitem><para>Causes include hereditary factors; blood transfusion reactions; immune disorders, acute viral or infectious agents; certain drugs, such as quinidine, penicillin, and methyldopa; and toxins, such as chemicals and venoms.</para>
</listitem></orderedlist></listitem></orderedlist></listitem>
<listitem><para><emphasis role="strong">Statistics</emphasis></para>
<orderedlist numeration="loweralpha" inheritnum="ignore" continuation="restarts">
<listitem><para>Morbidity: The most serious complications of severe anemia arise from tissue hypoxia. Shock, hypotension, or coronary and pulmonary insufficiency can occur. In a study conducted between 2009 and 2011, 152,757 (72%) of hospitalization discharge diagnoses contained the condition &ldquo;anemia,&rdquo; with 17% of those classified as severe. Discharge anemia was associated with severity-dependent increased odds for 30-day hospital readmission compared with those without anemia (Koch et al, 2014).</para></listitem>
<listitem><para>Mortality: 5219 people died of anemia during 2014 in the United States according to the Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. Persons with sickle cell anemia (Hgb SS) have the worst prognosis, since they have more frequent crises. The 2-year fatality rate for severe aplastic anemia is 70% without bone marrow transplantation or a response to immunosuppressive therapy. Untreated hemolytic-uremic syndrome carries a 40% mortality rate (CDC, 2014; Maakaron et al, 2016).</para></listitem>
<listitem><para>Cost: Because anemia rarely stands on its own and is listed as one diagnosis among others in many chronically ill patients with a variety of diseases, direct care costs are difficult to determine.</para>
</listitem></orderedlist></listitem></orderedlist>
<note id="ch0007s0224note0566">
<title><emphasis role="strong">GLOSSARY</emphasis></title>
<para><emphasis role="strong">Acquired anemia:</emphasis> Client is not born with anemia but develops it. Includes conditions and factors that can lead to anemia, such as poor diet, abnormal hormone (erythropoetin) levels, bone marrow suppression due to cancer treatment, certain medications and toxins, and pregnancy. Some anemias are mixed acquired and inherited (e.g., aplastic).</para>
<para><emphasis role="strong">Cheilitis:</emphasis> Inflammation of the lips with cracking at the corners of the mouth.</para>
<para><emphasis role="strong">Ecchymosis:</emphasis> Superficial bleeding (bruising) under the skin or mucous membrane.</para>
<para><emphasis role="strong">Erythropoiesis:</emphasis> Red blood cell (RBC) production in the bone marrow.</para>
<para><emphasis role="strong">Glossitis:</emphasis> Inflammation of tongue.</para>
<para><emphasis role="strong">Hematemesis:</emphasis> Bloody vomitus.</para>
<para><emphasis role="strong">Hematinic:</emphasis> An agent that improves the quality of blood by stimulating RBC production erythrocytes and/or the hemoglobin concentration. Examples include iron preparations and the B complex vitamins.</para>
<para><emphasis role="strong">Heme:</emphasis> The nonprotein, insoluble, iron compound, and constitutes the pigment portion or protein-free part of the hemoglobin molecule and is responsible for its oxygen-carrying properties.</para>
<para><emphasis role="strong">Inherited anemia:</emphasis> Gene for certain anemia is passed on by parents. Anemias of this type include sickle cell, thalassemia, Fanconi, and others. Some anemias are mixed acquired and inherited (e.g., aplastic).</para>
<para><emphasis role="strong">Koilonychia:</emphasis> Dystrophy of the nails, resulting in thinning and concave or spoon shape.</para>
<para><emphasis role="strong">Lymphadenopathy:</emphasis> Enlargement of the lymph nodes.</para>
<para><emphasis role="strong">Macrocytic anemia:</emphasis> The red blood cells are larger than normal. Major causes of this type are pernicious anemia and anemia related to alcoholism (Nabali, 2016).</para>
<para><emphasis role="strong">Melena:</emphasis> Black, tarry stools due to digested blood in the gastrointestinal (GI) tract.</para>
<para><emphasis role="strong">Microcytic anemia:</emphasis> The red blood cells are smaller than normal. The major causes of this type are iron deficiency anemia and thalassemia (inherited disorders of hemoglobin).</para>
<para><emphasis role="strong">Normocytic anemia:</emphasis> The red blood cells are normal in size but low in number. This type of anemia accompanies chronic diseases and kidney disorders.</para>
<para><emphasis role="strong">Petechiae:</emphasis> Small, purplish, hemorrhagic spots on the skin.</para>
<para><emphasis role="strong">Pica:</emphasis> Insatiable craving to eat nonfood items, such as starch, clay, crayons, and paper.</para>
<para><emphasis role="strong">Red blood cell characterization of anemias:</emphasis> Based on the mean corpuscular volume (MCV), or average RBC size, reported in the complete blood count (CBC) test: (1) <emphasis>microcytic:</emphasis> most commonly caused by iron deficiency; other causes include thalassemia, anemia of chronic disease, and sideroblastic anemia; (2) <emphasis>normocytic:</emphasis> may be caused by hemorrhage, hemolysis, bone marrow failure, anemia of chronic inflammation, or renal insufficiency; and (3) <emphasis>macrocytic</emphasis>: the larger red cells are always associated with insufficient <emphasis>numbers</emphasis> of cells and often also insufficient hemoglobin content per cell. Most are megaloblastic (cells are larger because they cannot produce DNA quickly enough to divide at the right time) and include vitamin B<subscript>12</subscript> or folate deficiencies caused by insufficient uptake or inadequate absorption through lack of intrinsic factor (pernicious anemia) (Rogers et al, 2012).</para>
<para><emphasis role="strong">Romberg&rsquo;s sign:</emphasis> Inability to maintain body balance when eyes are shut and feet are close together, sometimes noted with movement disorders accompanying pernicious anemia.</para>
<para><emphasis role="strong">Stomatitis:</emphasis> Inflammation, ulceration of mucosal lining of any structures in the mouth.</para>
</note>
<sect2 id="ch0007s0225"><title><emphasis role="strong">CARE SETTING</emphasis></title>
<para>Clients are treated at the community level except in the presence of severe cardiovascular or immune compromise. Although the medical treatments vary widely due to the many variations in anemia presentation, nursing care for the anemic client has a common theme: managing physical symptoms and maximizing quality-of-life issues.</para>
</sect2>
<sect2 id="ch0007s0226"><title><emphasis role="strong">RELATED CONCERNS</emphasis></title>
<para><link linkend="ch0013s0328">Acquired immunodeficiency syndrome (AIDS)</link></para>
<para><link linkend="ch0012s0308">Burns: thermal, chemical, and electrical&mdash;acute and convalescent phases</link></para>
<para><link linkend="ch0014s0370">Cancer, general considerations</link></para>
<para><link linkend="ch0006s0209">Cirrhosis of the liver</link></para>
<para><link linkend="ch0002s0027">Heart failure: chronic</link></para>
<para><link linkend="ch0014s0338">Psychosocial aspects of care</link></para>
<para><link linkend="ch0003s0099">Pulmonary tuberculosis (TB)</link></para>
<para><link linkend="ch0008s0249">Renal failure: chronic (end-stage renal disease)</link></para>
<para><link linkend="ch0013s0333">Rheumatoid arthritis (RA)</link></para>
<para><link linkend="ch0005s0144">Upper gastrointestinal bleeding</link></para>
<table frame="top" id="ch0007s0224ta0320"><title><emphasis role="strong">CLIENT ASSESSMENT DATABASE</emphasis></title>
<tgroup colsep="0" rowsep="0" cols="2">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">DIAGNOSTIC DIVISION<?lb?>MAY REPORT</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">MAY EXHIBIT</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">ACTIVITY/REST</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Fatigue, weakness, general malaise</para></listitem>
<listitem><para>Low exercise tolerance</para></listitem>
<listitem><para>Greater need for rest and sleep</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>****<emphasis>Note:</emphasis> Signs and symptoms listed here may be due to either the underlying disease or the anemia itself. For example, chronic kidney disease (CKD) and anemia of chronic disease (ACD) may present with very similar symptoms (Verma &amp; Stein, 2017).</para>
<itemizedlist mark="&bull;"><listitem><para>Tachycardia and tachypnea, dyspnea on exertion or at rest (severe or aplastic anemia)</para></listitem>
<listitem><para>Muscle weakness and decreased strength</para></listitem>
<listitem><para>Slumping shoulders, drooping posture, slow walk, and other cues indicative of fatigue</para></listitem>
<listitem><para>Lethargy, withdrawal, apathy, lassitude, and lack of interest in surroundings</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">CIRCULATION</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Angina (particularly in elderly)</para></listitem>
<listitem><para>Palpitations (compensatory tachycardia)</para></listitem>
<listitem><para>Cold hands and feet</para></listitem>
<listitem><para>Brittle nails</para></listitem>
<listitem><para>History of chronic blood loss, such as chronic GI bleeding, heavy menses (ID)</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Tachycardia</para></listitem>
<listitem><para>Systolic murmur (ID)</para></listitem>
<listitem><para>Blood pressure (BP)&mdash;increased systolic with stable diastolic and a widened pulse pressure, postural hypotension</para></listitem>
<listitem><para>Bounding pulse and throbbing carotid pulsations reflect increased cardiac output as a compensatory mechanism to provide oxygen and nutrients to cells.</para></listitem>
<listitem><para>Dysrhythmias, electrocardiogram abnormalities&mdash;ST-segment depression and flattening or depression of the T wave, tachycardia</para></listitem>
<listitem><para>Skin color&mdash;pallor of the skin, palms, and nailbeds, or grayish cast in black client; waxy, pale skin (aplastic, PA) or bright lemon-yellow (PA)</para></listitem>
<listitem><para>Nails brittle, spoon-shaped or koilonychia (ID)</para></listitem>
<listitem><para>Capillary refill delayed due to diminished blood flow to the periphery, resulting in vasoconstriction</para></listitem>
<listitem><para>Sclera blue or pearl white (ID), jaundice (PA), pale mucous membranes&mdash;conjunctiva, mouth, pharynx, lips</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">EGO INTEGRITY</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Negative feelings about self, ability to handle situation, events</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Depression</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">ELIMINATION</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>History of pyelonephritis, renal failure (ACD)</para></listitem>
<listitem><para>Flatulence, malabsorption syndrome (ID)</para></listitem>
<listitem><para>Hematemesis, fresh blood in stool, melena</para></listitem>
<listitem><para>Diarrhea or constipation</para></listitem>
<listitem><para>Diminished urine output</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Abdominal distention</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">FOOD/FLUID</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Nausea, vomiting, dyspepsia, anorexia</para></listitem>
<listitem><para>Low food intake, low intake of animal protein, high intake of cereal products (ID)</para></listitem>
<listitem><para>Mouth or tongue soreness, difficulty swallowing, ulcerations in pharynx (PA)</para></listitem>
<listitem><para>Pica (e.g., eating ice, dirt, paint, laundry starch, other substances with no nutritional value) (ID)</para></listitem>
<listitem><para>Self-imposed or prescribed dietary restrictions or idiosyncrasies; financial constraints (ID)</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Skin turgor poor with dry, shriveled appearance and loss of elasticity (ID)</para></listitem>
<listitem><para>Beefy red, smooth appearance of tongue (PA, folic acid and vitamin B<subscript>12</subscript> deficiencies)</para></listitem>
<listitem><para>Beefy red, smooth appearance of tongue (PA, folic acid and vitamin B<subscript>12</subscript> deficiencies)</para></listitem>
<listitem><para>Hair dry, brittle, thinning; premature graying (PA)</para></listitem>
<listitem><para>Cheilitis (ID)</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">HYGIENE</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Difficulty maintaining activities of daily living (ADLs)</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Unkempt appearance, poor personal hygiene</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">NEUROSENSORY</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Inability to concentrate</para></listitem>
<listitem><para>Insomnia</para></listitem>
<listitem><para>Fainting, dizziness, vertigo, tinnitus</para></listitem>
<listitem><para>Weakness, poor balance, wobbly legs, paresthesias of hands or feet (PA)</para></listitem>
<listitem><para>Sensation of being cold</para></listitem>
<listitem><para>Diminished vision and spots before eyes</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Mentation&mdash;notable slowing and dullness in response</para></listitem>
<listitem><para>Irritability, restlessness, depression, drowsiness, apathy</para></listitem>
<listitem><para>Disturbed coordination, ataxia, decreased vibratory and position sense, positive Romberg&rsquo;s sign, paralysis (PA)</para></listitem>
<listitem><para>Retinal hemorrhages (aplastic, PA)</para></listitem>
<listitem><para>Epistaxis, bleeding from other orifices (aplastic)</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">PAIN/DISCOMFORT</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Vague abdominal pains, headache (ID)</para></listitem>
<listitem><para>Oral pain</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">RESPIRATION</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Shortness of breath at rest and with activity</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Tachypnea</para></listitem>
<listitem><para>Dyspnea, particularly during and after exercise</para></listitem>
<listitem><para>Orthopnea</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">SAFETY</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Poor wound healing, frequent infections</para></listitem>
<listitem><para>Impaired vision</para></listitem>
<listitem><para>Cold and heat intolerance</para></listitem>
<listitem><para>Skin problems, including cracks in side of mouth (PA)</para></listitem>
<listitem><para>Previous or multiple blood transfusions</para></listitem>
<listitem><para>History of occupational exposure to chemicals&mdash;benzene, lead, insecticides, phenylbutazone, naphthalene (aplastic, hemolytic)</para></listitem>
<listitem><para>History of exposure to radiation, either as a treatment modality or by accident (aplastic, hemolytic)</para></listitem>
<listitem><para>History of cancer, cancer therapies (aplastic, hemolytic)</para></listitem>
</itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Low-grade fever</para></listitem>
<listitem><para>Generalized lymphadenopathy</para></listitem>
<listitem><para>Petechiae and ecchymosis (aplastic)</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">SEXUALITY</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Changes in menstrual flow&mdash;menorrhagia or amenorrhea in women (ID)</para></listitem>
<listitem><para>Loss of libido&mdash;both men and women</para></listitem>
<listitem><para>Impotence</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Pale cervix and vaginal walls</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">TEACHING/LEARNING</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Family tendency for anemia (ID, PA)</para></listitem>
<listitem><para>Past or present use of anticonvulsants, antibiotics, chemotherapeutic agents (bone marrow failure), aspirin, anti-inflammatory drugs, or anticoagulants</para></listitem>
<listitem><para>Chronic use of alcohol</para></listitem>
<listitem><para>Religious or cultural beliefs affecting treatment choices&mdash;refusal of blood transfusions</para></listitem>
<listitem><para>Recent or current episode of active bleeding (ID)</para></listitem>
<listitem><para>Prior surgeries&mdash;splenectomy, tumor excision, prosthetic valve replacement, surgical excision of duodenum or gastric resection, partial or total gastrectomy for weight loss or diseases (ID, PA)</para></listitem>
<listitem><para>Problems with wound healing or bleeding, chronic infections</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">DISCHARGE PLAN CONSIDERATIONS</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>May require assistance with treatment, such as injections, self-care activities, homemaker and maintenance tasks; changes in dietary plan</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para><inlinemediaobject><imageobject><imagedata fileref="pa.jpg"/></imageobject></inlinemediaobject> Refer to section at end of plan for postdischarge considerations.</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
</entry></row>
</tbody></tgroup></table>
<table frame="top" id="ch0007s0224ta0321"><title><emphasis role="strong">DIAGNOSTIC STUDIES</emphasis></title>
<tgroup colsep="0" rowsep="0" cols="3">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<colspec colnum="3" colname="3" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom" spanname="1-2">
<para><emphasis role="strong">TEST<?lb?>WHY IT IS DONE</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">WHAT IT TELLS ME</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">BLOOD TESTS</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Complete blood count (CBC):</emphasis> Battery of screening tests, which typically includes hemoglobin, hematocrit; RBC count, morphology, indices, and distribution width index; platelet count and size; and WBC count and differential.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Evaluates for known or suspected anemia. Types of anemias may be differentiated by the number of red blood cells as well as their color and shape. <emphasis>Note:</emphasis> Methods for measuring RBC mass are time-consuming and expensive. Thus, in practice, anemia is usually confirmed and expressed by measurement of the RBC count, Hgb concentration, and hematocrit (Hct) (Maakaron et al, 2016).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Hemoglobin (Hgb):</emphasis> The oxygen-carrying pigment and predominant protein in the RBCs.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Usual Hgb varies somewhat among healthy individuals, making a universal &ldquo;normal&rdquo; value elusive. For client with a known baseline level, a decrease of 2 g/dL or more is cause for concern and assessment. Both Hgb and Hct are decreased with blood loss and bone marrow suppression (Rogers et al, 2012).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Hematocrit (Hct):</emphasis> The proportion of packed RBCs to serum.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Aids in determining source of hemolytic anemia or anemias related to deficiencies in dietary intake or malabsorption. Sometimes used when a person has a family history of anemia; this test provides information on sickle cell anemia or thalassemia (Nabili, 2016).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">RBC (also called erythrocyte) count:</emphasis> Number of RBCs per unit volume.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Decreased in ID and PA; severely decreased in aplastic anemia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Reticulocyte count:</emphasis> Immature RBCs. Helps assess bone marrow function.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Decreased in PA and aplastic anemia. Elevated in blood loss and hemolytic and compensated anemias.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">RBC survival time:</emphasis> Evaluates age of RBCs.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Useful in the differential diagnosis of anemias because RBCs have shortened life spans in pernicious and hemolytic anemias.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Erythrocyte fragility test:</emphasis> Evaluates susceptibility of RBCs to breakdown (hemolysis) under certain conditions.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Decreased in ID. Increased fragility confirms hemolytic and autoimmune anemias.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Erythrocyte sedimentation rate (ESR):</emphasis> Measures rate at which RBCs settle.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>While not specific to a certain anemia, higher ESR indicates presence of inflammatory reaction, such as increased RBC destruction or malignant disease.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">WBCs:</emphasis> Total cell count and specific WBCs, called differential.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May be increased as in hemolytic anemia or decreased in aplastic anemia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Platelet count:</emphasis> Platelets have essential function in coagulation.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Decreased in blood loss and aplastic anemias. Increased in ID, posthemorrhagic, and hemolytic anemias.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Erythropoietin:</emphasis> Hormone that stimulates bone marrow to produce red blood cells.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Determines whether the amount of erythropoietin being produced is appropriate for the level of anemia present. It may be ordered to distinguish between a condition that is suppressing bone marrow function and an insufficiency of erythropoietin.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Serum iron panel</emphasis></para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Serum iron:</emphasis> Measures the level of iron in the liquid part of blood.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Iron is needed to help form adequate numbers of normal RBCs. Iron may be decreased or absent (ID) or elevated (hemolytic and aplastic anemias).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Total iron-binding capacity (TIBC):</emphasis> Measures the amount of iron that can be carried through blood by transferrin.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Increased in ID; normal or slightly reduced in PA.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Serum ferritin:</emphasis> Reflects the amount of stored iron in body.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Decreased in ID.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Vitamin B<subscript>12</subscript> (cobalamin) and folate (folic acid):</emphasis> Measures the concentration of vitamin B<subscript>12</subscript> and folate in the serum. The amount of folate inside RBCs may also be measured; it will normally be at a higher concentration inside the cell than in the serum.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Anemia caused by folic acid deficiency is common. Helps diagnose the cause of anemia or neuropathy (nerve damage) or to evaluate nutritional status in some clients.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Serum bilirubin:</emphasis> Product that results from the breakdown of Hgb.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Direct or total bilirubin is elevated in PA and hemolytic anemia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Serum lactate dehydrogenase (LDH):</emphasis> Serum LDH levels may occasionally be ordered to monitor damage caused by muscle trauma or injury and to help identify hemolytic anemia.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May be elevated in PA and hemolytic anemia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">OTHER ASSOCIATED STUDIES</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Schilling&rsquo;s test:</emphasis> Evaluates vitamin B<subscript>12</subscript> excretion by measuring urinary excretion.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>The Schilling&rsquo;s test and a therapeutic trial of vitamin B<subscript>12</subscript> injections help distinguish folic acid deficiency anemia from pernicious anemia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Guaiac:</emphasis> Tests for hidden or occult blood.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May be positive in urine, stools, and gastric contents, reflecting acute or chronic bleeding (ID).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Bone marrow aspiration/biopsy examination:</emphasis> May be done by needle aspirate or biopsy to identify changes in number, size, and shape of blood cells, helping to differentiate type of anemia.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Megaloblasts increased in PA; fatty marrow, with diminished or absence of blood cells at several sites, found in aplastic anemia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Upper endoscopy&mdash;also called esophagogastroduodenoscopy (EGD):</emphasis> Visualizes esophagus, stomach, and duodenum, using a thin flexible tube that can be looked through or seen on a TV monitor.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Checks for bleeding sites&mdash;acute or chronic upper GI bleeding&mdash;causing blood loss anemia.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Lower endoscopy&mdash;also called colonoscopy:</emphasis> Visualizes rectum and colon using a thin, flexible tube that can be looked through or seen on a TV monitor.</para></listitem></itemizedlist>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Checks for bleeding sites&mdash;acute or chronic lower GI bleeding&mdash;causing blood loss anemia.</para>
</entry></row></tbody></tgroup></table>
</sect2>
<sect2 id="ch0007s0227"><title><emphasis role="strong">NURSING PRIORITIES</emphasis></title>
<orderedlist numeration="arabic" inheritnum="ignore" continuation="restarts">
<listitem><para>Enhance tissue perfusion.</para></listitem>
<listitem><para>Provide nutritional and fluid needs.</para></listitem>
<listitem><para>Prevent complications.</para></listitem>
<listitem><para>Provide information about disease process, prognosis, and treatment regimen.</para></listitem></orderedlist>
</sect2>
<sect2 id="ch0007s0228"><title><emphasis role="strong">DISCHARGE GOALS</emphasis></title>
<orderedlist numeration="arabic" inheritnum="ignore" continuation="restarts">
<listitem><para>ADLs met by self or with assistance of others.</para></listitem>
<listitem><para>Complications prevented or minimized.</para></listitem>
<listitem><para>Disease process, prognosis, and therapeutic regimen understood.</para></listitem>
<listitem><para>Plan in place to meet needs after discharge.</para></listitem></orderedlist>
<note id="ch0007s0224note0567">
<title><emphasis role="strong">NURSING DIAGNOSIS: Activity Intolerance</emphasis></title>
<para><emphasis role="strong">May Be Related To</emphasis></para>
<para>Imbalance between oxygen supply and demand (anemia)</para>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Fatigue; generalized weakness</para>
<para>Abnormal heart rate or blood pressure response to activity</para>
<para>Electrocardiogram (ECG) change (e.g., arrhythmia, ischemia)</para>
<para>Exertional discomfort; dyspnea</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Endurance</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Report a measurable increase in activity tolerance, including performance of ADLs.</para>
<para>Demonstrate reduced physiological signs of intolerance&mdash;pulse, respirations, and BP within client&rsquo;s normal range.</para>
<para>Display laboratory values (Hgb/Hct) within acceptable range.</para>
</note>
<note role="none" id="ch0007s0224note0568"><table frame="top" id="ch0007s0224ta0322"><title/>
<tgroup colsep="0" rowsep="0" cols="3">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<colspec colnum="3" colname="3" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom" spanname="1-2">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Energy Management</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Assess client&rsquo;s ability to perform normal tasks and ADLs, noting reports of weakness, fatigue, and difficulty accomplishing tasks.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Influences choice of interventions and needed assistance.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Note changes in balance, gait disturbance, and muscle weakness.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May indicate neurological changes associated with vitamin B<subscript>12</subscript> deficiency, affecting client safety and increasing risk of injury.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor BP, pulse, and respirations during and after activity. Note adverse responses to increased levels of activity&mdash;increased heart rate and BP, dysrhythmias, dizziness, dyspnea, tachypnea, and cyanosis of mucous membranes and nailbeds.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Cardiopulmonary manifestations result from attempts by the heart and lungs to supply adequate amounts of oxygen to the tissues.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Recommend frequent rest periods or bedrest (rare), as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Activity may need to be curtailed until severe anemia is at least partially corrected to lower body&rsquo;s oxygen requirements and reduce strain on the heart and lungs.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Elevate head of bed, as tolerated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Enhances lung expansion to maximize oxygenation for cellular uptake. <emphasis>Note:</emphasis> May be contraindicated if hypotension is present.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Suggest client change position slowly; monitor for dizziness.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Postural hypotension or cerebral hypoxia may cause dizziness, fainting, and increased risk of injury.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Assist client to prioritize ADLs and desired activities. Alternate rest periods with activity periods.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Promotes adequate rest, maintains energy level, and alleviates strain on the cardiac and respiratory systems.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Provide or recommend assistance with activities and ambulation as necessary, allowing client to be an active participant as much as possible.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Although help may be necessary, self-esteem is enhanced when client does some things for self.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Plan activity progression with client, including activities that client views as essential. Increase activity levels, as tolerated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Promotes gradual return to a more normal activity level and improved muscle tone and stamina. Increases self-esteem and sense of control.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Identify and implement energy-saving techniques: shower chair and sitting to perform tasks.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Encourages client to do as much as possible, while conserving limited energy and preventing fatigue.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Instruct client to stop current activity if palpitations, chest pain, shortness of breath, weakness, or dizziness occur.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Cellular ischemia potentiates risk of infarction, and excessive cardiopulmonary strain and stress may lead to decompensation and failure.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Discuss importance of maintaining environmental temperature and body warmth, as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Vasoconstriction with shunting of blood to vital organs decreases peripheral circulation, impairing tissue perfusion. Client&rsquo;s comfort and need for warmth must be balanced with need to avoid excessive heat with resultant vasodilation, which reduces organ perfusion.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Collaborative</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor laboratory studies, such as Hgb/Hct, RBC count, and arterial blood gases (ABGs).</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Identifies deficiencies in RBC components affecting oxygen transport, treatment needs, and response to therapy.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Provide supplemental oxygen as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Maximizing oxygen transport to tissues improves ability to function.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Collaborate in treatment of underlying condition(s):</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer the following, as indicated:</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Whole blood, packed RBCs (PRCs); blood products (fresh-frozen plasma [FFP], platelets, blood factors) as indicated for the client&rsquo;s particular needs. Monitor closely for reactions during blood transfusion.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Increases number of oxygen-carrying cells; corrects deficiencies to reduce risk of hemorrhage in acutely compromised individuals. Transfusions are reserved for severe blood loss anemias with cardiovascular compromise and are used after other therapies have failed to restore homeostasis. <emphasis>Note:</emphasis> Packed red blood cells (PRBCs) are preferred over whole blood since they reduce complications associated with volume overload, immunogenic reactions, and storage. The American Association of Blood Banks (AABB) and The Joint Commission (TJC) have recommended restrictive transfusion practices (hemoglobin 7&ndash;8 g/dL) in stable hospitalized patients considering symptoms and not just Hgb levels in transfusion decisions. Additional AABB recommendations include avoiding blood products in hemodynamically stable patients with ID, using blood products to reverse warfarin only if a patient has serious bleeding or requires emergency procedures, and avoiding serial blood counts in stable patients (AABB, 2014; The Joint Commission, 2011).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Erythropoiesis-stimulating agents (ESAs), such as epoetin-Alpha (Procrit, Epogen [EPO]; darbepoetin [Aranesp]); peginesatide (Omontys), methoxy polyethylene glycol-epoetin beta (Micera)</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>ESAs have been shown to be effective in increasing erythrocyte and Hgb levels and reducing need for RBC transfusions in many clients with anemia of chronic disease, including kidney failure in patients on dialysis. <emphasis>Note:</emphasis> Concerns have been raised about side effects of ESAs and other health risks (e.g., thromboembolic phenomena, tumor progress in cancer, and increased mortality), and research continues (<ulink url="http://www.Drugs.com">Drugs.com</ulink>, 2015, 2017; Schrier et al, 2017).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Iron preparations, such as <emphasis role="strong">IV</emphasis> iron dextran complex (INFeD), ferinject (Injectafer), or <emphasis role="strong">oral</emphasis> iron (e.g., ferrous sulfate [Fer-Iron, Slow-FE] or carbonyl iron [Fesol, Iron Chews]), as indicated</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>The appropriate treatment of anemia due to blood loss is correction of the underlying condition and oral administration of iron preparations until the anemia is corrected and for several months afterward to ensure that body stores are replete with iron (Maakaron et al, 2016). <emphasis>Note:</emphasis> Certain populations are at sufficiently high risk for iron deficiency to warrant prophylactic iron therapy. These include anemia in pregnant women, women with menorrhagia, and consumers of a strict vegetarian diet (Fern&aacute;ndez-Gaxiola &amp; De-Regil, 2011).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Vitamins such as cyanocobalamin (also called vitamin B<subscript>12</subscript> [Ener-B, Calo-Mist]), folic acid (Folvite), and vitamin K</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Vitamins help to correct deficiencies and promote protein synthesis.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Prepare for surgical/other procedures, if indicated.</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Surgery is useful to control bleeding in clients who are anemic because of bleeding, such as in ulcers and uterine bleeding, or to remove spleen as treatment of autoimmune hemolytic anemia. Bone marrow and stem cell transplantation may be done in the presence of bone marrow failure&mdash;aplastic anemia.</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0224note0569">
<title><emphasis role="strong">NURSING DIAGNOSIS: imbalanced Nutrition: less than body requirements</emphasis></title>
<para><emphasis role="strong">May Be Related To</emphasis></para>
<para>Failure to ingest or inability to digest food or absorb nutrients</para>
<para>Biological factors</para>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Food intake less than recommended daily allowances</para>
<para>Weight loss or weight below ideal range; insufficient muscle tone</para>
<para>Abnormal laboratory studies</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Nutritional Status</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Demonstrate normalization of laboratory values.</para>
<para>Be free of/experience improvement in signs of malnutrition.</para>
<para>Verbalize understanding of causative factors when known and needed interventions to prevent complications.</para>
</note>
<note role="none" id="ch0007s0224note0570"><table frame="top" id="ch0007s0224ta0323"><title/>
<tgroup colsep="0" rowsep="0" cols="3">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<colspec colnum="3" colname="3" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom" spanname="1-2">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Nutrition Therapy</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Review nutritional history, including food preferences.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Identifies deficiencies and suggests possible interventions. <emphasis>Note:</emphasis> Daily meal diary over period of time may be necessary to identify anemia related to nutrient deficiencies such as no meat in diet&mdash;iron and vitamin B<subscript>12</subscript> deficiency, or few leafy vegetables in diet&mdash;folic acid deficiency.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Observe and record client&rsquo;s food intake.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Monitors caloric intake or insufficient quality of food consumption.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Weigh periodically as appropriate, such as weekly.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Monitors weight loss and effectiveness of nutritional interventions.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Recommend small, frequent meals and between-meal nourishment.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May enhance intake while preventing gastric distention. Use of liquid supplements such as Ensure, Boost, or similar product provides additional protein and calories.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Suggest bland diet, low in roughage, avoiding hot, spicy, or very acidic foods, as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>When oral lesions are present, pain may restrict type of foods client can tolerate.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Have client record and report occurrence of nausea or vomiting, flatus, and other related symptoms, such as irritability or impaired memory.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May reflect the effects of anemias (e.g., hypoxia or vitamin B<subscript>12</subscript> deficiency) on body organs and systems.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Encourage or assist with oral hygiene; use soft-bristled toothbrush for gentle brushing. Provide dilute, alcohol-free mouthwash if oral mucosa is ulcerated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Diminishes bacterial growth, minimizing possibility of infection. Special mouth-care techniques may be needed if tissue is fragile, ulcerated, or bleeding and pain is severe.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Collaborative</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Consult with nutritionist/dietitian.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Aids in establishing dietary plan to meet individual needs.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor laboratory studies, such as Hgb/Hct, blood urea nitrogen (BUN), prealbumin and albumin, protein, transferrin, serum iron, vitamin B<subscript>12</subscript>, folic acid, TIBC, and serum electrolytes.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Evaluates effectiveness of treatment regimen, including dietary sources of needed nutrients.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer medications, as indicated, for example:</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Vitamin and mineral supplements, such as cyanocobala-min (vitamin B<subscript>12</subscript>), folic acid (Folvite), and ascorbic acid (vitamin C)</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Replacements needed depend on type of anemia and presence of poor oral intake and identified deficiencies.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Iron preparations, such as <emphasis role="strong">oral</emphasis> iron (e.g., ferrous sulfate [Fer-Iron, Slow-FE] or carbonyl iron [Fesol, Iron Chews]) or <emphasis role="strong">IV</emphasis> injections such as iron dextran complex (INFeD), ferinject (Injectafer), as indicated</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>May be useful in some types of iron deficiency anemias. Oral preparations are taken between meals to enhance absorption and usually correct anemia and replace iron stores over a period of several months. Parenteral iron preparations are used in patients who are unable to absorb oral iron or who have increasing anemia despite adequate doses of oral iron (Harper &amp; Conrad, 2016; Maakaron et al, 2016).</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0224note0571">
<title><emphasis role="strong">NURSING DIAGNOSIS: risk for Infection</emphasis></title>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Malnutrition; alteration in skin integrity; stasis of body fluids; invasive procedures</para>
<para>Chronic disease; decrease in hemoglobin, leukopenia, decrease in granulocytes; suppressed inflammatory response</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client/Caregiver Will</emphasis></para>
<para><emphasis role="strong">Risk Control</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Identify behaviors to prevent and reduce risk of infection.</para>
<para><emphasis role="strong">Infection Severity</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Be free of signs of infection; achieve timely wound healing if present.</para>
</note>
<note role="none" id="ch0007s0224note0572"><table frame="top" id="ch0007s0224ta0324"><title/>
<tgroup colsep="0" rowsep="0" cols="2">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">Infection Protection</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Perform and promote meticulous handwashing by caregivers and client.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Prevents cross-contamination or bacterial colonization. <emphasis>Note:</emphasis> Client with severe or aplastic anemia may be at risk from normal skin flora.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Maintain strict aseptic techniques with procedures and wound care.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Reduces risk of bacterial colonization and infection.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Provide meticulous skin, oral, and perianal care.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Reduces risk of skin or tissue breakdown and infection.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Encourage frequent position changes and ambulation, coughing, and deep-breathing exercises.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Promotes ventilation of all lung segments and aids in mobilizing secretions to prevent pneumonia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Promote adequate fluid intake.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Assists in liquefying respiratory secretions to facilitate expectoration and prevent stasis of body fluids in lungs and bladder.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Emphasize need to monitor and limit visitors, as indicated. Provide protective isolation, if appropriate. Restrict live plants and cut flowers.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Limits exposure to infectious agents. Protective isolation may be required in aplastic anemia, when immune response is most compromised.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Monitor temperature. Note presence of chills and tachycardia with or without fever.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Reflective of inflammatory process or infection, requiring evaluation and treatment. <emphasis>Note:</emphasis> With bone marrow suppression, leukocytic failure may lead to fulminating infections.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Observe for wound erythema and drainage.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Indicators of local infection. <emphasis>Note:</emphasis> Pus formation may be absent if granulocytes are depressed.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="bi">Collaborative</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Obtain specimens for culture and sensitivity, as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Verifies presence of infection, identifies specific pathogen, and influences choice of treatment.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Administer topical antiseptics and systemic antibiotics.</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>May be used prophylactically to reduce colonization or used to treat specific infectious process.</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0224note0573">
<title><emphasis role="strong">NURSING DIAGNOSIS: deficient Knowledge regarding condition, prognosis, treatment, self-care, prevention of crisis, and discharge needs</emphasis></title>
<para><emphasis role="strong">May Be Related To</emphasis></para>
<para>Insufficient information or knowledge of resources; misinformation presented by others</para>
<para>Alteration in cognitive functioning or memory</para>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Insufficient knowledge</para>
<para>Inaccurate follow-through of instructions</para>
<para>Development of preventable complications</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Self-Management: Chronic Anemia</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Verbalize understanding of the nature of the disease process, causative factors, diagnostic procedures, and potential complications.</para>
<para>Verbalize understanding of therapeutic needs.</para>
<para>Initiate necessary behaviors or lifestyle changes and participate in treatment regimen.</para>
</note>
<note role="none" id="ch0007s0224note0574"><table frame="top" id="ch0007s0224ta0325"><title/>
<tgroup colsep="0" rowsep="0" cols="3">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<colspec colnum="3" colname="3" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom" spanname="1-2">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Teaching: Disease Process</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Provide information about specific anemia and explain that therapy depends on the type and severity of the anemia.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Provides knowledge base from which client can make informed choices. Allays anxiety and may promote cooperation with therapeutic regimen to manage a condition that may be long-lasting.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Discuss effects of anemias on preexisting conditions.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Anemia aggravates many underlying conditions, and resolution of anemia is impacted by aging and developmental issues, nutritional and socioeconomic issues, and acute and chronic conditions.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Review purpose and preparations for diagnostic studies.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Knowledge of what to expect can diminish anxiety.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Explain that blood taken for laboratory studies typically does not worsen anemia.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>This is often an unspoken concern that can potentiate client&rsquo;s anxiety. <emphasis>Note:</emphasis> For the vast majority of hospitalized clients, the blood loss associated with diagnostic testing is of little or no clinical significance. However, studies have confirmed that anemia is a common feature of critical illness, developing in 90% of clients by the third day following admission to intensive care. For around a half of these individuals, anemia is of sufficient severity (&lt;9 g/dL) to warrant red cell transfusion (Corwin et al, 2004; Tinmouth et al, 2008).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Review required diet alterations to meet specific dietary needs, as determined by type of anemia and deficiency.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Red meat, liver, seafood, green leafy vegetables, whole wheat bread, and dried fruits are sources of iron. Green vegetables, whole grains, liver, and citrus fruits are sources of folic acid and vitamin C, which enhance absorption of iron.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Discuss foods to avoid, such as coffee, tea, egg yolks, milk, fiber, and soy protein, at the time when client is eating high-iron foods.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>These foods block absorption of iron and should be taken at a different meal. For example, red meat and milk taken at the same time can block absorption of the iron from the meat.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Assess resources, including financial, and ability to obtain, store, and prepare food.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Inadequate resources may affect ability to purchase and prepare appropriate food items.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Refer to appropriate community resources when indicated, such as social services for food stamps and Meals on Wheels.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May need assistance with groceries and meal preparation.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Encourage cessation of smoking.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Smoking decreases available oxygen and causes vasoconstriction.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Suggest use of protective devices, such as sheepskin, egg-crate, alternating air pressure, or water mattress; heel and elbow protectors; and pillows, as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Avoids skin breakdown by preventing or reducing pressure against skin surfaces.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Review good oral hygiene and necessity for regular dental care.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Effects of anemia such as oral lesions and use of iron supplements increase risk of infection and bacteremia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Emphasize importance of reporting signs of fatigue, weakness, paresthesias, irritability, and impaired memory.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Indicates that anemia is progressing or failing to resolve, necessitating further evaluation and treatment changes.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Teaching: Prescribed Medication</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Collaborative</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Provide information about purpose, dosage, schedule, precautions, and potential side effects, interactions, and adverse reactions to all prescribed medications.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Information enhances cooperation with regimen. Recovery from anemias can be slow, requiring lengthy treatment and prevention of secondary complications.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>For the client on iron preparations:</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Discuss importance of taking only prescribed dosages.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Overdose of iron medication can be toxic.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Advise taking with meals or immediately after meals.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Iron is best absorbed on an empty stomach. However, iron salts are gastric irritants and can cause dyspepsia, diarrhea, and abdominal discomfort if taken on an empty stomach.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Discuss possibility of iron infusions and refer to healthcare provider.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Depleted iron stores may be best treated in this manner, if client is not responding or is intolerant of oral or injected iron preparations.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Instruct to avoid use of aspirin and other NSAIDs.</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Increases bleeding tendencies.</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0224note0575">
<para><emphasis role="strong">POTENTIAL CONSIDERATIONS</emphasis> following acute hospitalization (dependent on client&rsquo;s age, physical condition and presence of complications, personal resources, and life responsibilities)</para>
<itemizedlist mark="&bull;">
<listitem><para><emphasis role="bi">Activity Intolerance</emphasis>&mdash;imbalance between oxygen supply and demand</para></listitem>
<listitem><para><emphasis role="bi">imbalanced Nutrition: less than body</emphasis>&nbsp;<emphasis role="bi">requirements</emphasis>&mdash;failure to ingest or inability to digest food or absorb nutrients</para></listitem>
<listitem><para><emphasis role="bi">risk for</emphasis>&nbsp;<emphasis role="bi">Infection</emphasis>&mdash;inadequate secondary defenses (e.g., decreased hemoglobin, leukopenia, or decreased granulocytes, suppressed inflammatory response); inadequate primary defenses (e.g., broken skin, stasis of body fluids; invasive procedures); chronic disease; malnutrition</para></listitem>
<listitem><para><emphasis role="bi">ineffective Health Management</emphasis>&mdash;economic difficulties, perceived benefits/susceptibility, insufficient social support</para></listitem></itemizedlist>
</note>
</sect2></sect1>
<sect1 id="ch0007s0229"><title><emphasis role="strong">SICKLE CELL CRISIS</emphasis></title>
<orderedlist numeration="upperroman" inheritnum="ignore" continuation="restarts">
<listitem><para><emphasis role="strong">Pathophysiology</emphasis></para>
<orderedlist numeration="loweralpha" inheritnum="ignore" continuation="restarts">
<listitem><para>Sickle cell disease (SDC) is a severe hereditary form of anemia in which a mutated form of hemoglobin (called hemoglobin S or sickle hemoglobin) causes the red blood cells to change shape (sickle). The sickled cells can clump together inside cells and blood vessels, obstructing blood flow and causing tissue ischemia, which can progressively damage and destroy vital organs (Maakaron &amp; Taher, 2017; NIH, 2017).</para></listitem>
<listitem><para>After recurrent episodes of sickling, membrane damage occurs and the cells are no longer capable of resuming their normal shape upon reoxygenation. The resulting anemia (termed <emphasis>sickle cell anemia</emphasis>) is chronic and hemolytic in nature.</para></listitem>
<listitem><para><emphasis>Sickle cell crisis</emphasis> is a broad term that describes several different conditions, such as (1) aplastic crisis (temporary bone marrow failure), (2) hemolytic crisis (acute red cell destruction, leading to jaundice), and (3) vaso-occlusive crisis (VOC) (sudden, severe pain due to infarctions in the bones, organs, or nervous system). Conditions that can trigger a VOC include infection, pregnancy, alcohol or tobacco use, exposure to temperature extremes, dehydration, exposure to high altitude, and extreme physical or psychological stress, although a cause is not always identified. <inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> VOC episodes can occur from the first year of life onward (Vacca &amp; Blank, 2017).</para>
</listitem></orderedlist></listitem>
<listitem><para><emphasis role="strong">Etiology</emphasis></para>
<orderedlist numeration="loweralpha" inheritnum="ignore" continuation="restarts">
<listitem><para>Sickle hemoglobinopathies compose a group of genetic diseases, consisting of four genotypes: sickle cell anemia (HbSS), sickle hemoglobin C disease (HbSC), and the sickle cell thalassemias (S&beta;<superscript>+</superscript>- and S&beta;&deg;-thalassemia) (Ellison, 2012). The different forms of sickle cell disease are determined by the combination of genes inherited from the person&rsquo;s parents.</para></listitem>
<listitem><para>Vaso-occlusion can be caused by infections, dehydration, stress, exercise, temperature extremes, and smoking, associated with hypoxia and acidosis, inflammation, ischemia, and tissue infarction, and is responsible for a wide variety of the clinical complications of SCD (Vacca &amp; Blank, 2017).</para>
</listitem></orderedlist></listitem>
<listitem><para><emphasis role="strong">Complications</emphasis></para>
<itemizedlist mark="none">
<listitem><para/>
<orderedlist numeration="lowerroman" inheritnum="ignore" continuation="restarts">
<listitem><para>Painful episodes are the most common complication of SCD, often in extremities, ribs, sternum, vertebral column, or abdomen (Ohene-Frempong &amp; Gupta, 2015).</para></listitem>
<listitem><para>Central nervous system: The most severe manifestation is stroke. Cerebrovascular accidents (24% of people with sickle cell disease [SCD] have a stroke by the age of 45 years) (Verduzco &amp; Nathan, 2009). Ischemic strokes are more common in children and older adults and are less common in adults ages 20 to 29 (Yawn et al, 2014).</para></listitem>
<listitem><para>Lymphatic system: Splenic sequestration happens when a lot of sickled RBCs become trapped in the spleen. In most older children and adults with HgSS disease, the repetitive RBC sickling in the spleen eventually results in scarring, fibrosis, and a nonfunctional spleen (called autosplenectomy). Acute splenic sequestration (ASS) is a sudden life-threatening pooling of large amounts of blood in the spleen, leading to acute splenomegaly, profound anemia, and, in severe cases, hypovolemic shock. Death may occur in a few hours.</para></listitem>
<listitem><para>Cardiopulmonary system: There are several manifestations, including increased airway reactivity, nocturnal oxygen desaturation, increased risk of pneumonias, pulmonary embolism (PE), acute chest syndrome (ACS), sickle cell chronic lung disease (SCCLD), and pulmonary hypertension. Acute chest syndrome is a sudden-onset pulmonary condition that affects about 12% of adults but is more common in children (about 25%) (Meier &amp; Miller, 2012). <inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> In children below 9 years of age, infection is a more common etiology for ACS than in older children or adults (Heeney &amp; Mahoney, 2015). ACS is defined in severity categories (mild to very severe), and the severity categories apply equally to adults and children (Field &amp; DeBaun, 2017). Pulmonary hypertension is emerging as a relatively common complication and is one of the leading causes of morbidity and mortality in adults with SCD. Various studies have found that more than 40% of adults with SCD have pulmonary hypertension that worsens with age (Dahoui et al, 2010; Maakaron &amp; Taher, 2017).</para></listitem>
<listitem><para>Sexual and reproductive manifestations: Infertility in men with SCD appears to have multiple causes, including hypogonadism, sperm abnormalities, and erectile dysfunction (ED) due to priapism. In females, infertility may be a problem (studies not conclusive); however, onset of menses is often delayed, and menstrual bleeding is associated with increased SCD-related pain (Smith-Whitley, 2014). Mother/baby: There is a high risk of fetal loss due to spontaneous abortion. Placenta previa and abruption are common due to hypoxia and placental infarction. <inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> At birth, the infant often is premature or has low birth weight (Maakaron &amp; Taher, 2017).</para></listitem>
<listitem><para>Gastrointestinal and hepatic systems: <inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> Cholelithiasis is common, especially in children. The spleen is almost always involved in SCD and (<inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> often infarcted within the first 18 to 36 months of life, paralleling the disappearance of protective Hb F, resulting in hyposplenism or asplenism; liver dysfunction is common (many develop chronic hepatitis [B or C], acute sickle hepatic crisis, iron overload, pigment stones, and cirrhosis with liver failure) (Baneriee &amp; DeBaun, 2016).</para></listitem>
<listitem><para>Genitourinary involvement: Kidneys can lose ability to concentration. The prevalence of albuminuria and proteinuria is 30% within the first 3 decades of life and increases up to 70% in older patients. The development of nephrotic syndrome has been linked to progression to acute and chronic renal failure (Pham et al, 2000). <inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> Renal function is usually normal during adolescence but frequently becomes subnormal as chronic kidney disease progresses. The kidneys eventually shrink, and the capsular surface becomes grossly distorted and scarred.</para></listitem>
<listitem><para>Dermatologic involvement: Ischemic ulcers in extremities are due to arterial occlusion (either micro- or macro-occlusion) and can be a chronic, painful problem.</para></listitem>
<listitem><para><inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> In addition to any of the complications that adults can have, children also may experience growth retardation, delayed sexual maturation, and being underweight (Maakaron &amp; Taher, 2017). Dactylitis (hand-foot syndrome): Major and unresolved swelling of hands or feet is often first symptom noted in children (Pack-Mabien &amp; Haynes, 2009).</para>
</listitem></orderedlist></listitem></itemizedlist></listitem>
<listitem><para><emphasis role="strong">Statistics</emphasis></para>
<orderedlist numeration="loweralpha" inheritnum="ignore" continuation="restarts">
<listitem><para>Morbidity: Sickle cell disease is the most common inherited blood disorder in the United States. Although figures vary somewhat, SCD is occurring in approximately 1 in 365 black or African American births and 1 in 1400 Hispanic American births (NIH, 2017). It is believed there are approximately 100,000 people living with SCD in the United States (CDC, 2016; Maakaron &amp; Taher, 2017).</para></listitem>
<listitem><para>Mortality: Median survival rate for individuals with SCD is 48 years for women and 42 years for men (Maakaron &amp; Taher, 2017). Acute chest syndrome (ACS) is the most common cause of death (Maakaron &amp; Taher, 2017). <inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> Mortality rates for sickle cell&ndash;related death among black or African American children (younger than 4 years of age) fell by 42% from 1999 through 2002. This drop coincided with the introduction in 2000 of a vaccine that protects against invasive pneumococcal disease (CDC, 2016). In the same time period, the age groups with the highest mortality were 35 to 44 years (males) and 45 to 54 years (females); however, there was a tendency for longer survival than in the previous decade (Hamideh &amp; Alvarez, 2013; Heeney &amp; Mahoney, 2015).</para></listitem>
<listitem><para>Cost: In 2009, approximately $1.1 billion was spent for treatment of sickle cell anemia, with roughly 80% of that amount spent for hospital costs (ReutersHealth, 2009). For an average patient with SCD reaching age 45, total lifetime healthcare costs were estimated to be $953,640 per person (Kauf et al, 2009). ***It is likely that future costs will be greatly impacted by clinical trials for stem cells and biomodifier medications.</para>
</listitem></orderedlist></listitem></orderedlist>
<note id="ch0007s0229note0576">
<title><emphasis role="strong">GLOSSARY</emphasis></title>
<para><emphasis role="strong">Acute chest syndrome (ACS):</emphasis> A life-threatening complication defined as an infiltrate on a chest x-ray, accompanied by two or more other symptoms, which can include fever, cough, wheezing, tachypnea, or chest pain (reflects the unique nature of acute pulmonary illness in client with SCD).</para>
<para><emphasis role="strong">Dactylitis:</emphasis> Swollen, tender digits of the hands and feet, causing severe pain. Often first sign of sickle cell disease in babies.</para>
<para><emphasis role="strong">Genetic disease:</emphasis> The ultimate unit of inheritance, carried by the chromosome. Genes determine various characteristics, such as hair texture, skin color, height, shape of nose, lips, and so on, including the kind of hemoglobin in red blood cells (RBCs).</para>
<para><emphasis role="strong">Hemoglobin (Hgb):</emphasis> An iron-containing protein of the RBC, which carries oxygen to the tissues and gives the cell its red color.</para>
<para><emphasis role="strong">Hemolysis:</emphasis> Destruction of RBCs and subsequent release of hemoglobin.</para>
<para><emphasis role="strong">Hyperhemolytic crisis:</emphasis> A rapid, higher-than-normal rate of hemolysis; reticulocytes are increased in peripheral blood, and bone marrow is hyperplastic, leading to anemia and jaundice due to effects of hemolysis. Often associated with vaso-occlusive crisis.</para>
<para><emphasis role="strong">Hypoplastic/aplastic crisis:</emphasis> May be secondary to severe (usually viral) infection or folic acid deficiency, resulting in cessation of production of RBCs and bone marrow.</para>
<para><emphasis role="strong">Icterus (jaundice):</emphasis> Yellowing of the skin and the whites of the eyes caused by an accumulation of bile pigment in the blood.</para>
<para><emphasis role="strong">Priapism:</emphasis> Abnormal, painful, sustained erection of the penis, usually occurring without sexual desire. Can last for hours or days.</para>
<para><emphasis role="strong">Pulmonary hypertension:</emphasis> Increased pressure in the pulmonary arteries that carry blood from the heart to the lungs to pick up oxygen.</para>
<para><emphasis role="strong">Reticulocytes:</emphasis> Immature RBCs, typically composing about 1% of the red cells in the human body. Reticulocytes develop and mature in the red bone marrow and then circulate for about a day in the bloodstream before developing into mature RBCs.</para>
<para><emphasis role="strong">Sickle cell disease (SCD):</emphasis> A person is born with SCD, an inherited disorder of the RBCs where the individual inherits two genes for hemoglobin S, or a single S gene is combined with a second variant gene such as C or Thal.</para>
<para><emphasis role="strong">Sickle cell trait:</emphasis> A person who has sickle cell trait is a carrier of the sickle gene but does not have the disease or incur painful episodes and is generally not affected by the sickle hemoglobin. The gene combination for sickle trait is one gene for the usual hemoglobin (A) and one gene for sickle hemoglobin. <emphasis>Note:</emphasis> People with SCT can have children born with sickle cell disease.</para>
<para><emphasis role="strong">Splenic sequestration crisis:</emphasis> Occurs when the spleen suddenly traps large numbers of RBCs, causing splenomegaly, a drop in hemoglobin greater than or equal to 20%, hypovolemia, shock, and possible death.</para>
<para><emphasis role="strong">Thalassemia (Thal):</emphasis> An inherited disorder of the gene in the RBCs, which results in the impaired ability to produce hemoglobin.</para>
<para><emphasis role="strong">Vaso-occlusive/sickle cell crisis:</emphasis> Related to infection, dehydration, fever, hypoxia, and characterized by multiple infarcts of bones, joints, and target organs, with tissue pain and necrosis caused by plugs of sickled cells in the microcirculation.</para>
</note>
<sect2 id="ch0007s0230"><title><emphasis role="strong">CARE SETTING</emphasis></title>
<para>Sickle cell disease is generally managed at the community level, with many of the interventions included here being appropriate for this focus; however, this plan of care addresses sickle cell crisis, which usually requires hospitalization during the acute phase to address oxygenation and severe pain.</para>
</sect2>
<sect2 id="ch0007s0231"><title><emphasis role="strong">RELATED CONCERNS</emphasis></title>
<para><link linkend="ch0004s0114">Cerebrovascular accident (CVA)/stroke</link></para>
<para><link linkend="ch0005s0169">Cholecystitis with cholelithiasis</link></para>
<para><link linkend="ch0002s0027">Heart failure: chronic</link></para>
<para><link linkend="ch0014s0384">Pediatric considerations</link></para>
<para><link linkend="ch0003s0074">Pneumonia</link></para>
<para><link linkend="ch0014s0338">Psychosocial aspects of care</link></para>
<para><link linkend="ch0008s0249">Renal failure, chronic</link></para>
<para><link linkend="ch0004s0104">Seizure disorders</link></para>
<para><link linkend="ch0013s0318">Sepsis/septic shock</link></para>
<table frame="top" id="ch0007s0229ta0326"><title><emphasis role="strong">CLIENT ASSESSMENT DATABASE</emphasis></title>
<tgroup colsep="0" rowsep="0" cols="2">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>*****Depends on severity of condition and presence of complications.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">DIAGNOSTIC DIVISION<?lb?>MAY REPORT</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">MAY EXHIBIT</emphasis></para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">ACTIVITY/REST</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;">
<listitem><para>Lethargy, fatigue, weakness, general malaise</para></listitem>
<listitem><para>Decreased exercise tolerance, impaired mobility</para></listitem>
<listitem><para>Greater need for sleep and rest</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Listlessness, severe weakness, and increasing pallor (aplastic crisis)</para></listitem>
<listitem><para>Gait disturbances (pain, kyphosis, lordosis), inability to walk (pain)</para></listitem>
<listitem><para>Decreased range of motion (ROM)</para></listitem>
<listitem><para>Joint, bone deformities</para></listitem>
<listitem><para>Generalized retarded growth, tower-shaped skull with frontal bossing, disproportionately long arms and legs, short trunk, narrowed shoulders and hips, and long, tapered fingers</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">CIRCULATION</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Palpitations or anginal chest pain due to concomitant coronary artery disease (CAD), myocardial ischemia, or acute chest syndrome (ACS)</para></listitem>
<listitem><para><inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> Puffy, tender hands and feet, refusal to bear weight, irritability in children less than 2 years of age (Pack-Mabien, 2009)</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Apical pulse&mdash;point of maximal impulse (PMI) may be displaced to the left</para></listitem>
<listitem><para>Tachycardia, S-T elevation</para></listitem>
<listitem><para>Systolic heart murmurs may be heard over entire precordium</para></listitem>
<listitem><para><inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> Hypertension or abnormal blood pressure patterns (elevations and dips) in children (Maakaron &amp; Taher, 2017)</para></listitem>
<listitem><para>Blood pressure (BP)&mdash;widened pulse pressure</para></listitem>
<listitem><para>Capillary refill delayed (anemia or hypovolemia)</para></listitem>
<listitem><para>Generalized symptoms of shock&mdash;hypotension; rapid, thready pulse; and shallow respirations during sequestration crisis</para></listitem>
<listitem><para>Peripheral pulses throbbing on palpation</para></listitem>
<listitem><para>Bruits&mdash;reflects compensatory mechanisms of anemia; may also be auscultated over the spleen because of multiple splenic infarcts</para></listitem>
<listitem><para>Jugular vein distention (JVD) and general peripheral edema (concomitant heart failure [HF])</para></listitem>
<listitem><para><emphasis role="bi">Skin color:</emphasis> Pallor or cyanosis of skin, mucous membranes, and conjunctiva (<emphasis>Note:</emphasis> Pallor may appear as yellowish-brown color in brown-skinned clients and as ashen gray in black-skinned clients.)</para></listitem>
<listitem><para>Scleral icterus, generalized icteric coloring due to excessive RBC hemolysis</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">ELIMINATION</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Frequent voiding, voiding in large amounts</para></listitem>
<listitem><para>Nocturia</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Right upper quadrant (RUQ) abdominal tenderness, enlargement due to hepatomegaly or ascites</para></listitem>
<listitem><para>Left upper quadrant (LUQ) abdominal fullness; spleen may be enlarged and nonfunctional and may eventually become fibrotic and shrunken.</para></listitem>
<listitem><para>Dilute, pale, straw-colored urine; hematuria or smoky appearance from multiple renal infarcts</para></listitem>
<listitem><para>Asymptomatic proteinuria</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">EGO INTEGRITY</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Negative feelings about self, ability to deal with life or situation</para></listitem>
<listitem><para>Resentment and frustration with disease, fear of rejection from others</para></listitem>
<listitem><para>Concern regarding being a burden to significant others (SOs), financial concerns, possible loss of insurance benefits, lost time at work or school, fear of genetic transmission of disease</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Anxiety, restlessness, irritability, apprehension, withdrawal, narrowed focus, self-focusing, unresponsiveness to questions, regression, depression, decreased self-concept</para></listitem>
<listitem><para>Dependent relationship with whomever can offer security and protection</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">FOOD/FLUID</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Anorexia</para></listitem>
<listitem><para>Nausea, vomiting</para></listitem>
<listitem><para>Thirst</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> Child&rsquo;s height and weight usually in the lower percentiles (Maakaron &amp; Taher, 2017)</para></listitem>
<listitem><para>Dry skin and mucous membranes</para></listitem>
<listitem><para>Poor skin turgor with visible tenting during sequestration crisis, infection, and dehydration</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">HYGIENE</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Difficulty maintaining activities of daily living (ADLs) (pain or severe anemia)</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Unkempt appearance, poor personal hygiene</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">NEUROSENSORY</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Headaches or dizziness</para></listitem>
<listitem><para>Disturbances in pain and position sense</para></listitem>
<listitem><para>Visual disturbances due to retinal vascular changes</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Mental status usually unaffected except in cases of severe sickling (cerebral infarction and intracranial hemorrhage)</para></listitem>
<listitem><para>Meningeal irritation (intracranial hemorrhage)&mdash;decreasing level of consciousness (LOC), nuchal rigidity, focal neurological deficits, vomiting, severe headache</para></listitem>
<listitem><para>Weakness of the mouth, tongue, and facial muscles; aphasia (in cerebral infarction of dominant hemisphere)</para></listitem>
<listitem><para>Abnormal reflexes, decreased muscle strength and tone, abnormal involuntary movements, hemiplegia or sudden hemiparesis, quadriplegia</para></listitem>
<listitem><para>Ataxia, seizures</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">PAIN/DISCOMFORT</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Pain includes three types: acute recurrent painful crises, chronic pain syndromes, and neuropathic pain.</para></listitem>
<listitem><para>Pain onset is sudden and may be acute and severe, throbbing, of varied locations (two or more sites). (The acute painful crisis is the most common cause of hospitalization [Ballas et al, 2012].)</para></listitem>
<listitem><para>Pain may be localized or migratory and most commonly involves the lower back, in one or more joints or extremities.</para></listitem>
<listitem><para>Joint or bone pain may be low level and chronic or acute and accompanied by warmth, tenderness, erythema, and occasional effusions (vaso-occlusive crisis).</para></listitem>
<listitem><para>Intermittent pain in legs when walking</para></listitem>
<listitem><para>Bone pain in long bones of extremities (bone marrow infarction) (Maakaron &amp; Taher, 2017)</para></listitem>
<listitem><para>Recurrent, sharp, transient headaches</para></listitem>
<listitem><para>Abdominal tenderness and pain</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Sensitivity to palpation over affected areas</para></listitem>
<listitem><para>Guarding or holding joints in position of comfort, decreased ROM, resulting from joint pain and swelling</para></listitem>
<listitem><para>Maladaptive pain behaviors&mdash;guilt for being ill, denial of any aspect of disease, indulgence in precipitating factors such as overwork, strenuous exercise</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">RESPIRATION</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Dyspnea on exertion or at rest</para></listitem>
<listitem><para>History of repeated pulmonary infections, infarctions, pulmonary fibrosis, pulmonary hypertension, or cor pulmonale</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Acute respiratory distress&mdash;dyspnea, chest pain, and cyanosis (especially in crisis)</para></listitem>
<listitem><para><inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> Cough with fever (in children with acute chest syndrome; not always present in adults) (Vacca &amp; Blank, 2017)</para></listitem>
<listitem><para>Bronchial or bronchovesicular sounds in lung periphery, diminished breath sounds (pulmonary fibrosis)</para></listitem>
<listitem><para>Crackles, rhonchi, wheezes, diminished breath sounds (HF)</para></listitem>
<listitem><para>Increased anteroposterior (AP) diameter of the chest (barrel chest)</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">SAFETY</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>History of repeated, frequent blood transfusions</para></listitem>
<listitem><para>Jaundice with skin itching</para></listitem>
<listitem><para>Impaired vision (sickle retinopathy), decreased visual acuity (temporary or permanent blindness)</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Leg ulcers&mdash;especially common on the internal and external malleoli and the medial aspect of the tibia</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">SEXUALITY</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Loss of libido</para></listitem>
<listitem><para>Amenorrhea</para></listitem>
<listitem><para>Complications of pregnancy, including placenta previa and abruption; premature birth or fetal death</para></listitem>
<listitem><para>Priapism, impotence</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Delayed sexual maturity</para></listitem>
<listitem><para>Pale cervix and vaginal walls (anemia)</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">TEACHING/LEARNING</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Chronic anemic state</para></listitem>
<listitem><para>Pulmonary hypertension or cor pulmonale (multiple pulmonary infections and infarctions)</para></listitem>
<listitem><para>Chronic leg ulcers, delayed healing</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">DISCHARGE PLAN CONSIDERATIONS</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>May need assistance with shopping, transportation, self-care, homemaker and maintenance tasks</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para><inlinemediaobject><imageobject><imagedata fileref="pa.jpg"/></imageobject></inlinemediaobject> Refer to section at end of plan for postdischarge considerations.</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
</entry></row></tbody></tgroup></table>
<table frame="top" id="ch0007s0229ta0327"><title><emphasis role="strong">DIAGNOSTIC STUDIES</emphasis></title>
<tgroup colsep="0" rowsep="0" cols="3">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<colspec colnum="3" colname="3" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom" spanname="1-2">
<para><emphasis role="strong">TEST<?lb?>WHY IT IS DONE</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">WHAT IT TELLS ME</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">BLOOD TESTS</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Complete blood count (CBC):</emphasis> Battery of screening tests, which typically includes Hgb; hematocrit (Hct); RBC count, morphology, indices, and distribution width index; platelet count and size; and white blood cell (WBC) count and differential.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Hgb and total RBCs are decreased. Young WBCs (leukocytes) are elevated, especially in vaso-occlusive crisis. Platelets are often increased. <emphasis>Note:</emphasis> Anemia is often well tolerated by the client; however, a major drop in Hgb from previously recorded values indicates a hematologic crisis. If the reticulocyte count is normal, splenic sequestration is the probable cause. If the reticulocyte count is low, an aplastic crisis is the probable cause.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Red blood cells</emphasis></para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Reticulocyte count:</emphasis> Measures how fast red blood cells are made by the bone marrow and released into the blood.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Young RBCs (reticulocytes) can be low or elevated if anemia is longstanding. If the reticulocyte count is normal, splenic sequestration is the probable cause. If the reticulocyte count is low, an aplastic crisis is the probable cause. <emphasis>Note:</emphasis> The life span of an RBC is normally 90 to 120 days, while the life of a sickle cell is 10 to 20 days, indicating how fragile sickle cells are and how rapidly they are destroyed as they circulate (Vacca &amp; Blank, 2017).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Stained RBC (erythrocyte) examination:</emphasis> Evaluates changes in morphology of RBCs.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Demonstrates partially or completely sickled, crescent-shaped cells, Howell-Jolly bodies, basophilic stippling, and occasional nucleated RBCs (normoblasts).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">High-performance liquid chromatography (HPLC):</emphasis> Separates different forms of proteins in a column and can detect mutant forms of hemoglobin.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>This technique differentiates between usual hemoglobin (A), sickle hemoglobin (S), and many other different kinds of hemoglobin. In sickle cell <emphasis role="bi">trait,</emphasis> more than half of the hemoglobin is normal (hemoglobin A) and less than half is abnormal (hemoglobin S). In sickle cell <emphasis role="bi">disease,</emphasis> almost all hemoglobin is hemoglobin S with some hemoglobin called hemoglobin F (Thompson &amp; Steinberg, 2015). <inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject>&nbsp;<emphasis>Note:</emphasis> Screening tests for SCD are performed routinely on newborns in most states. Prenatal diagnosis is possible by molecular genetic testing if the beta-globin-related hemoglobinopathies (HBB) pathogenic variants have been identified in the parents.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Sickle-turbidity tube test (Sickledex):</emphasis> Detects the presence of hemoglobin S in blood.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Positive if 10% of hemoglobin S is present but does not differentiate between sickle cell anemia and sickle cell trait.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Alkaline phosphatase (ALP):</emphasis> Enzyme found primarily in the liver.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Elevated during vaso-occlusive crisis, reflecting bone and liver damage.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Lactate dehydrogenase (LDH):</emphasis> Indicator of the existence and severity of acute or chronic tissue damage.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Elevated because of RBC hemolysis.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Serum iron:</emphasis> Iron balance is not easily achieved in sickle cell disease.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Deficiency is associated with premature destruction of young RBCs. However, the iron stores released by hemolysis may be available for reuse; therefore, serum iron deficiency is not always present. <inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> A very high iron level is associated with frequent blood transfusions for sickle cell anemia&mdash;a condition more common in children than adults.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">OTHER DIAGNOSTIC STUDIES</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Bone x-rays and scans:</emphasis> Evaluate skeletal changes.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May demonstrate bone infarction, osteomyelitis, avascular necrosis of hip, and so forth. <emphasis>Note:</emphasis> In the spine, &ldquo;H-shaped deformity&rdquo; of the vertebrae is common (formerly termed &ldquo;Lincoln Log&rdquo; appearance) (Ramirez &amp; Asrat, 2017).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Chest x-ray:</emphasis> Performed to check for pulmonary infiltrate.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May confirm presence of acute chest syndrome if a new consolidation or infiltrate is accompanied by other symptoms such as chest pain, elevated temperature, or hypoxemia (Field &amp; DeBaun, 2017; Heeney &amp; Mahoney, 2015).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Magnetic resonance imaging (MRI):</emphasis> An imaging test that uses magnets and radio waves to create pictures of the body.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>The definitive test to rule out cerebral infarct. Also identifies bone marrow changes due to acute and chronic bone marrow infarction, marrow hyperplasia, osteomyelitis, and osteonecrosis (Maakaron &amp; Taher, 2017).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Transcranial Doppler (TCD) studies:</emphasis> A noninvasive ultrasound technology for imaging blood flow in the cerebral arteries and veins.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Detects large vessel disease that is often involved in overt cerebral vascular accidents in patients with SCD (Meier &amp; Miller, 2012). <inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject>&nbsp;<emphasis>Note:</emphasis> The Stroke Prevention Trial in Sickle Cell Anemia (STOP) demonstrated the value of TCD screening for children with SCD at high risk for ischemic cerebral injury, including stroke (Naffaa et al, 2015).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Echocardiography</emphasis></para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Can identify pulmonary hypertension or cardiac involvement associated with anemia (e.g., enlarged heart).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Urine/fecal urobilinogen:</emphasis> Substance formed in the intestine from the breakdown of bilirubin; some is excreted in feces and some is reabsorbed and excreted in bile or urine.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>These sensitive indicators of RBC destruction are increased.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Abdominal/pelvic ultrasound:</emphasis> Performed to evaluate condition of organs.</para></listitem></itemizedlist>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Documents spleen size and presence of biliary or kidney stones.</para>
</entry></row></tbody></tgroup></table>
</sect2>
<sect2 id="ch0007s0232"><title><emphasis role="strong">NURSING PRIORITIES</emphasis></title>
<orderedlist numeration="arabic" inheritnum="ignore" continuation="restarts">
<listitem><para>Promote adequate cellular oxygenation and perfusion.</para></listitem>
<listitem><para>Alleviate pain.</para></listitem>
<listitem><para>Prevent complications.</para></listitem>
<listitem><para>Provide information about disease process, prognosis, and treatment needs.</para></listitem></orderedlist>
</sect2>
<sect2 id="ch0007s0233"><title><emphasis role="strong">DISCHARGE GOALS</emphasis></title>
<orderedlist numeration="arabic" inheritnum="ignore" continuation="restarts">
<listitem><para>Oxygenation and perfusion are adequate to meet cellular needs.</para></listitem>
<listitem><para>Pain relieved or controlled.</para></listitem>
<listitem><para>Complications prevented or minimized.</para></listitem>
<listitem><para>Disease process, future expectations, potential complications, and therapeutic regimen understood.</para></listitem>
<listitem><para>Plan in place to meet needs after discharge.</para></listitem></orderedlist>
<note id="ch0007s0229note0577">
<title><emphasis role="strong">NURSING DIAGNOSIS: impaired Gas Exchange</emphasis></title>
<para><emphasis role="strong">May Be Related To</emphasis></para>
<para>Altered blood flow [altered oxygen-carrying capacity of the blood, reduced RBC life span or premature destruction, abnormal RBC structure, sensitivity to low-oxygen occlusions created by sickled cells packing together within the capillaries]</para>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Abnormal breathing pattern; dyspnea, use of accessory muscles</para>
<para>Cyanosis (hypoxia)</para>
<para>Restlessness, confusion, somnolence; fatigue</para>
<para>Tachycardia</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Respiratory Status: Gas Exchange</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Demonstrate improved ventilation and oxygenation as evidenced by respiratory rate within normal limits, absence of cyanosis, use of accessory muscles, and clear breath sounds.</para>
<para>Participate in ADLs without weakness and fatigue.</para>
<para>Display improved or normal pulmonary function tests.</para>
</note>
<note role="none" id="ch0007s0229note0578"><table frame="top" id="ch0007s0229ta0328"><title/>
<tgroup colsep="0" rowsep="0" cols="3">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<colspec colnum="3" colname="3" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom" spanname="1-2">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Respiratory Monitoring</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor respiratory rate and depth, use of accessory muscles, and areas of cyanosis.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Indicators of adequacy of respiratory function or degree of compromise and therapy needs and effectiveness.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Auscultate breath sounds, noting presence or absence, and adventitious sounds.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Development of atelectasis and stasis of secretions can impair gas exchange.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor vital signs; note changes in cardiac rhythm.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Changes in vital signs and development of dysrhythmias reflect effects of hypoxia on cardiovascular system.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Investigate reports of chest pain and increasing fatigue. Observe for signs of increased fever, cough, and adventitious breath sounds.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Reflective of developing acute chest syndrome, which increases the workload of the heart and oxygen demand.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Assess LOC and mentation regularly.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Brain tissue is very sensitive to decreases in oxygen, and changes in mentation may be an early indicator of developing hypoxia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Ventilation Assistance</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Assist in turning, coughing, and deep-breathing exercises.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Promotes optimal chest expansion, mobilization of secretions, and aeration of all lung fields; reduces risk of stasis of secretions and pneumonia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Evaluate activity tolerance; limit activities to those within client&rsquo;s tolerance or place client on bedrest. Assist with ADLs and mobility, as needed.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Reduction of the metabolic requirements of the body reduces the oxygen requirements and degree of hypoxia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Encourage client to alternate periods of rest and activity. Schedule rest periods, as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Protects from excessive fatigue and reduces oxygen demands and degree of hypoxia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Demonstrate and encourage use of relaxation techniques, such as guided imagery and visualization.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Relaxation decreases muscle tension and anxiety and, hence, the metabolic demand for oxygen.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Promote extra fluid intake, such as 2 to 3 L/d within cardiac tolerance.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Sufficient hydration is necessary to provide for mobilization of secretions and to prevent hyperviscosity of blood with associated capillary occlusion.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Screen health status of visitors and staff.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Protects client from potential sources of respiratory infection.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Collaborative</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer supplemental humidified oxygen, as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Maximizes oxygen transport to tissues, particularly in the presence of pulmonary insults or pneumonia. <emphasis>Note:</emphasis> Oxygen should be given only in the presence of confirmed hypoxemia because oxygen can suppress erythropoietin levels, further reducing the production of RBCs.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor laboratory studies&mdash;CBC (especially noting Hgb and WBCs), blood cultures, arterial blood gases (ABGs) and pulse oximetry, chest x-ray, and pulmonary function tests (when available).</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Client is particularly prone to acute chest syndrome and pneumonia (which is potentially fatal because of its hypoxemic effect of increased sickling). <emphasis>Note:</emphasis> Most individuals with sickle cell anemia have hemoglobin (Hgb) values of 6 to 10 g/dL. The hemoglobin S molecule has a low affinity for oxygen (which allows for adequate tissue oxygenation). During a vaso-occlusive crisis, a client&rsquo;s Hgb level often declines by at least 1 g/dL.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Perform or assist with chest physiotherapy, intermittent positive-pressure breathing (IPPB), and incentive spirometry.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Mobilizes secretions and increases aeration of lung fields.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer packed RBCs (PRCs) or exchange transfusions, as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Simple blood transfusion increases the number of oxygen-carrying cells, dilutes the percentage of hemoglobin S, and improves circulation. PRCs are used because they are less likely to create circulatory overload. Exchange blood transfusions are indicated when the client&rsquo;s condition is deteriorating and may be done for cases of stroke (Kassim et al, 2015) and acute chest syndrome. <emphasis>Note:</emphasis> Studies have shown that blood transfusion therapy for patients with SCD and abnormal TCD velocities can dramatically reduce risk of stroke (Yates, 2017). Partial transfusions are sometimes used prophylactically in high-risk situations, such as chronic, severe leg ulcers, preparation for general anesthesia, and third trimester of pregnancy.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer medications, as indicated, for example:</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Antibiotics, such as amoxicillin plus clavulanic acid (Augmentin), third-generation cephalosporins (e.g., ceftriaxone [Rocephin]), among others</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Broad-spectrum antibiotics are started immediately pending culture results of suspected infections, then may be changed when the specific pathogen is identified. <inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> Because infection is one of the most common causes of ACS in children and adolescents, broad-spectrum antibiotic coverage has been recommended for all children presenting with ACS (Heeney &amp; Mahoney, 2015).</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0229note0579">
<title><emphasis role="strong">NURSING DIAGNOSIS: acute/chronic Pain</emphasis></title>
<para><emphasis role="strong">May Be Related To</emphasis></para>
<para>Biological injury agent (e.g., intravascular sickling with localized stasis, occlusion, infarction, and necrosis; activation of pain fibers due to deprivation of oxygen and nutrients, accumulation of noxious metabolites)</para>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Self-report of intensity and characteristics of pain, using standardized pain scale; proxy report of pain behavior and activity changes (e.g., family member, care provider)</para>
<para>Guarding and protective behaviors</para>
<para>Facial grimacing, narrowed or self-focus; sleep disturbances</para>
<para>Changes in physiological parameter in acute pain (e.g., blood pressure, heart and respiratory rate)</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Pain Level</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Verbalize relief or control of pain.</para>
<para><emphasis role="strong">Pain Control</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Demonstrate relaxed body posture, freedom of movement, and ability to sleep and rest appropriately.</para>
</note>
<note role="none" id="ch0007s0229note0580"><table frame="top" id="ch0007s0229ta0329"><title/>
<tgroup colsep="0" rowsep="0" cols="3">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<colspec colnum="3" colname="3" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom" spanname="1-2">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Pain Management: Acute/Chronic</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Assess reports of pain, including location, duration, and intensity (0 to 10 or similar coded scale). Have client help differentiate current pain from typical or usual pain problems.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Acute pain in patients with sickle cell disease can be localized, migratory, or more generalized and described as throbbing, gnawing, or severe and incapacitating. Pain is caused by ischemic tissue injury resulting from the occlusion of microvascular beds by sickled erythrocytes during an acute crisis. Typically, acute pain occurs deep in the bones and muscles of back, ribs, and limbs and lasts 5 to 7 days. However, client may also have chronic pain from previous sickle cell damage (usually bone pain that is present daily) and chronic nerve pain caused by damage from sickle cell blockage or other conditions, such as diabetes.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Observe nonverbal pain cues, such as gait disturbances, body positioning, reluctance to move, and facial expressions, and physiological manifestations of acute pain&mdash;elevated BP, tachycardia, and increased respiratory rate. Explore discrepancies between verbal and nonverbal cues.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Nonverbal cues may aid in evaluation of pain and effectiveness of therapy. Pain is unique to each client; therefore, one may encounter varying descriptions because of individualized perceptions. <inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject>&nbsp;<emphasis>Note:</emphasis> Evaluating pain in infants, children, and adolescents is not as simple as using a coded scale. Attention must be paid to caregivers&rsquo; reports and child&rsquo;s behavior (e.g., inconsolable crying, changes in crying patterns, curling up in a fetal position, changes in sleep patterns; going silent; withdrawing from touch, refusing eye contact).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Discuss with the client/SO what pain relief measures were effective in the past.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Involves client/SO in care and allows for identification of remedies that have already been found to relieve pain. Helpful in establishing individualized treatment needs.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Explore alternative pain relief measures, such as relaxation techniques, biofeedback, yoga, meditation, and distraction&mdash;visual, auditory, tactile, kinesthetic, guided imagery, and breathing techniques.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Cognitive-behavioral interventions may reduce reliance on pharmacological therapy and enhance client&rsquo;s sense of control, especially when dealing with chronic pain.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Provide support for and carefully position affected extremities.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Reduces edema, discomfort, and risk of injury, especially if osteomyelitis is present.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Apply local massage gently to affected areas.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Helps reduce muscle tension.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Plan activities during peak analgesic effect.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Maximizes movement of joints, enhancing mobility.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Maintain adequate fluid intake.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Dehydration increases sickling vaso-occlusion and corresponding pain.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Collaborative</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Apply warm, moist compresses to affected joints or other painful areas. Avoid use of ice or cold compresses.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Warmth causes vasodilation and increases circulation to hypoxic areas. Cold causes vasoconstriction and compounds the crisis.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer medications by appropriate route (such as continuous infusion or around-the-clock intermittent IV or oral, as indicated), for example:</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Various types of analgesics are needed to manage different types of pain.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Opioids including morphine (Astramorph, Duramorph), hydromorphone (Dilaudid), and nalbuphine (Nubain); long-acting opiate combinations, such as morphine (MS Contin) and oxycodone (Oxycontin), hydrocodone (Vicodin); oxycodone and acetaminophen (Percocet)</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Opioids are the mainstay of pain control during crisis and are usually administered via patient-controlled analgesia (PCA). Oral preparations are preferred for longer-term treatment and can be initiated while client is still on IV analgesia. <emphasis>Note:</emphasis> Meperidine should not be used to treat acute sickle cell pain in client with impaired renal function, history of seizure disorder, or those on serotoninergic medications (e.g., certain antidepressants and combination drugs containing serotonin-norepinephrine reuptake inhibitors).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Nonopioid analgesics, such as acetaminophen (Tylenol); nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen (Advil, Motrin); Ketrolac</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Acetaminophen and NSAIDs add to the effects of opioids during painful crisis. Acetaminophen can be used for control of headache, pain, and fever. <inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> Ketrolac (a nonsedating analgesic) may be used in children to relieve spine, thoracic, and abdominal pain (often accompanies hypoventilation in acute chest syndrome) (Heeney &amp; Mahoney, 2015). <emphasis>Note:</emphasis> Aspirin should be avoided because it alters blood pH and can make cells sickle more easily.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Consult with or refer to physical therapy.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Determines and provides appropriate therapies, such as massage, heat therapies, and guided exercise.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer and monitor RBC transfusion.</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Although transfusion does not halt the pain in an acute crisis, frequency of painful crises may be reduced by regular partial exchange transfusions to maintain population of normal RBCs.</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0229note0581">
<title><emphasis role="strong">NURSING DIAGNOSIS: risk for ineffective Tissue Perfusion [specify: cardiac, cerebral, gastrointestinal, peripheral]</emphasis></title>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Coagulopathy (e.g., vaso-occlusive nature of sickling, inflammatory response)</para>
<para>Hypovolemia; hypoxemia</para>
<para>Deficient knowledge of aggravating factors</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Tissue Perfusion</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Demonstrate improved tissue perfusion as evidenced by stabilized vital signs, strong and palpable peripheral pulses, adequate urine output, absence of pain; usual mentation; normal capillary refill; skin warm and dry; nailbeds and lips of natural pale, pink color; and absence of paresthesias.</para>
</note>
<note role="none" id="ch0007s0229note0582"><table frame="top" id="ch0007s0229ta0330"><title/>
<tgroup colsep="0" rowsep="0" cols="3">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<colspec colnum="3" colname="3" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom" spanname="1-2">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Circulatory Care: Arterial [or] Venous</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Insufficiency</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Impaired systemic and cardiovascular perfusion</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor vital signs carefully. Assess pulses for rate, rhythm, and volume. Note changes in blood pressure.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Sludging and sickling in peripheral vessels may lead to complete or partial obliteration of a vessel with diminished perfusion to surrounding tissues.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Assess heart sounds and pulses for dysrhythmias.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May reflect problems with cardiac output (systemic dehydration and/or hypoxemia), electrolyte imbalances, or local or systemic sickling causing inadequate myocardial perfusion.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Assess for restlessness, changes in level of consciousness, increased capillary refill time, diminished peripheral pulses, and pale, cool skin.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Indicative of inadequate systemic perfusion.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Note onset of hypotension with rapid, weak, thready pulse and tachypnea with shallow respirations.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Sudden massive splenic sequestration of cells can lead to systemic shock.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Investigate reports of chest pain.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>To evaluate for potential myocardial ischemia, inadequate systemic oxygenation, or perfusion of organs.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Impaired general and peripheral perfusion</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Assess extremities for skin texture, edema, and ulcerations, especially of internal and external ankles.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Edema may reflect both systemic and peripheral effects of sickle cell disease. Reduced peripheral circulation often results in skin and underlying tissue changes (e.g., ulcerations) and delayed healing.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Investigate reports of eye pain or vision disturbances.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Changes may reflect occlusion of vasculature and nerves of the eye.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> Evaluate for developing edema&mdash;including hands and feet in children and genitalia in boys and men.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Vaso-occlusion or circulatory stasis may lead to edema of extremities and priapism, potentiating risk of tissue ischemia and necrosis. <inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject>&nbsp;<emphasis>Note:</emphasis> Edematous hands and feet are often first sign of SCD in young children.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Maintain comfortable environmental temperature and body warmth without overheating. Avoid hypothermia.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Prevents vasoconstriction, aids in maintaining circulation and perfusion. Excessive body heat may cause diaphoresis, adding to insensible fluid losses and risk of dehydration. Hypothermia may exacerbate cardiovascular compromise with severe anemia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor urine output.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Decreased output may be indicative of dehydration, impaired cardiac output, or impaired renal perfusion because of vascular occlusions. (Refer to ND: <link linkend="ch0007s0229note0583">risk for deficient Fluid Volume</link>, following; and CP: <link linkend="ch0008s0244">Renal Failure/Acute</link>/<link linkend="ch0008s0249">Chronic</link>.)</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Risk for impaired respiratory system perfusion</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor respirations, noting rate outside of acceptable parameters and drop in pulse oximetry. Note client reports of/demonstration of difficult breathing.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May indicate presence of oxygen exchange problems, presence of respiratory infection, or acute chest syndrome.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Assess skin for coolness, pallor, cyanosis, and diaphoresis.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Changes reflect diminished circulation and hypoxia potentiating capillary occlusion. (Refer to ND: <link linkend="ch0007s0229note0577">impaired Gas Exchange</link>.)</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Risk for ineffective cerebral perfusion</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Note changes in level of consciousness and mentation; reports of headaches, dizziness; development of sensory or motor deficits, such as hemiparesis or paralysis; and seizure activity.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Changes may reflect diminished perfusion to the brain and central nervous system (CNS) due to ischemia or infarction (stroke). <inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject>&nbsp;<emphasis>Note:</emphasis> Researchers have demonstrated that the scenario of high blood pressure and anemia occurring together places children with SCD at serious danger for symptomless or so-called silent stroke, which causes subclinical brain damage (Wolf et al, 2015). (Refer to CP: <link linkend="ch0004s0114">Cerebral Vascular Accident/Stroke</link>, if indicated.)</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Ineffective Gastrointestinal Perfusion</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Auscultate abdomen to evaluate for peristaltic activity, especially in the presence of vomiting and abdominal pain.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May indicate presence of bowel ischemia or obstruction, or other abdominal pathology, such as cholecystitis (<inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> especially common in children) (Maakaron &amp; Taher, 2017).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Note increasing abdominal girth, especially when accompanied by general deterioration in clinical status (i.e., sudden weakness, pale lips, rapid breathing, excessive thirst, belly pain, and rapid heartbeat) and severe anemia.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May indicate presence of splenic sequestration (occurs when large numbers of sickled red blood cells become trapped in the spleen, causing it to suddenly enlarge). <inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> This condition is more common in infants and young children. Without emergency medical care, splenic sequestration can cause death in a matter of hours (Thompson, 2015).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Collaborative</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor laboratory studies, such as the following:</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Arterial blood gases (ABGs), liver and kidney function tests</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Decreased tissue perfusion may lead to gradual infarction of organ tissues, such as the brain, liver, spleen, kidney, and skeletal muscle, with consequent multiorgan failure.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Serum electrolytes; provide replacements as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Electrolyte losses, especially sodium and potassium, are increased during crisis because of fever, diarrhea, vomiting, diaphoresis, and presence of acidosis.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer oxygen by appropriate route and assist with respiratory treatment measures, such as coughing, deep-breathing exercises, and incentive spirometer.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Improves oxygenation and reduces risk of pulmonary complications. (Refer to ND: <link linkend="ch0007s0229note0577">impaired Gas Exchange</link>, above.)</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer intravenous (IV) solutions, such as 0.45 normal saline, via an infusion pump.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Hydration lowers the hemoglobin S concentration, which decreases the sickling tendency and also reduces blood viscosity, which helps to maintain perfusion. Infusion pump may prevent circulatory overload. <emphasis>Note:</emphasis> Lactated Ringer&rsquo;s solution or D<subscript>5</subscript>W may cause RBC hemolysis and potentiate thrombus formation.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer hydroxyurea (hydroxycarbamide [Droxia, Hydrea]) and observe for possible side effects.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Hydroxyurea, a cytotoxic agent, reduces or prevents many complications of SCD by increasing the circulation of normal or fetal hemoglobin (HbF). It dramatically decreases the number of VOC episodes and the need for transfusions and hospitalizations and is given to prevent crises. <emphasis>Note:</emphasis> Hydroxyurea is not used in the acute setting, as it takes weeks to months to be effective, and thus is used to treat complications. <inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> This drug is used across the life span, including in infants and young children, as long as renal clearance is effective (Rodgers &amp; George, 2017; Vacca &amp; Blank, 2017).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer deferoxamine (Desferal) and vitamin C.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Chelation therapy may be indicated to correct iron overload associated with regular, frequent transfusions. Vitamin C may enhance iron excretion, especially in clients who are vitamin deficient. <emphasis>Note:</emphasis> Phlebotomy and exchange transfusions may be used in conjunction with chelation therapy.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Prepare for and assist with procedures as needed (e.g., surgical intervention or needle aspiration of blood from corpora cavernosa).</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Sickling within the penis can cause priapism and edema. Removal of sludged, sickled cells can improve circulation, decreasing psychological trauma and risk of necrosis and infection.</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0229note0583">
<title><emphasis role="strong">NURSING DIAGNOSIS: risk for deficient Fluid Volume</emphasis></title>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Factors influencing fluid needs (e.g., hypermetabolic state or fever, inflammatory or vaso-occlusive processes; deviations affecting intake or absorption)</para>
<para>Active fluid loss (compromised regulatory function; renal parenchymal damage or infarctions limiting the kidney&rsquo;s ability to concentrate urine)</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Hydration</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Maintain adequate fluid balance as evidenced by individually appropriate urine output with a near-normal specific gravity, stable vital signs, moist mucous membranes, good skin turgor, and prompt capillary refill.</para>
</note>
<note role="none" id="ch0007s0229note0584"><table frame="top" id="ch0007s0229ta0331"><title/>
<tgroup colsep="0" rowsep="0" cols="2">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">Fluid Monitoring</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Maintain accurate intake and output (I&amp;O). Weigh daily.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Client may reduce fluid intake during periods of crisis because of malaise and anorexia. Dehydration from vomiting, diarrhea, and fever may reduce urine output and precipitate a vaso-occlusive crisis.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Note urine characteristics and specific gravity.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>The kidney can lose its ability to concentrate urine, resulting in excessive losses of dilute urine and fixation of the specific gravity.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Monitor vital signs, comparing with client&rsquo;s usual or previous readings. Take BP in lying, sitting, and standing positions, if possible.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Reduction of circulating blood volume can occur from increased fluid loss, resulting in hypotension and tachycardia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Observe for fever, changes in level of consciousness, poor skin turgor, dryness of skin and mucous membranes, and pain.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Symptoms are reflective of dehydration and hemoconcentration with consequent vaso-occlusive state.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Monitor vital signs closely during blood transfusions and note presence of dyspnea, crackles, rhonchi, wheezes, diminished breath sounds, cough, frothy sputum, and cyanosis.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Client&rsquo;s heart may already be weakened and prone to failure because of chronic demands placed on it by the anemic state. Heart may be unable to tolerate the added fluid volume from transfusions or rapid IV fluid administered to treat crisis or shock.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="bi">Collaborative</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Administer IV fluids, as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Replaces fluid deficits; may reverse renal concentration of RBCs and reduce potential for kidney failure.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Monitor laboratory studies, for example: Hgb/Hct</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Elevations may indicate hemoconcentration. Posttransfusion Hgb level of 8 to 9 g/dL is generally recommended to avoid the risk of hyperviscosity that may occur several days after transfusion when RBCs sequestered in the spleen may return to the circulation and increase the Hgb levels.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Serum and urine electrolytes</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Kidneys&rsquo; loss of ability to concentrate urine may result in serum depletions of NA<superscript>+</superscript>, K<superscript>&minus;</superscript>, and CL<superscript>&minus;</superscript>, necessitating replacement.</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0229note0585">
<title><emphasis role="strong">NURSING DIAGNOSIS: impaired physical Mobility</emphasis></title>
<para><emphasis role="strong">May Be Related To</emphasis></para>
<para>Activity intolerance; decreased endurance</para>
<para>Pain/discomfort; joint stiffness; loss of integrity of bone structures (osteoporosis, osteomyelitis)</para>
<para>Prescribed movement restrictions (bedrest)</para>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Limited joint ROM, reluctance to initiate movement; slowed movement, gait changes</para>
<para>Generalized weakness</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Mobility</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Maintain or increase strength and function of affected body parts.</para>
<para>Participate in activities with absence of or improvement in gait disturbances, increased joint ROM, and absence of inflammatory signs.</para>
</note>
<para><emphasis role="strong">****Refer to CP: <link linkend="ch0014s0355">Extended/Long Term Care</link>; ND: <link linkend="ch0004s0129note0281">impaired physical Mobility</link> for appropriate actions and interventions</emphasis>.</para>
<note id="ch0007s0229note0586">
<title><emphasis role="strong">NURSING DIAGNOSIS: risk for impaired Skin Integrity</emphasis></title>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Impaired circulation (venous stasis and vaso-occlusion); impaired sensation</para>
<para>Mechanical factors&mdash;pressure; alteration in skin turgor</para>
<para>Alteration in fluid volume [including presence of edema]</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Tissue Integrity: Skin and Mucous Membranes</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Prevent dermal ischemic injury.</para>
<para>Display improvement in wound or lesion healing if present.</para>
<para><emphasis role="strong">Risk Control</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Participate in behaviors to reduce risk factors and skin breakdown.</para>
</note>
<note role="none" id="ch0007s0229note0587"><table frame="top" id="ch0007s0229ta0332"><title/>
<tgroup colsep="0" rowsep="0" cols="2">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">Skin Surveillance</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Reposition frequently, even when sitting in chair.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Prevents prolonged tissue pressure where circulation is already compromised, reducing risk of tissue trauma and ischemia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Inspect skin pressure points regularly for pallor or redness and provide gentle massage.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Poor circulation may predispose to rapid skin breakdown.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Protect bony prominences with sheepskin, heel and elbow protectors, or pillows, as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Decreases pressure on tissues, preventing skin breakdown.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Keep skin surfaces dry and clean and linens dry and wrinkle-free.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Moist, contaminated areas provide excellent media for growth of pathogenic organisms.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Monitor ischemic areas, leg bruises, cuts, and bumps closely for ulcer formation.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Potential entry sites for pathogenic organisms. In presence of altered immune system, this increases risk of infection and delayed healing.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Elevate lower extremities when sitting.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Enhances venous return, reducing venous stasis and edema formation.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="bi">Collaborative</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Provide egg-crate, alternating air pressure, or water mattress.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Reduces tissue pressure and aids in maximizing cellular perfusion to prevent dermal injury.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Provide wound care as indicated, such as cleansing and debriding open wounds and ulcers according to protocol.</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Improvement or delayed healing reflects status of tissue perfusion and effectiveness of interventions. <emphasis>Note:</emphasis> These clients are at increased risk of serious complications because of lowered resistance to infection and decreased nutrients for healing.</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0229note0588">
<title><emphasis role="strong">NURSING DIAGNOSIS: risk for Infection</emphasis></title>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Chronic illness; malnutrition; [extremes of age]</para>
<para>Alteration in skin integrity, tissue destruction (e.g., tissue and bone marrow infarction, necrosis and increased gut permeability, liver fibrosis, loss of spleen [autosplenectomy]); stasis of body fluids, decrease in ciliary action</para>
<para>Decrease in hemoglobin; inadequate vaccination; immunosuppression [increased environmental exposure]</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Risk Control: Infectious Process</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Be free of infection; achieve timely wound healing; be free of preventable complications.</para>
<para>Verbalize understanding of individual causative or risk factors.</para>
<para>Identify interventions to prevent or reduce risk of infection.</para>
</note>
<para><emphasis role="strong">***Refer to CPs: <link linkend="ch0003s0074">Pneumonia</link>, <link linkend="ch0013s0318">Sepsis/Septicemia</link>, <link linkend="ch0011s0293">Fractures</link>; ND: <link linkend="ch0007s0229note0588">risk for Infection</link> for assessments and interventions related to prevention or management of infection.</emphasis></para>
<note id="ch0007s0229note0589">
<title><emphasis role="strong">NURSING DIAGNOSIS: ineffective Health Management</emphasis></title>
<para><emphasis role="strong">May Be Related To</emphasis></para>
<para>Difficulty managing complex treatment regimen or navigating complex healthcare systems</para>
<para>Perceived seriousness of condition, susceptibility, benefit, or barrier</para>
<para>Insufficient knowledge of therapeutic regimen</para>
<para>Family pattern of healthcare; decisional conflict; excessive demands; insufficient social support</para>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Difficulty with prescribed regimen</para>
<para>Failure to take action to reduce risk factors</para>
<para>Ineffective choices in daily living for meeting health goals</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Self-Management: Chronic Disease</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Verbalize understanding of disease process, including symptoms of crisis and potential complications.</para>
<para>Verbalize understanding of therapeutic needs.</para>
<para>Initiate necessary behaviors or lifestyle changes to prevent complications.</para>
<para>Participate in continued medical follow-up, genetic counseling, and family planning services.</para>
</note>
<note role="none" id="ch0007s0229note0590"><table frame="top" id="ch0007s0229ta0333"><title/>
<tgroup colsep="0" rowsep="0" cols="3">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<colspec colnum="3" colname="3" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom" spanname="1-2">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Teaching: Disease Process</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Review disease process and treatment needs.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Provides knowledge base from which client can make informed choices.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Review crisis precipitating factors, such as the following:</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Cold environmental temperatures, failure to dress warmly when engaging in winter activities; wearing tight, restrictive clothing; stressful situations</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Causes peripheral vasoconstriction, which may result in sludging of the circulation, increased sickling, and may precipitate a vaso-occlusive crisis.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Strenuous physical activity or contact-type sports and extremely warm temperatures</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Increases metabolic demand for oxygen and increases insensible fluid losses (evaporation and perspiration), leading to dehydration, which may increase blood viscosity and tendency to sickle.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Travel to places more than 7000 ft above sea level or flying in unpressurized aircraft</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Decreased oxygen tension present at higher altitudes causes hypoxia and potentiates sickling of cells. <emphasis>Note:</emphasis> Even though commercial airline cabins are pressurized, low cabin humidity increases risk of dehydration.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Encourage consumption of at least 3 to 4 L of fluid daily, during a steady state, increasing to 6 to 8 L (as individually tolerated, prescribed, or required) during a painful crisis or while engaging in activities that might precipitate dehydration.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Prevents dehydration and consequent hyperviscosity that can potentiate sickling and crisis.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Discuss continuation of use of prescribed medications, such as hydroxyurea (Hydrea).</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Has been found to reduce frequency of pain episodes in adults.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Encourage ROM exercise and regular physical activity with a balance between rest and activity.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Prevents bone demineralization and may reduce risk of fractures. Aids in improving general health status and muscle and bone strength.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Review client&rsquo;s current diet, reinforcing the importance of diet including meats and dairy, green leafy vegetables, citrus fruits, and wheatgerm. Provide necessary instruction regarding supplementary vitamins such as folic acid.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Nutritious foods, including vitamins, folate, and B<subscript>12</subscript> in greater quantities than usual, are essential because of increased demands placed on bone marrow. Folic acid supplements are frequently ordered to prevent aplastic crisis.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Emphasize importance of avoiding smoking and alcohol consumption; identify appropriate medical assistance and community support groups for smoking cessation.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Nicotine induces peripheral vasoconstriction and decreases oxygen tension, which may contribute to cellular hypoxia and sickling. Alcohol increases the possibility of dehydration, which precipitates sickling. Maintaining these changes in behavior or lifestyle may require prolonged support.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Discuss principles of skin and extremity care and protection from injury. Encourage prompt treatment of cuts, insect bites, sores, and lesions.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Because of impaired tissue perfusion, especially in the periphery, distal extremities are especially susceptible to altered skin integrity and infection.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Include instructions on care of leg ulcers that might develop.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Fosters independence and maintenance of self-care at home.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Instruct client to avoid persons with infections such as upper respiratory infections (URIs).</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Altered immune response places client at risk for infections, especially bacterial bronchitis and pneumonia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Recommend avoiding cold remedies and decongestants containing ephedrine and large amounts of caffeine. Stress the importance of reading labels on over-the-counter (OTC) drugs and consulting healthcare provider before consuming any drugs or herbal supplements.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Those remedies containing vasoconstrictors may decrease peripheral tissue perfusion and cause sludging of sickled cells.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Discuss conditions for which medical attention should be sought, such as the following:</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Urine that appears blood tinged or smoky</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Symptoms suggestive of sickling in the renal medulla.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Indigestion, persistent vomiting, diarrhea, high fever, and excessive thirst</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Dehydration may trigger a vaso-occlusive crisis.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Increasingly severe joint or bone pain</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May signify a vaso-occlusive crisis due to sickling in the bones or spleen, leading to ischemia or infarction or onset of osteomyelitis.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Severe chest pain, with or without cough</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May reflect acute chest syndrome, with pulmonary infiltrates or pneumonia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Abdominal pain; gastric distress following meals</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Cholelithiasis, primarily with bilirubin stones, is present in more than 50% of adults.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Priapism episode persisting over 4 hours with no resolution</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Suggestive of sickling in the penis.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Persistent fever greater than 100&deg;F (38&deg;C); increasing fatigue and pallor; dizziness, drowsiness; and nonhealing leg ulcers</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Suggestive of infections that may precipitate a vasoocclusive crisis if dehydration develops. <emphasis>Note:</emphasis> Severe infections are the most frequent cause of aplastic crisis.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Any neurological symptom or sign</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Stroke can occur due to cerebral infarction, although it is more common in children than adults. Without long-term transfusion therapy, approximately one-third of clients will experience recurrent strokes.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Review and strengthen coping abilities, such as how to deal appropriately with anxiety, getting adequate information, and using relaxation techniques.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Promotes client&rsquo;s sense of control and may avert a crisis.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Recommend wearing a medical alert bracelet or carrying a wallet card.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May prevent inappropriate treatment in emergency situation.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Discuss genetic implications of the condition. Encourage SO and family members to seek testing to determine presence of hemoglobin S.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Screening may identify other family members with sickle cell trait. Hereditary nature of the disease with the possibility of transmitting the mutation may have a bearing on reproductive decisions.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Explore concerns regarding childbearing and family planning.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Provides opportunity to correct misconceptions and present information necessary to make informed decisions.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Refer to community resources and obstetrician knowledgeable about sickle cell disease, as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Evidence shows that pregnant client has increased risk of infections (e.g., pneumonia and genitourinary tract infections), gestational hypertension, intrauterine growth retardation, eclampsia, preterm labor, and postpartum infections (Vichinsky, 2017).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Encourage client to have routine follow-ups, such as:</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Periodic laboratory studies, such as CBC</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Monitoring may be needed long term to review status of anemia and to identify potential complications.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Biannual dental examination</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Sound oral hygiene limits opportunity for bacterial invasion and sepsis.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Annual ophthalmological examination</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Detects development of sickle retinopathy with either proliferative or nonproliferative ocular changes predisposing to retinal hemorrhage and increased intraocular pressure.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Immunizations</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Annual influenza vaccination is essential. <inlinemediaobject><imageobject><imagedata fileref="pp.jpg"/></imageobject></inlinemediaobject> For infants with sickle cell disease, provide a suggested schedule for well-child visits to ensure that immunizations and other aspects of routine pediatric care are followed. For children aged 1 to 3 years with hemoglobin (Hb) SS and HbS&ndash;&beta;-0 thalassemia, consider visits every 3 months, to be certain that parents have sufficient antibiotics for prophylaxis (when used) and to encourage compliance with SCD therapies.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Determine need for vocational and career guidance.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Sedentary career may be necessary because of decreased oxygen-carrying capacity and diminished exercise tolerance.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Encourage participation in community support groups available to clients and SO, such as the Sickle Cell Disease Association of America, March of Dimes, public health services, and visiting nurse.</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Helpful in adjustment to long-term situation; reduces feelings of isolation and enhances problem-solving through sharing of common experiences. <emphasis>Note:</emphasis> Failure to resolve concerns and deal with situation may require more intensive therapy and psychological support.</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0229note0591">
<para><emphasis role="strong">POTENTIAL CONSIDERATIONS</emphasis> following acute hospitalization (dependent on client&rsquo;s age, physical condition and presence of complications, personal resources, and life responsibilities)</para>
<itemizedlist mark="&bull;">
<listitem><para><emphasis role="bi">acute/chronic Pain</emphasis>&mdash;physical agent (e.g., intravascular sickling with localized stasis, occlusion, infarction, and necrosis; activation of pain fibers due to deprivation of oxygen and nutrients, accumulation of noxious metabolites)</para></listitem>
<listitem><para><emphasis role="bi">risk for deficient Fluid Volume</emphasis>&mdash;increased fluid needs (hypermetabolic state or fever, inflammatory processes), active fluid loss (renal parenchymal damage or infarctions limiting the kidney&rsquo;s ability to concentrate urine [hyposthenuria])</para></listitem>
<listitem><para><emphasis role="bi">risk for Infection</emphasis>&mdash;chronic disease; broken skin, tissue destruction, stasis of body fluids, decreased ciliary action</para></listitem></itemizedlist>
</note>
</sect2></sect1>
<sect1 id="ch0007s0234"><title><emphasis role="strong">ADULT LEUKEMIAS</emphasis></title>
<orderedlist numeration="upperroman" inheritnum="ignore" continuation="restarts">
<listitem><para><emphasis role="strong">Pathophysiology</emphasis>&mdash;Malignant disorders of the blood and bone marrow in which unrestrained proliferation of white blood cells occurs and is usually accompanied by anemia, impaired blood clotting, and enlargement of the lymph nodes, liver, and spleen.</para>
<orderedlist numeration="loweralpha" inheritnum="ignore" continuation="restarts">
<listitem><para>Blood cells originate primarily in the marrow of bones, such as the sternum, iliac crest, and cranium, and begin as immature cells (blasts or stem cells) that differentiate and mature into red blood cells (RBCs), platelets, and various types of WBCs (National Cancer Institute [NCI], 2017a).</para></listitem>
<listitem><para>Production of normal blood cells is markedly decreased, leading to anemia, thrombocytopenia, neutropenia</para></listitem>
<listitem><para>Rapid growth of immature or ineffective WBCs and delayed cell death lead to their accumulation in bone marrow, blood, spleen, and liver.</para>
</listitem></orderedlist></listitem>
<listitem><para><emphasis role="strong">Categories (American Cancer Society [ACS], n.d; Hu, 2016; Seiter, 2017; Swierzewski, 2015)</emphasis></para>
<orderedlist numeration="loweralpha" inheritnum="ignore" continuation="restarts">
<listitem><para>Leukemia is classified by how quickly it progresses. Acute leukemia is fast-growing and can overwhelm the body within weeks or months. Chronic leukemia is slow-growing and progressively worsens over time.</para></listitem>
<listitem><para>Leukemia is also classified according to the type of white blood cell that is multiplying&mdash;that is, lymphocytes (immune system cells), granulocytes (bacteria-destroying cells), or monocytes (macrophage-forming cells).</para></listitem>
<listitem><para>The leukemia designation also includes the site where the cancer develops (i.e., lymphocytes, myeloid [arising from bone marrow])</para></listitem>
<listitem><para>Although leukemia is among the most common childhood cancers, it most often occurs in adults (most frequently diagnosed among people aged 65&ndash;74) (NCI, 2017a).</para></listitem>
<listitem><para>The four types of leukemia that occur most frequently in adults are acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and chronic lymphocytic leukemia (CLL).</para>
<orderedlist numeration="arabic" inheritnum="ignore" continuation="restarts">
<listitem><para>Acute leukemias</para>
<orderedlist numeration="lowerroman" inheritnum="ignore" continuation="restarts">
<listitem><para>Acute leukemia cells begin to replicate before any immune functions have developed. These abnormalities result in loss of the body&rsquo;s ability to fight infections and prevent bleeding.</para></listitem>
<listitem><para>Acute leukemias, in general, progress rapidly without treatment but can be kept in remission in a high percentage of individuals who undergo appropriate therapy. As a group, older clients tend to have worse treatment outcomes than younger ones (i.e., they experience greater treatment-related toxicity, lower remission rates, shorter disease-free survival times, and shorter overall survival times).</para></listitem>
<listitem><para>The most common form of acute leukemias in adults (especially those 65 or older) is acute myelogenous leukemia (AML).</para></listitem>
<listitem><para>AML (also known as acute myeloid leukemia, acute granulocytic leukemia, and nonlymphocytic leukemia) is a rapidly progressing cancer of blood and bone marrow, caused by damage to the DNA of developing cells in the bone marrow. It affects a group of white blood cells (called myeloid cells), which normally develop into the various types of mature blood cells (e.g., RBCs, WBCs, and platelets). The abnormal cells are unable to function properly, and they can amass, crowding out healthy cells.</para></listitem>
<listitem><para>Acute lymphoblastic leukemia (also called acute lymphocytic leukemia [ALL]) is a rapidly progressing cancer of blood, where abnormal blood cells (leukemia cells) accumulate in bone marrow and replace healthy functional lymphocytes with leukemia cells that can&rsquo;t mature properly. Typically, ALL is associated with having more B lymphocytes than T lymphocytes, which (1) allows invasion of infection and (2) prevents destruction of previously infected cells. The leukemia cells are then carried in the bloodstream to other organs and tissues, including the brain, liver, lymph nodes, and testes, where they continue to grow and divide.</para>
</listitem></orderedlist></listitem>
<listitem><para>Chronic leukemias</para>
<orderedlist numeration="loweralpha" inheritnum="ignore" continuation="restarts">
<listitem><para>Chronic leukemias develop gradually and progress more slowly than acute forms. The cells generally begin to form in bone marrow, mature partly (but not completely), and can affect white blood cells, red blood cells, and platelets. Leukemia cells survive longer than normal cells and can build up, crowding out normal cells. At some point, leukemia cells leave the bone marrow and spill into the bloodstream, where they can spread to other organs. Chronic leukemias can take a long time to cause problems but are generally harder to cure than acute leukemias.</para></listitem>
<listitem><para>Whether the leukemia is myeloid or lymphocytic is determined by which bone marrow cells the cancer starts in.</para></listitem>
<listitem><para>The most common form of chronic leukemia in adults is chronic lymphocytic leukemia (CLL). CLL accounts for about one-quarter of all leukemias, mainly affecting older adults with an average age of 71 at time of diagnosis (ACS, n.d.). CLL can spread to other parts of the body, including lymph nodes or other organs such as the liver and spleen, resulting in infections, anemia, and easy bleeding. CLL eventually causes the bone marrow to fail.</para></listitem>
<listitem><para>Chronic myelogenous leukemia (CML) is a slowly progressing blood and bone marrow disease that usually occurs after middle age. CML (also called chronic myeloid leukemia) starts in certain blood-forming cells of the bone marrow and invades the blood. In CML, a genetic change takes place in an early immature type of myeloid cells that produce RBCs, platelets, and most types of WBCs, except lymphocytes. CML constitutes about 10% of all leukemias.</para></listitem>
<listitem><para>Most people with CML (and some people with AML and ALL) have a particular genetic marker (the Philadelphia chromosome [Ph1]), which causes uncontrolled proliferation of all types of white blood cells and platelets. Another distinctive feature of CML is its invariable conversion, if untreated, to a more rapidly fulminating acute type, leading to rapid death (NCI, 2017a; Sherbenou &amp; Drucker, 2007; Swierzewski, 2015).</para></listitem>
<listitem><para>CML tends to occur more in middle-age and older-age persons. Studies have shown that most cases occur in older adults, with more than half occurring after age 67 (Leukemia &amp; Lymphoma Society, 2016&ndash;2017).</para></listitem></orderedlist>
</listitem></orderedlist></listitem></orderedlist></listitem>
<listitem><para><emphasis role="strong">Etiology</emphasis></para>
<orderedlist numeration="loweralpha" inheritnum="ignore" continuation="restarts">
<listitem><para>Exact cause is unknown.</para></listitem>
<listitem><para>Risk factors include the following (Seiter, 2017):</para>
<orderedlist numeration="lowerroman" inheritnum="ignore" continuation="restarts">
<listitem><para>Antecedent histological disorders: diseases of the bone marrow, such as myelodysplastic syndrome (MDS)</para></listitem>
<listitem><para>Environmental exposures: radiation, benzene (found in some work areas, gasoline-related industries, and cigarette smoke) (Phillips, 2012)</para></listitem>
<listitem><para>Prior chemotherapy for other malignancies</para></listitem>
<listitem><para>Genetics or congenital disorders: Some congenital disorders that predispose patients to AML include Down&rsquo;s syndrome, Fanconi&rsquo;s anemia, and neurofibromatosis.</para>
</listitem></orderedlist></listitem></orderedlist></listitem>
<listitem><para><emphasis role="strong">Classification or Staging (Hu, 2016; NCI, 2017a)</emphasis></para>
<para>In general, because leukemias start in the bone marrow and have often spread to other organs by the time of diagnosis, there is no traditional clinical staging but rather are described as untreated, in remission, or recurrent and are classified according to their genotypes, or their unique characteristics, in order to determine the most appropriate therapy. In recent years, researchers have discovered that cellular characteristics such as genetic makeup and numbers of specific cell types help to classify leukemia and predict its outcome.</para>
<orderedlist numeration="loweralpha" inheritnum="ignore" continuation="restarts">
<listitem><para>The most popular classification method for acute leukemia is the French-American-British (FAB) system. For example, according to the FAB classification, acute leukemia is divided into eight subtypes of acute myelogenous leukemia (AML) and three subtypes of acute lymphocytic leukemia (ALL) (NCI, 2017a). Acute promyelocytic leukemia (APL) is one subtype of AML that is considered a medical emergency because of its sudden onset and a significant risk of death due to hemorrhage (17%&ndash;29%) more than other leukemias (Draper, 2016).</para></listitem>
<listitem><para>Chronic leukemia is classified by phase (i.e., chronic phase, accelerated phase, and blast phase [or &ldquo;blast crisis&rdquo;]) and is defined by the number of blasts (immature leukemia cells) in the blood and bone marrow. Chronic leukemia uses two different staging systems, both based on the parts of the body affected by the leukemia. For example, chronic lymphocytic leukemia (CLL) is classified by one of two cytologic staging systems, known as the Rai classification and Binet staging, respectively (NCI, 2017a; Swierzewski, 2015).</para>
</listitem></orderedlist></listitem>
<listitem><para><emphasis role="strong">Statistics</emphasis></para>
<orderedlist numeration="loweralpha" inheritnum="ignore" continuation="restarts">
<listitem><para>Morbidity: Based on 2010 to 2014 data, the Survey, Epidemiology, and End Results program (SEER) projected that an estimated 62,130 new cases of leukemia (all types) would be diagnosed in 2017 in the United States, more often in males than females (National Cancer Institute, SEER, 2017a). Based on SEER data gleaned from 2008 to 2013, 60.6% of people diagnosed with leukemia will survive 5 years or more. Advances in the treatment of AML have resulted in substantially improved complete remission (CR) rates (ACS, 2017a).</para></listitem>
<listitem><para>Mortality: Approximately 24,500 deaths from all leukemias were reported for 2010 (National Cancer Institute, SEER, 2017a). Estimated deaths from ALL in 2017 were 1440, and deaths from AML in the same period were estimated at 10,590 (ACS, 2017a). A majority (up to 82%) of those with CLL live 5 to 10 years; however, the presence of complications may shorten survival to 2 to 3 years. The 5-year survival rate for CML increased from 31% in 1992 to 56% for those diagnosed during 2002 to 2008 (National Cancer Institute, SEER, 2017a).</para></listitem>
<listitem><para>Cost: Estimated national expenditures for care were $6.3 billion in 2016 (NCI, 2017b).</para>
</listitem></orderedlist></listitem></orderedlist>
<note id="ch0007s0234note0592">
<title><emphasis role="strong">GLOSSARY</emphasis></title>
<para><emphasis role="strong">Anemia:</emphasis> A low red blood cell (RBC) count. Red blood cells carry oxygen around the body. This condition may contribute to weakness, fatigue, or shortness of breath.</para>
<para><emphasis role="strong">Blast cell:</emphasis> Blood cell that is not fully developed and is still immature.</para>
<para><emphasis role="strong">Leukopenia:</emphasis> A low white blood cell (WBC) count. A decrease in the production of functional WBCs (leukocytes) weakens the body&rsquo;s immune defense, which can make one more prone to infections.</para>
<para><emphasis role="strong">Lymphocytic or lymphoblastic:</emphasis> A cancerous change takes place in a type of marrow cell that forms lymphocytes.</para>
<para><emphasis role="strong">Lymphopenia:</emphasis> Low number of lymphocytes in the blood.</para>
<para><emphasis role="strong">Myelogenous or myeloid:</emphasis> Cancerous change takes place in a type of marrow cell that normally goes on to form red cells, some types of white cells, and platelets.</para>
<para><emphasis role="strong">Neutropenia:</emphasis> Abnormal decrease in the number of neutrophils (type of white blood cell [WBC] that fights infection) in the blood.</para>
<para><emphasis role="strong">Normocytic, normochromic anemia:</emphasis> Anemia associated with disturbances of red cell formation and related to endocrine deficiencies, chronic inflammation, and condition in which cancer is spread widely throughout the body or, in some cases, to a relatively large region of the body.</para>
<para><emphasis role="strong">Progenitor stem cell transplant:</emphasis> Reestablishment of normal bone marrow function through the infusion of cells committed to forming a specific type of blood cell line&mdash;red blood cells (RBCs), WBCs, or platelets. The source of the cells may be from the peripheral blood, bone marrow, or umbilical cord and placenta. The donor may be the client himself or herself (autologous transplant), a genetically compatible relative or individual (allogeneic transplant), or donated cord blood. Syngeneic transplant describes the use of an identical twin as donor.</para>
<para><emphasis role="strong">Thrombocytopenia:</emphasis> Disorder in which there are not enough platelets to perform normal clotting functions. This condition is sometimes associated with abnormal bleeding.</para>
<para><emphasis role="strong">Tumor lysis syndrome (TLS):</emphasis> Metabolic derangement produced by rapid tumor breakdown as a consequence of therapy. TLS is most likely to occur in clients who have hematologic malignancies (Kaplow &amp; Iyere, 2016). It is characterized by hyperuricemia due to DNA breakdown, hyperkalemia because of cytosol breakdown, hyperphosphatemia because of protein breakdown, and hypocalcemia secondary to hyperphosphatemia. As phosphate level increases, serum calcium decreases. These derangements can result in acute renal failure, cardiac dysrhythmias, and sudden death from hyperkalemia or hypocalcemia.</para>
</note>
<sect2 id="ch0007s0235"><title><emphasis role="strong">CARE SETTING</emphasis></title>
<para>Client receives acute inpatient care on medical or oncology unit for initial evaluation and intermittently for treatment, and then care is provided at the community level.</para>
</sect2>
<sect2 id="ch0007s0236"><title><emphasis role="strong">RELATED CONCERNS</emphasis></title>
<para><link linkend="ch0014s0370">Cancer, general considerations</link></para>
<para><link linkend="ch0014s0338">Psychosocial aspects of care</link></para>
<table frame="top" id="ch0007s0234ta0334"><title><emphasis role="strong">CLIENT ASSESSMENT DATABASE</emphasis></title>
<tgroup colsep="0" rowsep="0" cols="2">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Data depend on degree and duration of the disease and other organ involvement.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">DIAGNOSTIC DIVISION<?lb?>MAY REPORT</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">MAY EXHIBIT</emphasis></para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">ACTIVITY/REST</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Fatigue, increased need for sleep; malaise</para></listitem>
<listitem><para>Weakness, inability to engage in usual activities</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Muscle wasting</para></listitem>
<listitem><para>Somnolence, lethargy</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">CIRCULATION</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Palpitations</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Tachycardia, heart murmurs</para></listitem>
<listitem><para>Pallor of skin, mucous membranes</para></listitem>
<listitem><para>Cranial nerve deficits and signs of cerebral hemorrhage</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">EGO INTEGRITY</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Feelings of helplessness, hopelessness</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Mood changes, confusion</para></listitem>
<listitem><para>Depression, withdrawal, anxiety, fear, anger, irritability</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">ELIMINATION</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Diarrhea</para></listitem>
<listitem><para>Bright red blood or tarry stools</para></listitem>
<listitem><para>Perianal tenderness, pain</para></listitem>
<listitem><para>Blood in urine, decreased urine output</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Diarrhea</para></listitem>
<listitem><para>Bright red blood or tarry stools</para></listitem>
<listitem><para>Perianal abscess</para></listitem>
<listitem><para>Hematuria</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">FOOD/FLUID</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Loss of appetite, change in taste</para></listitem>
<listitem><para>Nausea; vomiting</para></listitem>
<listitem><para>Weight loss</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Anorexia; vomiting</para></listitem>
<listitem><para>Abdominal distention, enlarged liver or spleen, decreased bowel sounds</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">NEUROSENSORY</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Lack of or decreased coordination</para></listitem>
<listitem><para>Muscle cramping</para></listitem>
<listitem><para>Dizziness; numbness, tingling, paresthesias</para></listitem>
<listitem><para>Mood changes, confusion, disorientation, lack of concentration</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Muscle irritability</para></listitem>
<listitem><para>Uncoordinated movements</para></listitem>
<listitem><para>Seizure activity</para></listitem>
<listitem><para>Mood changes, confusion, disorientation, lack of concentration</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">PAIN/DISCOMFORT</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Abdominal pain</para></listitem>
<listitem><para>Bone, joint pain&mdash;knees, hips, shoulders, long bones sternum</para></listitem>
<listitem><para>Headaches</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Guarding or distraction behaviors, restlessness</para></listitem>
<listitem><para>Self-focus</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">RESPIRATION</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Shortness of breath with minimal exertion</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Dyspnea, tachypnea</para></listitem>
<listitem><para>Cough</para></listitem>
<listitem><para>Decreased breath sounds</para></listitem>
<listitem><para>Crackles, rhonchi</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">SAFETY</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>History of recent or recurrent infections</para></listitem>
<listitem><para>Falls</para></listitem>
<listitem><para>Visual disturbances or impairment</para></listitem>
<listitem><para>Nosebleeds or other hemorrhages, spontaneous uncontrollable bleeding with minimal trauma</para></listitem>
<listitem><para>Skin and tissue changes</para></listitem>
<listitem><para>History of exposure to chemicals&mdash;benzene (commercially used toxic liquid that is also present in lead-free gasoline), or excessive levels of ionizing radiation</para></listitem>
<listitem><para>Exposure to virus&mdash;human T-cell leukemia or lymphoma virus 1 (HTLV-1)</para></listitem>
</itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Fever, infections</para></listitem>
<listitem><para>Papilledema and exophthalmos; retinal hemorrhages</para></listitem>
<listitem><para>Bleeding from orifices or tissues</para></listitem>
<listitem><para>Gum hypertrophy (may be indicative of AML)</para></listitem>
<listitem><para>Petechiae; bruises, purpura</para></listitem>
<listitem><para>Leukemic infiltrates (flesh-colored to violet-colored papules, plaques, or nodules in the dermis)</para></listitem>
<listitem><para>Jaundice</para></listitem>
<listitem><para>Swollen lymph nodes in neck, armpit, or groin</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">SEXUALITY</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Changes in libido</para></listitem>
<listitem><para>Changes in menstrual flow, menorrhagia</para></listitem>
<listitem><para>Testicular pain; impotence</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">TEACHING/LEARNING</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Previous treatment with chemotherapy&mdash;especially alkalizing agents</para></listitem>
<listitem><para>Chromosomal disorder&mdash;Down&rsquo;s syndrome or Fanconi&rsquo;s aplastic anemia</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">DISCHARGE PLAN CONSIDERATIONS</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>May need assistance with therapy and treatment needs and supplies, shopping, food preparation, self-care activities, homemaker and maintenance tasks, transportation</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para><inlinemediaobject><imageobject><imagedata fileref="pa.jpg"/></imageobject></inlinemediaobject> Refer to section at end of plan for postdischarge considerations.</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
</entry></row></tbody></tgroup></table>
<table frame="top" id="ch0007s0234ta0335"><title><emphasis role="strong">DIAGNOSTIC STUDIES</emphasis></title>
<tgroup colsep="0" rowsep="0" cols="3">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<colspec colnum="3" colname="3" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom" spanname="1-2">
<para><emphasis role="strong">TEST<?lb?>WHY IT IS DONE</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">WHAT IT TELLS ME</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">BLOOD TESTS</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis>Note:</emphasis> Once a diagnosis of leukemia is obtained, additional tests may be performed. These tests may include (and are not limited to) immunophenotyping, fluorescence in situ hybridization (FISH), and IgVH gene mutation test. These more sophisticated tests are not included in this text.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Complete blood count (CBC):</emphasis> The most common screening and diagnostic test to demonstrate leukemia. Typically includes hemoglobin (Hgb), hematocrit (Hct), RBC count and morphology and distribution width index, platelet count and size, and WBC count and differential.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>RBC and platelet production is decreased by the leukemic cells and suppression of normal bone marrow activity. WBCs are usually elevated, and in acute leukemia, blasts cells (typically found in bone marrow) may be present in circulating blood. <emphasis>Note:</emphasis> Normally, blasts constitute 5% or less of healthy bone marrow, but in acute, newly diagnosed, or recurrent leukemia, the blasts remain immature and multiply continuously, eventually constituting between 30% and 100% of the bone marrow (Pui et al, 2008)</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">White blood cell (WBC) count and differential:</emphasis> Evaluates numbers and characteristics of each of the five types of WBCs: neutrophils, lymphocytes (B cells and T cells), monocytes, eosinophils, and basophils within the bloodstream.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Persons with ALL or AML often have too many leukocytes&mdash;count may be more than 50,000/cm&mdash;with increased numbers of immature WBCs (&ldquo;shift to left&rdquo;). Leukemic blast cells may be present.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Platelet count:</emphasis> Platelets have essential function in coagulation.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May vary from normal to very low (&lt;50,000/mm). <emphasis>Note:</emphasis> Significant bleeding typically does not occur until platelet level drops below 20,000/mm.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Prothrombin time (PT)/activated partial thromboplastin time (aPTT):</emphasis> Determines bleeding and clotting time.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May be prolonged. Disseminated intravascular coagulation (DIC) may occur with AML, but it is especially common in acute promyelocytic leukemia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Blood chemistries:</emphasis> Measures the type and amount of enzymes, minerals, and other substances within the blood.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Identifies kidney or liver damage that may be caused by leukemic cell breakdown or by drugs used for chemotherapy.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Alkaline phosphatase (ALP):</emphasis> Aids in differential diagnosis.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Elevated with CML.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Lactic dehydrogenase (LDH):</emphasis> Substance released by tumors and found in blood.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>It is considered an accurate marker for the severity of the disease and used to establish a baseline to monitor for response to treatment.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Serum vitamin B<subscript>12</subscript>:</emphasis> May aid in differential diagnosis of type of leukemia and other myeloproliferative conditions.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Can be increased with CML and some forms of acute leukemia; normal in CLL and undifferentiated stem cell leukemia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Uric acid:</emphasis> Waste product resulting from the breakdown of nitrogen-containing compounds (purines).</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Commonly elevated in client with chemotherapy induction. However, if uric acid is significantly elevated, it is indicative of kidney problems, often associated with tumor lysis syndrome (TLS) (see <link linkend="ch0007s0239note0604">Glossary</link>).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">OTHER DIAGNOSTIC STUDIES</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Computed tomography (CT) scan:</emphasis> Computer-assisted x-ray that produces cross-sectional images of the body.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>CT scans are not usually used in client with leukemia unless metastasis is suspected. In such cases, CT scan may detect changes in the lymph nodes around the heart, trachea, or abdomen. Lymph node enlargement is more common in patients with ALL or CLL with potential for compression of organs or internal structures, such as airway obstruction or obstructive uropathy. Scans of liver and spleen may reveal splenomegaly.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">X-rays:</emphasis> Determine areas of involvement.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May reveal enlarged lymph nodes in the chest, a localized mass in the lungs, or evidence that leukemia has spread to bones or joints.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Bone marrow aspiration and biopsy:</emphasis> May be done by needle aspirate or biopsy for microscopic examination of fluid and tissues within the marrow to determine the number, size, and shape of the various cell types as well as the proportion of mature to immature cells.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Although signs of leukemia are evident in CBC results and platelet counts, a bone marrow biopsy may be necessary for a definitive diagnosis. The bone marrow examination determines the cell type, the type of erythropoiesis, and the maturity of the leukopoietic and erythropoietic cells.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">DEFINITIVE DIAGNOSTIC STUDIES</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Cytogenetic analysis:</emphasis> Cells are studied to see if chromosomal abnormalities are present.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Examination of chromosome abnormalities from samples of peripheral blood, bone marrow, or lymph nodes can indicate prognostic features and direct treatment options.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Flow cytometry (also called immunophenotyping):</emphasis> Uses antibodies to treat the bone marrow or biopsy samples; specific cells undergo a color change that can be identified under microscope.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Allows for identification of cells and differentiating characteristics of specific types of leukemia.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top" spanname="1-2">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Lumbar puncture:</emphasis> Determines if cancer has spread to spinal column or brain.</para></listitem></itemizedlist>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>May reveal leukemic cells in cerebrospinal fluid (CSF).</para>
</entry></row></tbody></tgroup></table>
</sect2>
<sect2 id="ch0007s0237"><title><emphasis role="strong">NURSING PRIORITIES</emphasis></title>
<orderedlist numeration="arabic" inheritnum="ignore" continuation="restarts">
<listitem><para>Prevent infection during acute phases of disease and treatment.</para></listitem>
<listitem><para>Maintain circulating blood volume.</para></listitem>
<listitem><para>Alleviate pain.</para></listitem>
<listitem><para>Promote optimal physical functioning.</para></listitem>
<listitem><para>Provide psychological support.</para></listitem>
<listitem><para>Provide information about disease process, prognosis, and treatment needs.</para></listitem></orderedlist>
</sect2>
<sect2 id="ch0007s0238"><title><emphasis role="strong">DISCHARGE GOALS</emphasis></title>
<orderedlist numeration="arabic" inheritnum="ignore" continuation="restarts">
<listitem><para>Complications prevented or minimized.</para></listitem>
<listitem><para>Pain relieved or controlled.</para></listitem>
<listitem><para>Activities of daily living (ADLs) met by self or with assistance.</para></listitem>
<listitem><para>Dealing with disease realistically.</para></listitem>
<listitem><para>Disease process, prognosis, and therapeutic regimen understood.</para></listitem>
<listitem><para>Plan in place to meet needs after discharge.</para></listitem></orderedlist>
<para><emphasis role="strong">***Refer to CP: <link linkend="ch0014s0370">Cancer</link> for further discussion and expansion of interventions related to cancer care and for client teaching.</emphasis></para>
<note id="ch0007s0234note0593">
<title><emphasis role="strong">NURSING DIAGNOSIS: risk for Infection</emphasis></title>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Stasis of body fluids, traumatized tissue, invasive procedures</para>
<para>Immature WBCs with low granulocyte and abnormal/immature lymphocyte count; immunosuppression, bone marrow suppression; pharmaceutical agents</para>
<para>Malnutrition; chronic disease</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Risk Control: Infectious Process</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Identify actions to prevent or reduce risk of infection.</para>
<para>Demonstrate techniques or lifestyle changes to promote safe environment and achieve timely healing.</para>
</note>
<note role="none" id="ch0007s0234note0594"><table frame="top" id="ch0007s0234ta0336"><title/>
<tgroup colsep="0" rowsep="0" cols="3">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<colspec colnum="3" colname="3" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom" spanname="1-2">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Infection Protection</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Place in private room. Screen and limit visitors, as indicated. Prohibit use of live plants or cut flowers. Restrict fresh fruits and vegetables or make sure they are washed or peeled.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Protect client from potential sources of pathogens and infection. <emphasis>Note:</emphasis> Profound bone marrow suppression, neutropenia, and chemotherapy place client at great risk for infection.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Model and require good handwashing protocol for all personnel and visitors.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Prevents cross-contamination and reduces risk of infection.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor temperature. Note correlation between temperature elevations and chemotherapy treatments. Observe for fever associated with tachycardia, hypotension, and subtle mental changes.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Although fever may accompany some forms of chemotherapy, progressive hyperthermia occurs in some types of infections, and fever unrelated to drugs or blood products occurs in most leukemia clients. <emphasis>Note:</emphasis> Septicemia may occur without fever.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Prevent chilling. Force fluids and administer tepid sponge bath.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Helps reduce fever, which contributes to fluid imbalance, discomfort, and central nervous system (CNS) complications.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Encourage frequent turning and deep breathing.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Prevents stasis of respiratory secretions, reducing risk of atelectasis and pneumonia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Auscultate breath sounds, noting crackles and rhonchi; inspect secretions for changes in characteristics, such as increased sputum production or change in sputum color. Observe urine for signs of infection: cloudy, foul smelling, or presence of urgency or burning with voids.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Early intervention is essential to prevent sepsis or septicemia in immunosuppressed person.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Handle client gently. Keep linens dry and wrinkle-free.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Prevents sheet burns (friction injury) and skin excoriation.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Inspect skin for tender, erythematous areas and open wounds. Cleanse skin with appropriate antibacterial solutions.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May indicate local infection. <emphasis>Note:</emphasis> Open wounds may not produce pus because of insufficient number of granulocytes.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Inspect oral mucous membranes. Provide good oral hygiene. Use a soft toothbrush, sponge, or swabs for frequent mouth care.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>The oral cavity is an excellent medium for growth of organisms and is susceptible to ulceration and bleeding.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Promote good perianal hygiene. Examine perianal area at least daily during acute illness. Provide sitz baths, using Betadine or Hibiclens&trade;, if indicated. Avoid rectal temperatures and use of suppositories.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Promotes cleanliness, reducing risk of perianal abscess; enhances circulation and healing. <emphasis>Note:</emphasis> Perianal abscess can contribute to septicemia and death in immunosuppressed clients.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Coordinate procedures and tests to allow for uninterrupted rest periods.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Conserves energy for healing and cellular regeneration.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Encourage increased intake of fluids and foods high in protein with adequate fiber.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Promotes healing and prevents dehydration. <emphasis>Note:</emphasis> Constipation potentiates retention of toxins and risk of rectal irritation and tissue injury.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Prepare for/assist with invasive procedures, such as venipuncture, insertion of semipermanent central lines or ports, maintaining sterile technique for insertions and site care per protocol.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Break in skin could provide an entry for pathogenic and potentially lethal organisms. Use of central venous lines, such as tunneled catheter or implanted port, can effectively reduce need for frequent invasive procedures and risk of infection. <emphasis>Note:</emphasis> Myelosuppression may be cumulative in nature, especially when multiple drug therapy, including steroids, is prescribed.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Collaborative</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor laboratory studies, such as the following:</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>CBC, noting whether WBC count falls or sudden changes occur in neutrophils</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Decreased numbers of normal or mature WBCs can result from the disease process or chemotherapy, compromising the immune response and increasing risk of infection.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Gram&rsquo;s stain cultures and sensitivity</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Verifies presence of infections; identifies specific organisms and appropriate therapy.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Review serial chest x-rays.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Indicator of development or resolution of respiratory complications.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Prepare for and assist with leukemia-specific treatments, such as chemotherapy with neoplastic agents; biological therapy (immune modulators [such as interferons] and gene-directed agents [such as imatinib]); radiation, bone marrow and stem cell transplantation. (Refer to ND: <link linkend="ch0007s0239note0613">deficient Knowledge</link> at end of this care plan for information regarding leukemia-specific medications and other treatments.)</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Leukemia treatment falls into two categories: (1) treatment to fight the cancer and (2) treatment to relieve symptoms of the disease and the side effects of therapy (supportive care). A variety of treatment options are available, depending on the type and phase of the client&rsquo;s disease. The most widely used antileukemic treatment is chemotherapy (of which there are many different drugs), typically given in cycles, sometimes referred to as induction, consolidation, and maintenance (Hu, 2016; Seiter, 2017).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer other medications, as indicated, for example:</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Anti-infectives, such as ofloxacin (Ocuflox) and rifampin (Rifadin)</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May be given prophylactically or to treat specific infection, especially in febrile client who has prolonged granulocytopenia or too few mature neutrophils (Seiter, 2017).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Colony-stimulating factors (CSFs), such as sargramostim (Leukine), filgrastim (Neupogen), and pegfilgrastim (Neulasta)</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Restores WBCs destroyed by chemotherapy and reduces risk of severe infection and death in certain types of leukemia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Avoid use of aspirin-containing antipyretics.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Aspirin can cause gastric bleeding and further decrease platelet count.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Provide nutritious diet, high in protein and calories, avoiding raw fruits, vegetables, or uncooked meats.</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Proper nutrition enhances immune system. Minimizes potential sources of bacterial contamination.</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0234note0595">
<title><emphasis role="strong">NURSING DIAGNOSIS: risk for deficient Fluid Volume</emphasis></title>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>[Hypertonic or hypotonic dehydration associated with chronic illness, malnutrition, inadequate free water, renal insufficiency or failure]; compromised regulatory system</para>
<para>Active fluid loss&mdash;vomiting, hemorrhage, diarrhea</para>
<para>Insufficient fluid intake&mdash;nausea, anorexia</para>
<para>Factors influencing fluid needs&mdash;hypermetabolic state, fever, predisposition for kidney stone formation and tumor lysis syndrome</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Hydration</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Demonstrate adequate fluid volume, as evidenced by stable vital signs; palpable pulses; urine output, specific gravity, and pH within normal limits.</para>
<para><emphasis role="strong">Risk Control: Dehydration</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Identify individual risk factors and appropriate interventions.</para>
<para>Initiate behaviors or lifestyle changes to prevent development of dehydration.</para>
</note>
<note role="none" id="ch0007s0234note0596"><table frame="top" id="ch0007s0234ta0337"><title/>
<tgroup colsep="0" rowsep="0" cols="3">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<colspec colnum="3" colname="3" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom" spanname="1-2">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Fluid Management</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor intake and output (I&amp;O). Calculate insensible losses and fluid balance. Note decreased urine output in the presence of adequate hydration.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>These symptoms can occur if circulating volume depletion (shock) is present or if complications of chemotherapy are occurring. <emphasis>Note:</emphasis> In the setting of chemotherapy induction, kidney function can be impaired by tumor lysis syndrome (TLS). TLS is the result of cancer cells being destroyed, resulting in toxins (from cell death), and the release of large amounts of potassium, phosphate, and nucleic acids into systemic circulation. This process impairs kidney renal tubular function and filtration (acute kidney injury), potentially leading to renal failure. TLS is an oncologic emergency (Larson &amp; Pui, 2017).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Weigh daily.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Measure of adequacy of fluid replacement and kidney function. Continued intake greater than output may indicate renal insult or obstruction.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor blood pressure (BP) and heart rate.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Changes may reflect effects of hypovolemia associated with bleeding or dehydration.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Evaluate skin turgor, capillary refill, and general condition of mucous membranes.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Indirect indicators of fluid status.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Note presence of nausea or fever.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Affects intake, fluid needs, and route of replacement.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Encourage liberal fluids when oral intake is resumed.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Promotes urine flow, prevents uric acid precipitation, and enhances clearance of antineoplastic drugs.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Bleeding Precautions</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Inspect skin and mucous membranes for petechiae and ecchymotic areas; note bleeding gums, frank or occult blood in stools and urine, and oozing from invasive line sites.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Suppression of bone marrow and platelet production places client at risk for spontaneous or uncontrolled bleeding.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Implement measures to prevent tissue injury and bleeding: gentle brushing of teeth or gums with soft toothbrush, cotton swab, or sponge-tipped applicator; using electric razor instead of sharp razors when shaving; avoiding forceful nose blowing and needlesticks when possible; and using sustained pressure such as sandbags or pressure dressings on oozing puncture or intravenous (IV) sites.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Fragile tissues and altered clotting mechanisms increase the risk of hemorrhage following even minor trauma.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Limit oral care to mouth rinse, if indicated, such as a mixture of 1/4 tsp baking soda and 1/8 tsp salt in 8 oz water, or may use hydrogen peroxide in water or saline for bleeding or infected oral tissue. Avoid mouthwashes with alcohol.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>When bleeding is present, even gentle brushing may cause more tissue damage. Alcohol has a drying effect and may be painful to irritated tissues.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Provide soft foods.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May help reduce risk of gum bleeding.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Fluid Management</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Collaborative</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer IV and electrolyte solutions, as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Maintains fluid and electrolyte balance in the absence of oral intake. Hydration prevents or minimizes tumor lysis syndrome and reduces risk of renal complications. The goal of IV hydration is to improve renal perfusion and glomerular filtration, and induce a high urine output to minimize the likelihood of uric acid or calcium phosphate precipitation in the tubules. <emphasis>Note:</emphasis> IV hydration can lead to potentially dangerous fluid overload in patients with underlying acute kidney injury or cardiac dysfunction (particularly if the patient is in an edematous state). In this setting, close monitoring of vital signs and urine output is mandatory, transfusion (if needed) should be given slowly and in low volume, and diuretics can be given to maintain urine output.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer medications, as indicated, for example:</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Antiemetics: such as ondansetron (Zofran), inapsine (Droperidol), aprepitant (Emend), and dronabinol (Marinol)</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared side effects of chemotherapy. With the correct use of antiemetics, CINV can be prevented in 70% to 80% of patients (NCI, 2017d; Jordan et al, 2014). Relieving nausea and vomiting can reduce fluid deficits and enhance oral intake.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Allopurinol (Zyloprim), rasburicase (Elitek)</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Drugs such as these may be given prophylactically to prevent TLS at chemotherapy induction and duration of treatment or to improve renal excretion of toxic by-products from tumor lysis. Reduces the chances of nephropathy as a result of uric acid production.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Bleeding Precautions</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor laboratory studies, including red blood cells, platelets, and Hgb/Hct.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Low red blood cell counts can be associated with the leukemia (anemia because of reduction in/destruction of bone marrow cells). If Hgb and Hct are both decreased, bleeding may be occurring. Platelets are the blood cells responsible for blood clotting. When the platelet count is less than 20,000/mm because of proliferation of WBCs or bone marrow suppression, client is prone to spontaneous bleeding.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Assist with insertion/maintain central vascular access device, such as subclavian or tunneled catheter or implanted port, as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Client with leukemia may require central vascular access to ensure delivery of intravenous therapy and to eliminate peripheral venipuncture as source of bleeding.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer packed RBCs, platelets, and clotting factors.</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Transfusions may be required from time to time to correct anemia and support clotting. Platelets or fresh-frozen plasma (FFP) may be used to prevent or treat hemorrhage (Seiter, 2017).</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0234note0597">
<title><emphasis role="strong">NURSING DIAGNOSIS: acute Pain</emphasis></title>
<para><emphasis role="strong">May Be Related To</emphasis></para>
<para>Physical agents&mdash;enlarged organs and lymph nodes, bone marrow packed with leukemic cells</para>
<para>Chemical agents&mdash;antileukemic treatments</para>
<para>Psychological&mdash;anxiety, fear</para>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Verbalized/coded reports of pain</para>
<para>Guarding behaviors</para>
<para>Expressive behaviors&mdash;facial grimacing, restlessness</para>
<para>Changes in vital signs</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Pain Level</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Report pain is relieved or controlled.</para>
<para>Appear relaxed and able to sleep and rest appropriately.</para>
<para><emphasis role="strong">Pain Control</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Demonstrate behaviors to manage pain.</para>
</note>
<note role="none" id="ch0007s0234note0598"><table frame="top" id="ch0007s0234ta0338"><title/>
<tgroup colsep="0" rowsep="0" cols="3">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<colspec colnum="3" colname="3" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom" spanname="1-2">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Pain Management: Acute</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Investigate reports of pain. Note changes in intensity (using 0 to 10 [or similar] scale) and location of pain.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Helpful in understanding client&rsquo;s situation and intervention needs and monitoring potential of developing complications.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor vital signs, noting changes in blood pressure, heart rate, and breathing pattern. Note nonverbal cues, such as facial mask of pain, grimacing, crying, withdrawal, muscle tension, and restlessness.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Indicators of acute pain that can corroborate verbal reports or may be only indicators in client unable or unwilling to verbalize pain. Client with long-term condition may have acute pain superimposed on chronic pain issues and be reluctant to report new symptoms. Older client may or may not report pain but may have more pain behaviors.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Determine client&rsquo;s acceptable level of pain and help client achieve pain control.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Pain is a subjective experience and needs to be fully addressed by care providers to promote the best possible quality of life. Client may report having a level of discomfort that is manageable (e.g., can do desired activities when pain is reduced from a 10 to a 3). Another client may need to be pain-free in order to function.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Provide quiet environment and reduce stressful stimuli: noise, lighting, and constant interruptions.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Promotes rest and enhances coping abilities.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Place in position of comfort, and support joints and extremities with pillows and other padding.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May decrease associated bone and joint discomfort.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Reposition periodically and provide or assist with gentle range-of-motion (ROM) exercises.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Improves tissue circulation and joint mobility.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Provide comfort measures, such as massage, cool packs, and psychological support, including encouragement and presence, as appropriate.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Nonpharmacologic measures can enhance effects of medication.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Review and promote client&rsquo;s own comfort interventions&mdash;position and physical activity or nonactivity.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Successful management of pain requires client involvement. Use of effective techniques provides positive reinforcement, promotes sense of control, and prepares client for interventions to be used after discharge.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Evaluate and support client&rsquo;s coping mechanisms.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Using own learned perceptions and behaviors to manage pain can help client cope more effectively.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Encourage use of stress management techniques, such as deep-breathing exercises, guided imagery, visualization, and Therapeutic Touch.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Facilitates relaxation, augments pharmacological therapy, and enhances coping abilities.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Assist with or provide diversional activities and relaxation techniques.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Helps with pain management by redirecting attention.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Collaborative</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor uric acid level as appropriate.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Rapid turnover and destruction of leukemic cells during chemotherapy can elevate uric acid, causing swollen painful joints in some clients. <emphasis>Note:</emphasis> Massive infiltration of WBCs into joints can also result in intense pain.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer medications, as indicated, for example:</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Analgesics, such as acetaminophen (Tylenol)</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Given for mild pain not relieved by comfort measures. <emphasis>Note:</emphasis> Avoid aspirin-containing products because they may potentiate hemorrhage.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Opioids, such as codeine, morphine, and hydromorphone (Dilaudid)</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Routinely scheduled medication administration or patient-controlled analgesia (PCA) is beneficial in preventing peaks and valleys associated with intermittent drug administration and increases client&rsquo;s sense of control.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Antianxiety agents, such as diazepam (Valium) and lorazepam (Ativan)</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>May be given to enhance the action of analgesics and opioids.</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0234note0599">
<title><emphasis role="strong">NURSING DIAGNOSIS: Fatigue</emphasis></title>
<para><emphasis role="strong">May Be Related To</emphasis></para>
<para>Physiological condition (e.g., disease state; malnutrition; anemia)</para>
<para>Stressors; anxiety; negative life events; sleep deprivation</para>
<para>Altered body chemistry (e.g., medications, chemotherapy)</para>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Insufficient energy; impaired ability to maintain usual routines or physical activity</para>
<para>Tiredness, nonrestorative sleep pattern; increase in physical symptoms</para>
<para>Lethargy; apathy; drowsiness; alteration in concentration</para>
<para>Disinterest in surroundings; ineffective role performance</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Fatigue Level</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Report improved sense of energy; measurable increase in activity tolerance.</para>
<para>Participate in ADLs to level of ability.</para>
<para>Demonstrate a decrease in physiological signs of intolerance&mdash;pulse, respiration, and BP remain within client&rsquo;s normal range.</para>
</note>
<note role="none" id="ch0007s0234note0600"><table frame="top" id="ch0007s0234ta0339"><title/>
<tgroup colsep="0" rowsep="0" cols="2">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">Energy Management</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Be aware of client&rsquo;s particular type and severity of leukemia, as well as typical treatment-related symptoms and/or side effects.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Cancer-related fatigue (CRF) is one of the most common side effects of cancer and its treatments and can affect client in varying degrees of magnitude and at different times.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Evaluate and document client&rsquo;s reports of fatigue, using fatigue inventory or numeric (or similar scale), noting client&rsquo;s account of inability to participate in desired activities. Determine alleviating and exacerbating factors.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Evaluation and documentation of subjective reports and objective signs of fatigue are useful for the client and necessary for healthcare provider to establish baseline and effects of interventions. Effects of the disease process, anemia, tumor-induced toxins, pain, depression, and malnutrition associated with chemotherapy can be cumulative, especially during acute and active treatment phase (NCI, 2017d). <emphasis>Note:</emphasis> CRF often comes on suddenly, does not result from activity or exertion, and is not relieved by rest or sleep.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Note client&rsquo;s nutritional status, including appetite, ability and desire to eat, current weight, presence of generalized and muscle weakness.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Factors interfering with intake of needed nutrients can exacerbate fatigue.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Assess for pain and effectiveness of pain management interventions. Note side effects of prescribed analgesics.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Unrelieved pain often increases fatigue. And while pharmacologic pain management can improve client&rsquo;s sense of energy, the medications themselves can exacerbate fatigue.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Determine presence of/client&rsquo;s level of emotional distress (e.g., frustration, fear, anxiety, depression).</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Many stressors are associated with the disease process, treatments and treatment-related symptoms, and lifestyle impact. Interventions are needed ongoing (both within and without medications) to promote client&rsquo;s emotional comfort and reduce associated fatigue.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Active-listen to client/SO concerns and coping. Provide information about disease process and desired treatment responses. Provide supportive presence and interventions.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Client may or may not have information about disease process or expectations for treatment. Information (e.g., that sometimes treating the anemia can reduce the fatigue) can improve client/SO&rsquo;s coping abilities. Additional supportive interventions may be needed when client is severely ill or fatigue is chronic.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Encourage client at home to keep a diary of daily routines and energy levels for 1 week, noting activities that increase fatigue.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Helps client prioritize activities and arrange them around fatigue pattern.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Provide quiet environment for sleep and uninterrupted rest periods. Encourage rest periods before activities known to increase fatigue.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Restores energy needed for activity and cellular regeneration and tissue healing.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Implement (and teach) energy-saving techniques, such as sitting rather than standing, or alternate; use shower chair and furniture with good support; combine activities, reducing number of individual actions, reduce sudden or prolonged strains, and so on. Assist with ambulation or other activities, as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Maximizes available energy for self-care tasks.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Recommend frequent small, nutritious, high-protein meals and snacks throughout the day if client is able to eat.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Smaller meals require less energy for ingestion and digestion than larger meals. Increased intake provides fuel for energy. (Refer to CP: <link linkend="ch0014s0370">Cancer, general considerations</link>: ND: <link linkend="ch0014s0355note0574">imbalanced Nutrition: less than body requirements</link>.)</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Determine presence and level of attentional fatigue. Provide and encourage use of diversional activities, as tolerated and desired.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>The planned use of attention-restoring activities (e.g., watching grandchildren play, following a simple recipe, attending a movie, window gardening) can improve mood and fatigue associated with inactivity and depression.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="bi">Collaborative</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Review laboratory studies (initial and ongoing) such as CBC and red blood cell indices, nutrition state indicators, and vitamin levels.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>These lab values (among others) can help identify presence/degree of anemia and other disease- or treatment-related factors associated with fatigue.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Refer to appropriate medical providers, and assist in management of underlying condition, as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Sometimes treating the disease symptoms (e.g., anemia) will relieve the fatigue. But other interventions may be needed over time, such as discontinuation of certain anticancer drugs, implementation of dietary changes, and titration of pain medications, initiation of physical activity (e.g., graded walking program) to manage fatigue and its effect on client&rsquo;s quality of life.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Administer medications (e.g., nutrient components and vitamin supplements; psychostimulants and antidepressants), as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Enteral/parenteral feedings, supplemental protein, calories, or vitamins can improve energy, and medications to manage emotional issues/depression can improve mood and reduce fatigue (NCI, 2017a).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Provide supplemental oxygen, as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Maximizes oxygen available for cellular uptake, improving tolerance of activity, especially in the setting of severe anemia, cardiopulmonary or renal complications.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Administer blood and blood components, as indicated.</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Correcting anemia can improve client&rsquo;s stamina and tolerance for activity.</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0234note0601">
<title><emphasis role="strong">NURSING DIAGNOSIS: deficient Knowledge regarding disease, prognosis, treatment, self-care, and discharge needs</emphasis></title>
<para><emphasis role="strong">May Be Related To</emphasis></para>
<para>Insufficient information/knowledge of resources</para>
<para>Information misinterpretation</para>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Insufficient knowledge</para>
<para>Inaccurate follow-through of instructions</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Knowledge: Acute Illness Care/Knowledge: Chronic Disease Management</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Verbalize understanding of condition, disease process, and potential complications.</para>
<para>Verbalize understanding of therapeutic needs.</para>
<para>Initiate necessary lifestyle changes.</para>
<para>Participate in treatment regimen.</para>
</note>
<note role="none" id="ch0007s0234note0602"><table frame="top" id="ch0007s0234ta0340"><title/>
<tgroup colsep="0" rowsep="0" cols="3">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<colspec colnum="3" colname="3" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<spanspec spanname="1-3" namest="1" nameend="3"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom" spanname="1-2">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Teaching: Disease Process</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Review client&rsquo;s specific form of leukemia and treatment plan, including:</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Treatments can include various individual and combinations of therapies.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Medications, using newer classes of drugs such as <emphasis role="bi">Bcr-Abl tyrosine kinase inhibitors</emphasis> (e.g., imatinib mesylate [Gleevec], dasatinib [Sprycel]); <emphasis role="bi">histone deacetylase inhibitors (HDACs)</emphasis> (e.g., vorinostat [Zolinza]); <emphasis role="bi">hypomethylating or demethylating agents</emphasis> (e.g., azacitidine [Vidaza] and decitabine [Dacogen]); <emphasis role="bi">immunomodulators</emphasis> (e.g., lenalidomide [Revlimid], thalidomide [Thalomid]); <emphasis role="bi">monoclonal antibodies</emphasis> (e.g., rituximab [Rituxan]); <emphasis role="bi">antibody-drug conjugates</emphasis> (e.g., brentuximab vedotin [Adcetris]); <emphasis role="bi">proteasome inhibitors</emphasis> (e.g., bortezomib [Velcade] and carfilzomib [Kyprolis]); <emphasis role="bi">chemotherapy agents</emphasis> (e.g., daunorubicin [Cerubidine], mitoxantrone cytarabine [Novantone], idarubicin [Idamycin])</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>In the past 10 years, several new drugs (and new uses for established drugs) have greatly improved rates of blood cancer cure and remission (LLS, 2014&ndash;2015). Many treatments are targeted to the specific cancer, and combining treating agents is common (Hu, 2016; LLS, 2014&ndash;2015; Seiter, 2017).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Radiation therapy</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Kills cancer cells by exposure to high-energy radiation.</para>
<para>Radiation therapy is typically part of a treatment program including drugs.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Gene therapy</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Gene therapy alters a gene&rsquo;s DNA or RNA expression to disable oncogenes (see <link linkend="ch0007s0239note0604">Glossary</link>) and prevents the formation of corresponding oncoproteins. Gene therapy is considered &ldquo;personalized medicine&rdquo; that can be applied if there is enough information about the individual and/or the specific disease to tailor the treatment (LLS, 2014&ndash;2015).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Stem cell transplantation (SCT), including peripheral stem cell transplant or umbilical cord blood transplant</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>After chemotherapy and/or radiation, the injured bone marrow is replenished by a transplant of stem cells, which can manufacture the necessary new blood cells. Stem cell transplantation may be autologous (uses client&rsquo;s own stem cells) or allogenic (donor cells).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Surgery</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>While rare, surgery may be performed to remove an enlarged spleen or to install a venous access device to give medications and withdraw blood samples (Swierzewski, 2015).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Discuss side effects of treatment, as indicated, and possible solutions.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Client may want opportunity to prepare for certain side effects, such as temporary hair loss. Client and significant other (SO) may benefit from knowledge that certain discomforts, such as nausea, vomiting, weakness, mouth sores, bruising, and anorexia, are treatment related, not indications of escalating disease, and will subside.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Inform client and SO of potential sexual side effects of treatment and provide opportunity to consider options. Discuss sperm banking and pregnancy issues, when appropriate, before beginning treatment.</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>In males, permanent sterility can occur as a result of radiation when combined with certain chemotherapeutic agents. In females, menstruation may cease during the active phase of treatment, with older women subsequently experiencing menopause. Pregnancy should be avoided during treatment and for 2 to 3 years after treatment as that is when recurrence is most common. Vaginal dryness can be a distressing side effect as well.</para>
</entry></row>
</tbody></tgroup></table></note>
<para><emphasis role="strong">For additional interventions, refer to CP: <link linkend="ch0014s0370">Cancer: General Considerations</link>; ND: deficient Knowledge.</emphasis></para>
<note id="ch0007s0234note0603">
<para><emphasis role="strong">POTENTIAL CONSIDERATIONS</emphasis> following acute hospitalization (dependent on client&rsquo;s age, physical condition and presence of complications, personal resources, and life responsibilities)</para>
<itemizedlist mark="&bull;">
<listitem><para><emphasis role="bi">risk for</emphasis>&nbsp;<emphasis role="bi">Infection</emphasis>&mdash;alterations in mature WBCs (low granulocyte and abnormal lymphocyte count), increased number of immature lymphocytes, immunosuppression, bone marrow suppression (effects of therapy/transplant)</para></listitem>
<listitem><para><emphasis role="bi">ineffective Role Performance</emphasis>&mdash;situational crisis, physical illness, fatigue, stressors</para></listitem>
<listitem><para><emphasis role="bi">ineffective Health Management</emphasis>&mdash;difficulty managing complex treatment regimen, decisional conflicts, excessive demands, perceived benefit, powerlessness economically disadvantaged</para></listitem>
<listitem><para><emphasis role="bi">interrupted Family</emphasis>&nbsp;<emphasis role="bi">Processes</emphasis>&mdash;situational crisis (illness, disabling and expensive treatments); shift in health status of a family member, shift in family roles</para></listitem></itemizedlist>
</note>
</sect2></sect1>
<sect1 id="ch0007s0239"><title><emphasis role="strong">ADULT LYMPHOMAS</emphasis></title>
<orderedlist numeration="upperroman" inheritnum="ignore" continuation="restarts">
<listitem><para><emphasis role="strong">Pathophysiology</emphasis></para>
<orderedlist numeration="loweralpha" inheritnum="ignore" continuation="restarts">
<listitem><para><emphasis>Lymphoma</emphasis> is a general term for many blood cancers that originate in the lymphatic system.</para></listitem>
<listitem><para>Malignant growth involving reticuloendothelial and lymphoid system, resulting in accumulation of abnormal lymphocytes in lymph tissue forming masses; may travel to distant sites, including the lungs, liver, gastrointestinal (GI) tract, meninges, skin, and bones (NCI, 2017c).</para></listitem>
<listitem><para>Major sites of lymphoid tissue are lymph nodes, spleen, thymus gland, adenoids and tonsils, and digestive tract. Lymphoma is the second most common primary malignancy occurring in the head and neck (Dunleavy, Kass, &amp; Wilson, 2017).</para>
</listitem></orderedlist></listitem>
<listitem><para><emphasis role="strong">Classifications and treatments (Dunleavy et al, 2017; LSS, 2014&ndash;2015)</emphasis></para>
<orderedlist numeration="loweralpha" inheritnum="ignore" continuation="restarts">
<listitem><para>Lymphomas are divided into two major categories: Hodgkin&rsquo;s lymphoma (HL), formerly called Hodgkin&rsquo;s disease, and non-Hodgkin&rsquo;s lymphoma (NHL).</para></listitem>
<listitem><para>Staging (typically using the Ann Arbor Staging system I&ndash;IV) provides a general idea of how far the disease has spread and how it should be treated. This is done after testing determines which parts of the body are affected.</para></listitem>
<listitem><para>Letters of the alphabet are also used in conjunction with the stage to further describe the lymphoma. The most important ones are A and B. For example, if the client complains of fever, weight loss, or excessive night sweats (called &ldquo;B&rdquo; symptoms), a &ldquo;B&rdquo; is added to the stage description. If none of these symptoms exist, an &ldquo;A&rdquo; is added. If any organ that does not belong to the lymph system is involved, it is denoted with an &ldquo;E&rdquo; for extranodal (organ involvement) after the stage. If the spleen is involved, the corresponding letter is &ldquo;S.&rdquo; An &ldquo;X&rdquo; designation is used for bulky lymphadenopathy (a cancer with considerable tumor masses that may be felt or seen) (Dunleavy et al, 2017).</para>
<orderedlist numeration="lowerroman" inheritnum="ignore" continuation="restarts">
<listitem><para>Hodgkin&rsquo;s lymphoma (HL) is divided into two main classifications: (1) classical HL (CHL), which accounts for most cases of HL, and (2) nodular lymphocyte-predominant HL.</para>
<orderedlist numeration="arabic" inheritnum="ignore" continuation="restarts">
<listitem><para>A characteristic that distinguishes CHL is the presence of a large malignant cell called the Reed-Sternberg (R-S) cell. This characteristic does not appear in nodular lymphocyte-predominant HL.</para></listitem>
<listitem><para>HL status is grouped for treatment (after staging) as early favorable, early unfavorable, and advanced.</para></listitem>
<listitem><para>HL is now considered to be one of the most curable forms of cancer.</para></listitem>
<listitem><para><emphasis role="strong">HL treatments</emphasis> for early stage (I and II) HL include some form of chemotherapy (usually combinations of drugs), plus limited radiation (external or internal involved field or site) therapy, and sometimes bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT). Treatment for advanced stage HL is typically combination chemotherapy (Canellos, 2016; LymphomaInfo.net, 2016; PDQ&trade; Adult Treatment Editorial Board, 2017).</para>
</listitem></orderedlist></listitem>
<listitem><para>Non-Hodgkin&rsquo;s lymphoma (NHL) (LSS, 2014&ndash;2015; PDQ&trade; Adult Editorial Board, 2017)</para>
<orderedlist numeration="arabic" inheritnum="ignore" continuation="restarts">
<listitem><para>Most common cancer of the lymphatic system</para></listitem>
<listitem><para>Incidence is consistently higher than HL, with NHL the sixth most common cancer in the United States (LSS, 2014&ndash;2015).</para></listitem>
<listitem><para>Divided into two broad categories: B-cell or T-cell lymphomas. B-cell lymphomas develop from abnormal B cells and account for 85% of all NHLs. T-cell lymphomas develop from abnormal T cells and account for the remaining 15% of all NHLs.</para></listitem>
<listitem><para>B-cell lymphomas are designated as indolent (slow-growing) or (fast-growing).</para>
<orderedlist numeration="loweralpha" inheritnum="ignore" continuation="restarts">
<listitem><para>Indolent B-cell lymphomas: These lymphomas are characterized by a slow progression because the client can remain well for several years without therapy. These lymphomas include multiple subtypes (e.g., cutaneous T cell, follicular, and small lymphocytic [SLL]). Indolent lymphomas are, however, usually not considered curable because the cancer grows too slowly to be targeted accurately by most conventional therapies (Cyberfamily Staff, 2017).</para></listitem>
<listitem><para>Aggressive B-cell lymphomas: These include diffuse large B-cell lymphoma (DLBC), and Burkitt&rsquo;s, mantle-cell, and lymphoblastic lymphomas. DLBC is the most common type of NHL, making up about 30% of all lymphomas (Freedman &amp; Friedberg, 2017). The standard treatment of advanced DLBCL is combination chemotherapy plus immunotherapy.</para></listitem></orderedlist>
</listitem>
<listitem><para><emphasis role="strong">NHL treatments</emphasis> differ from person to person, depending on the type and stage and whether the disease is indolent or aggressive. In general, treatments include chemotherapy, radiation (whole body or specific zone), newer versions of established agents, immunotherapy (such as monoclonal antibody therapy [Mab]), radioimmunotherapy (which combines radiotherapy with monoclonal antibody therapy), and stem cell bone marrow transplantation. Surgery may be performed to remove the lymphoma in certain circumstances (e.g., gastrointestinal lymphoma with perforation, or splenectomy) (Duleavy et al, 2017; LymphomaInfo.net, 2016; PDQ&trade; Adult Editorial Board, 2017).</para></listitem></orderedlist>
</listitem></orderedlist></listitem></orderedlist></listitem>
<listitem><para><emphasis role="strong">Etiology</emphasis></para>
<orderedlist numeration="loweralpha" inheritnum="ignore" continuation="restarts">
<listitem><para>Exact causes are unknown.</para></listitem>
<listitem><para>Several factors have been linked to an increased risk (Iarocci, 2017; Mayo Clinic Staff, 2017).</para>
<orderedlist numeration="lowerroman" inheritnum="ignore" continuation="restarts">
<listitem><para>Age: Risk of NHL generally increases with advancing age. It is most common in people 60 or older and is greatly increased in people between the ages of 80 and 84 (LLS, 2014&ndash;2015).</para></listitem>
<listitem><para>Infections: Bacteria, viruses, and parasites have all been implicated in the development various lymphomas, including HL and NHL. For example, human T-lymphocytic virus type 1 (HTLV-1) has been linked to adult T-cell leukemia-lymphoma (ATL); Epstein-Barr virus (EBV) has been linked to Burkitt&rsquo;s lymphoma; <emphasis>Helicobacter pylori</emphasis> (<emphasis>H. pylori</emphasis>) has been linked to gastric lymphoma of mucosa-associated lymphoid tissue (MALT), a rare type of NHL.</para></listitem>
<listitem><para>Medical conditions that suppress the immune system, such as HIV, rheumatoid arthritis; conditions requiring immunosuppressive therapy, such as organ transplantation</para></listitem>
<listitem><para>Exposure to toxic chemicals: occupational exposure to pesticides, herbicides, or benzene and other solvents; woodworking</para>
</listitem></orderedlist></listitem></orderedlist></listitem>
<listitem><para><emphasis role="strong">Statistics</emphasis></para>
<orderedlist numeration="loweralpha" inheritnum="ignore" continuation="restarts">
<listitem><para>Morbidity: In 2017, there were an estimated 630,037 people living with non-Hodgkin&rsquo;s lymphoma in the United States and 186,607 people living with Hodgkin&rsquo;s lymphoma (LLS, 2016&ndash;2017). The National Cancer Institute SEER report estimated 72,240 new cases of NH for 2017. <ulink url="http://www.Cancer.net">Cancer.net</ulink> estimated that 8260 people would be diagnosed with HL in 2017. The 5-year survival rate, according to <ulink url="http://www.Cancer.net">Cancer.net</ulink>, is 85% to 87% for HL and, according to SEER, is 71% for NHL.</para></listitem>
<listitem><para>Mortality: In 2017, according to SEER and <ulink url="http://www.Cancer.net">Cancer.net</ulink>, there were an estimated 21,200 deaths (1060 from HL and 20,140 from NHL).</para></listitem>
<listitem><para>Cost: In 2016, the national direct costs for care were an estimated $14 billion (NCI, 2017b).</para>
</listitem></orderedlist></listitem></orderedlist>
<note id="ch0007s0239note0604">
<title><emphasis role="strong">GLOSSARY</emphasis></title>
<para><emphasis role="strong">Bone marrow transplant (BMT):</emphasis> Bone marrow is taken from a compatible donor or the client&rsquo;s own body, prior to high-dose chemotherapy and/or radiation treatment. After treatment, the marrow, which may or may not have been treated with chemotherapy, is reinfused into the patient to restore the immune system.</para>
<para><emphasis role="strong">Erythroderma:</emphasis> Generalized redness (erythema) of the skin involving more than 90% of the body surface with variable scaliness (lesions). Skin is red and warm to touch. Client appears uncomfortable, with complaints of intense skin itching and pain and of feeling cold. The most common malignant cause is cutaneous T-cell lymphoma (CTCL) (Mistry et al, 2015).</para>
<para><emphasis role="strong">Hilar lymphadenopathy:</emphasis> Enlargement of the tracheobronchial and pulmonary lymph nodes.</para>
<para><emphasis role="strong">Lymphopenia:</emphasis> Low number of lymphocytes in the blood.</para>
<para><emphasis role="strong">Neuralgia:</emphasis> Pain in the distribution of a nerve or nerve pathway.</para>
<para><emphasis role="strong">Normocytic, normochromic anemia:</emphasis> Anemia associated with disturbances of red blood cell (RBC) formation, which is related to endocrine deficiencies, chronic inflammation, and condition in which cancer is spread widely throughout the body or, in some cases, to a relatively large region of the body.</para>
<para><emphasis role="strong">Pel-Ebstein fever:</emphasis> Fever pattern common in HL, in which temperature varies during each 24-hour period but never reaches normal.</para>
<para><emphasis role="strong">Peripheral blood cell transplantation:</emphasis> The most common form of stem cell transplant with the source of stem cells being the circulating blood, rather than the bone marrow. Client with NHL can have either an autologous or an allogeneic peripheral blood cell transplant, depending on whether or not his or her own stem cells are suitable for use and whether a suitable donor can be found.</para>
<para><emphasis role="strong">Stem cell transplant:</emphasis> Reestablishment of normal bone marrow function through the infusion of cells committed to forming a specific type of blood cell line&mdash;RBCs, white blood cells (WBCs), or platelets. The source of the cells may be from the peripheral blood, bone marrow, or umbilical cord and placenta. The donor may be the client (autologous transplant), a genetically compatible relative or individual (allogeneic transplant), or donated cord blood. Syngeneic transplant describes the use of an identical twin as donor.</para>
<para><emphasis role="strong">Superior vena cava syndrome (SVC):</emphasis> Obstruction of venous drainage from enlarged lymph nodes due to lymphoma disease.</para>
<para><emphasis role="strong">Tumor lysis syndrome:</emphasis> Metabolic derangement produced by rapid tumor breakdown as a consequence of therapy for some lymphomas (e.g., Burkitt&rsquo;s lymphoma, lymphoblastic lymphoma, or B-cell acute lymphoblastic leukemia). It is characterized by hyperuricemia because of DNA breakdown, hyperkalemia because of cytosol breakdown, hyperphosphatemia because of protein breakdown, and hypocalcemia secondary to hyperphosphatemia. As phosphate level goes up, serum calcium goes down. These derangements can result in acute renal failure, cardiac dysrhythmias, and sudden death from hyperkalemia or hypocalcemia. <emphasis>Note:</emphasis> In studies, laboratory evidence of TLS has been found much more frequently (42%) than the clinical symptoms of TLS (6%) (Ikeda et al, 2017).</para>
</note>
<sect2 id="ch0007s0240"><title><emphasis role="strong">CARE SETTING</emphasis></title>
<para>The client receives acute inpatient care on a medical unit for initial evaluation and treatment and then at the community level. This plan of care addresses potential complications that may be encountered in acute care or palliative settings.</para>
</sect2>
<sect2 id="ch0007s0241"><title><emphasis role="strong">RELATED CONCERNS</emphasis></title>
<para><link linkend="ch0007s0234">Adult leukemias</link></para>
<para><link linkend="ch0007s0224">Anemias&mdash;iron deficiency, anemia of chronic disease, pernicious, aplastic, hemolytic</link></para>
<para><link linkend="ch0014s0370">Cancer: general considerations</link></para>
<para><link linkend="ch0014s0338">Psychosocial aspects of care</link></para>
<para><link linkend="ch0013s0318">Sepsis/septic shock</link></para>
<para><link linkend="ch0005s0144">Upper gastrointestinal bleeding</link></para>
<table frame="top" id="ch0007s0239ta0341"><title><emphasis role="strong">CLIENT ASSESSMENT DATABASE</emphasis></title>
<tgroup colsep="0" rowsep="0" cols="2">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">DIAGNOSTIC DIVISION<?lb?>MAY REPORT</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">MAY EXHIBIT</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">ACTIVITY/REST</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Fatigue</para></listitem>
<listitem><para>Weakness or general malaise</para></listitem>
<listitem><para>Loss of productivity and decreased exercise tolerance</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Diminished strength, slumping of the shoulders, slow walk, and other cues indicative of fatigue</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">CIRCULATION</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Palpitations, chest pain</para></listitem>
<listitem><para>Painless swelling of one or more lymph nodes (common early sign in both HL and NHL)</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Tachycardia, dysrhythmias</para></listitem>
<listitem><para>Painless swelling of the lymph nodes, beginning in the neck and progressing to axillary, inguinal, mediastinal, and mesenteric regions</para></listitem>
<listitem><para>Cyanosis and edema of the face and neck or arms due to superior vena cava syndrome, a rare occurrence, but more common in lymphomas with large mediastinal mass</para></listitem>
<listitem><para>Pallor</para></listitem>
<listitem><para>Diaphoresis, night sweats</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">EGO INTEGRITY</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Increased stress from school, job, family</para></listitem>
<listitem><para>Fear related to diagnosis and possibility of dying</para></listitem>
<listitem><para>Concerns about diagnostic testing and treatment modalities&mdash;chemotherapy, radiation therapy, surgery</para></listitem>
<listitem><para>Financial concerns&mdash;hospital costs, treatment expenses, fear of losing job-related benefits because of lost time from work</para></listitem>
<listitem><para>Relationship status&mdash;fear and anxiety related to being a burden on family and significant other (SO)</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Varied behaviors&mdash;angry, withdrawn, passive</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">ELIMINATION</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Changes in characteristics of urine or stool</para></listitem>
<listitem><para>History of intestinal obstruction, such as intussusception or malabsorption syndrome (infiltration from retroperitoneal lymph nodes)</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Decreased output, dark and concentrated urine, anuria</para></listitem>
<listitem><para>Abdomen: Right upper quadrant (RUQ) tenderness and enlargement on palpation (hepatomegaly); left upper quadrant (LUQ) tenderness and enlargement on palpation (splenomegaly)</para></listitem>
<listitem><para>Bowel and bladder dysfunction (spinal cord compression occurs late)</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">FOOD/FLUID</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Anorexia</para></listitem>
<listitem><para>Dysphagia (pressure on the esophagus)</para></listitem>
<listitem><para>Severe nausea and vomiting, often treatment related</para></listitem>
<listitem><para>Recent unexplained weight loss</para></listitem>
<listitem><para>Drenching night sweats of whole body (HL)</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Abdominal distention, enlarged spleen (NHL)</para></listitem>
<listitem><para>Ascites and edema of the lower extremities (inferior vena cava obstruction from intra-abdominal lymph node enlargement associated with NHL)</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">NEUROSENSORY</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Nerve pain reflecting compression of nerve roots by enlarged lymph nodes in the brachial, lumbar, and sacral plexuses</para></listitem>
<listitem><para>Muscle weakness, paresthesia</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Lethargy, withdrawal, general lack of interest in surroundings</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">PAIN/DISCOMFORT</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Bone pain (NHL)</para></listitem>
<listitem><para>Tenderness or pain over involved lymph nodes&mdash;in or around the mediastinum (chest)</para></listitem>
<listitem><para>Stiff neck</para></listitem>
<listitem><para>Abdominal pain (NHL)</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Self-focusing; guarding behaviors</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">RESPIRATION</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Dyspnea on exertion or at rest, chest pain</para></listitem>
<listitem><para>Persistent cough with shortness of breath (HL)</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Dyspnea, tachypnea</para></listitem>
<listitem><para>Dry, nonproductive cough (hilar lymphadenopathy)</para></listitem>
<listitem><para>Hoarseness, laryngeal paralysis (pressure from enlarged nodes on the laryngeal nerve)</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">SAFETY</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>History of frequent or recurrent infections (abnormalities in cellular immunity predispose client to systemic herpes virus infections, tuberculosis [TB], toxoplasmosis, or bacterial infections); history of infectious mononucleosis (higher risk of HL in client with high titers of EBV)</para></listitem>
<listitem><para>HIV positive: Risk of NHL is higher in these clients compared with the general population. However, antiretroviral therapy (ART) has cut the rate of NHL in HIV-positive people significantly (Blahd, 2016).</para></listitem>
<listitem><para>Administration of immunosuppressive drugs after organ transplantation</para></listitem>
<listitem><para>History or presence of ulcers, <emphasis>H. pylori</emphasis></para></listitem>
<listitem><para>Waxing and waning pattern of lymph node size</para></listitem>
<listitem><para>Cyclical pattern of evening temperature elevations lasting a few days to weeks (Pel-Ebstein fever) followed by alternate afebrile periods; drenching night sweats without chills</para></listitem>
<listitem><para>Rash, itching</para></listitem>
<listitem><para>Whole-body red, itchy skin</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Unexplained, intermittent persistent fever without symptoms of infection (HL)</para></listitem>
<listitem><para>Generalized pruritus and urticaria (HL)</para></listitem>
<listitem><para>Scleral icterus and a generalized jaundice related to liver damage and consequent obstruction of bile ducts by enlarged lymph nodes (may be a late sign)</para></listitem>
<listitem><para>Tonsillar or other lymph node enlargement</para></listitem>
<listitem><para>Patchy areas of loss of melanin pigmentation (vitiligo)</para></listitem>
<listitem><para>Ethroderma (red skin inflamed skin on more than 90% of the body)</para></listitem></itemizedlist>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">SEXUALITY</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Concerns about sterility, fertility, and pregnancy</para></listitem>
<listitem><para>Decreased libido</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">TEACHING/LEARNING</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>Familial risk factors&mdash;higher incidence of HL among families than in general population</para></listitem>
<listitem><para>Occupational exposure to pesticides and herbicides or other chemicals&mdash;benzene, creosote, lead, formaldehyde, paint thinner</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">DISCHARGE PLAN CONSIDERATIONS</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para>May need assistance with medical therapies and supplies, self-care activities, and homemaker or home maintenance tasks, transportation, shopping</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para><inlinemediaobject><imageobject><imagedata fileref="pa.jpg"/></imageobject></inlinemediaobject> Refer to section at end of plan for postdischarge considerations.</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
</entry></row></tbody></tgroup></table>
<table frame="top" id="ch0007s0239ta0342"><title><emphasis role="strong">DIAGNOSTIC STUDIES</emphasis></title>
<tgroup colsep="0" rowsep="0" cols="2">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">TEST<?lb?>WHY IT IS DONE</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">WHAT IT TELLS ME</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">BLOOD TESTS</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Blood studies may vary from completely normal to marked abnormalities.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis>Note:</emphasis> In stage I, few clients have abnormal blood findings.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Complete blood count (CBC):</emphasis> Battery of screening tests, which typically includes hemoglobin (Hgb); hematocrit (Hct); RBC count, morphology, indices, and distribution width index; platelet count and size; and WBC count and differential.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>RBC production may be decreased due to the lymphoma and suppression of bone marrow activity. Client with HL may have mild to severe normocytic, normochromic anemia associated with hypersplenism. WBCs are variable; that is, they may be normal, decreased, or markedly elevated.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Differential WBCs:</emphasis> Percentage of each of the five types of mature WBCs: neutrophils, lymphocytes (B cells and T cells), monocytes, eosinophils, and basophils.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Increased percentage of neutrophils, monocytes, basophils, and eosinophils may be found initially, but these lymphocytes can be profoundly decreased by suppression of marrow activity or by lymphoma treatments. A relative or absolute lymphopenia is a late sign.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Platelets:</emphasis> Platelets have essential function in coagulation.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Decreased in bone marrow involvement or as a side effect of therapy.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Erythrocyte sedimentation rate (ESR):</emphasis> Useful to monitor clients in remission and to detect early evidence of recurrence of disease.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Elevated during active stages and indicates inflammatory or malignant disease.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Serum lactate dehydrogenase (LDH):</emphasis> Substance released by tumors; important prognostic indicator in NHL.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Elevated; may indicate a more aggressive form of NHL.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">OTHER DIAGNOSTIC STUDIES</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Chest x-ray:</emphasis> Determines lung involvement, status of airway, and presence of complications.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May reveal mediastinal or hilar adenopathy, nodular infiltrates, or pleural effusions.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">X-rays or bone scans of thoracic, lumbar vertebrae, proximal extremities, pelvis, or areas of bone tenderness:</emphasis> Determines areas of involvement and assists in staging.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Bone lesions often associated with acute form of adult T-cell or diffuse large B-cell lymphomas.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Computed tomography (CT) scans: e.g., head, neck, chest, abdomen, pelvis:</emphasis> Generally accepted as the primary staging modality for suspected lymphoma and for evaluating therapy response.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Used to assess the extent of disease and responsiveness to therapy. Detects enlarged lymph nodes as well as enlargement of liver and spleen. <emphasis>Note:</emphasis> CT scanning of the head and/or neck is mandatory for client with head and neck presentation or symptoms of cranial neuropathies such as hearing loss, vertigo, or visual changes (Dunleavy et al, 2017). Most people have repeated CT scans to monitor the status of their disease or evaluate for recurrence.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Positron emission tomography (PET) scan:</emphasis> Type of nuclear scan that follows course of injected radioactive glucose. <emphasis role="bi">Positron emission tomography (PET)&ndash;CT scan:</emphasis> Procedure that combines pictures from both procedures. (Done at the same time on the same machine.)</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Malignant cells take up more glucose than normal cells. Thus, PET scanning identifies hypermetabolic areas that suggest malignancy and assists with staging of the disease. <emphasis>Note:</emphasis> Combined images from PET-CT scans provide a more detailed picture than either test would make by itself.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Abdominal ultrasound:</emphasis> Aids in identifying additional sites and assesses organ status.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Evaluates extent of involvement of retroperitoneal lymph nodes and determines size of kidneys and patency of urinary tract in preparation for chemotherapy.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Biopsies (fine-needle aspiration or excisional)</emphasis></para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Establishes diagnosis and cell type involved <emphasis>Note:</emphasis> Presence of Reed-Sternberg cells from blood and lymph cells confirms diagnosis of HL (Foster &amp; Prevost, 2012).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Bone marrow:</emphasis> Sampling may be done by needle aspirate or excisional biopsy to determine bone involvement and staging.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Detects different types of chromosome aberrations and can be used to plan treatment and measure the results of treatment.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Cytogenetic analysis:</emphasis> Cells are studied to see if chromosomal abnormalities are present.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Often used to determine the type of lymphoma cells present. For example, each disease subtype has a specific pattern of markers on its cell surface.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Flow cytometry:</emphasis> Method of counting types of cells with fluorescent tags on the surfaces of the cells.</para></listitem></itemizedlist>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>For some of the more aggressive types of lymphoma, this test can sometimes detect residual disease long before it grows large enough to be detected by any other means.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<itemizedlist mark="&bull;"><listitem><para><emphasis role="bi">Laparotomy or laparoscopy</emphasis></para></listitem></itemizedlist>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Procedures may be done to examine organs inside abdomen for signs of disease and to obtain tissue samples for cytology.</para>
</entry></row></tbody></tgroup></table>
</sect2>
<sect2 id="ch0007s0242"><title><emphasis role="strong">NURSING PRIORITIES</emphasis></title>
<orderedlist numeration="arabic" inheritnum="ignore" continuation="restarts">
<listitem><para>Provide physical and psychological support during extensive diagnostic testing and treatment regimen.</para></listitem>
<listitem><para>Prevent complications.</para></listitem>
<listitem><para>Alleviate pain.</para></listitem>
<listitem><para>Provide information about disease process, prognosis, and treatment needs.</para></listitem></orderedlist>
</sect2>
<sect2 id="ch0007s0243"><title><emphasis role="strong">DISCHARGE GOALS</emphasis></title>
<orderedlist numeration="arabic" inheritnum="ignore" continuation="restarts">
<listitem><para>Complications prevented or minimized.</para></listitem>
<listitem><para>Individual situation dealt with realistically.</para></listitem>
<listitem><para>Pain relieved or controlled.</para></listitem>
<listitem><para>Disease process, prognosis, possible complications, and therapeutic regimen understood.</para></listitem>
<listitem><para>Plan in place to meet needs after discharge.</para></listitem></orderedlist>
<para><emphasis role="strong">***Refer to CPs: <link linkend="ch0014s0370">Cancer: General Considerations</link> for shared related nursing diagnoses such as Pain, Fatigue, Nausea, Nutrition, Anxiety, Self-Esteem and Grieving, to accomplish corresponding nursing priorities and discharge goals.</emphasis></para>
<para><emphasis role="strong">See also other related cancer care plans for nursing interventions related to treatments such as radiation, chemotherapy, and bone marrow transplant.</emphasis></para>
<note id="ch0007s0239note0605">
<title><emphasis role="strong">NURSING DIAGNOSIS: risk for impaired Gas Exchange</emphasis></title>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>[Altered oxygen-carrying capacity of blood]</para>
<para>[Tracheobronchial obstruction (disease invasion: enlarged mediastinal nodes and airway edema (HL and NHL), superior vena cava syndrome (NHL)]</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Respiratory Status: Ventilation</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Maintain a normal, effective respiratory pattern, free of dyspnea, cyanosis, or other signs of respiratory distress, and arterial blood gases (ABGs) within normal limits (WNL).</para>
</note>
<note role="none" id="ch0007s0239note0606"><table frame="top" id="ch0007s0239ta0343"><title/>
<tgroup colsep="0" rowsep="0" cols="2">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">Ventilation Assistance</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Ascertain presence of lymphoma affecting head and neck; determine client&rsquo;s particular disease condition, stage, and severity of lymphoma and treatment status (e.g., postsurgery, in chemotherapy, or experiencing late and long-lasting treatment side effects).</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Aids in establishing baseline respiratory status and can point to potential cause and needed interventions if client is having difficulty breathing. For example, symptoms may be associated with late-stage primary lymphoma of head or neck (not easily treated). Conversely, client might be in the immediate postoperative phase for throat and neck surgery with tissue and airway edema (more easily treated condition). Also, chemotherapies, radiation, or splenectomy render the client more prone to lung infections and lung damage. While both conditions can lead to shortness of breath, lung damage is much more likely to present poor prognosis. <emphasis>Note:</emphasis> It has been established that lymphoma is the second most common primary malignancy occurring in the head and neck (Dunleavy et al, 2017).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Assess and monitor respiratory rate, depth, and rhythm. Note reports of dyspnea or use of accessory muscles, nasal flaring, and altered chest excursion.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Changes (e.g., tachypnea, dyspnea, and use of accessory muscles) may indicate progression of disease- or treatment-related respiratory involvement, requiring prompt intervention.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Place client in position of comfort, usually with head of bed elevated or sitting upright, leaning forward with weight supported on arms, and feet dangling.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Maximizes lung expansion, decreases work of breathing, and reduces risk of aspiration.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Reposition and assist with turning periodically.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Promotes aeration of all lung segments and mobilizes secretions.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Instruct in and assist with deep-breathing techniques and pursed-lip or abdominal diaphragmatic breathing, if indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Helps promote gas diffusion and expansion of small airways. Provides client with some control over respiration, helping to reduce anxiety.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Evaluate skin color, noting pallor or development of cyanosis, particularly in nailbeds, ear lobes, and lips.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Proliferation of WBCs and anemia can reduce oxygen-carrying capacity of the blood, leading to systemic hypoxemia.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Assess respiratory response to activity. Note reports of dyspnea and increased fatigue. Schedule rest periods between activities.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Decreased cellular oxygenation reduces activity tolerance. Rest reduces oxygen demands and minimizes fatigue and dyspnea.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Encourage energy-saving techniques, such as rest periods before and after meals, use of shower chair, and sitting for care.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Aids in reducing fatigue and dyspnea and conserves energy for cellular regeneration and respiratory function.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Promote bedrest and provide care as indicated during acute or prolonged exacerbation.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Worsening respiratory involvement and hypoxia may necessitate cessation of activity to prevent more serious respiratory compromise.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Encourage expression of feelings. Acknowledge reality of situation and normality of feelings.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Anxiety increases oxygen demand, and hypoxemia potentiates respiratory distress or cardiac symptoms, which in turn escalates anxiety.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Provide calm, quiet environment.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Promotes relaxation, conserving energy and reducing oxygen demand.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Observe for neck vein distention, headache, dizziness, periorbital or facial edema, dyspnea, and stridor.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>NHL client is at risk for superior vena cava syndrome (SVC) when lymphoma has invaded the mediastinum, which can result in tracheal deviation and airway obstruction, an oncological emergency.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Provide support to family and SOs.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Development of SVC is very frightening for client and family because it may indicate the end stage of disease process. Keeping family informed may diminish their anxiety and minimize transmission to client.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="bi">Collaborative</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Assist with treatment of disease process and side effects of therapies.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Interventions to correct or manage anemia can improve oxygenation.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Provide supplemental oxygen by appropriate route.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Maximizes oxygen available for circulatory uptake, aids in reducing hypoxemia improving tolerance of activity, especially in the setting of severe anemia, cardiopulmonary or renal complications.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Monitor laboratory studies, such as ABGs and pulse oximetry.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Measures adequacy of respiratory function and effectiveness of therapy.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Administer analgesics and tranquilizers, as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Reducing physiological responses to pain and anxiety decreases oxygen demands and may limit respiratory compromise.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Assist with respiratory treatments and adjuncts, such as intermittent positive-pressure breathing (IPPB) and incentive spirometer, if appropriate.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Promotes maximal aeration of all lung segments, preventing atelectasis.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Assist with intubation and mechanical ventilation.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May be necessary to support respiratory function until airway edema is resolved in acutely ill hospitalized client.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Prepare for other procedures&mdash;thrombolysis, emergency radiation, endovascular stenting, or thoracentesis when indicated.</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>SVC rarely presents as an acute emergency, but when it does, life-saving treatments must be immediately carried out.</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0239note0607">
<title><emphasis role="strong">NURSING DIAGNOSIS:</emphasis>&nbsp;<emphasis role="strong">acute/chronic Pain</emphasis></title>
<para><emphasis role="strong">May Be Related To</emphasis></para>
<para>Physical injury agents&mdash;[neoplasm of lymphoid tissue; disease invasion of organs]; nerve compression, ischemia; [treatment-related damage to peripheral nerves]</para>
<para>Chemical injury agents&mdash;chemotherapy</para>
<para>Alteration in sleep pattern, anxiety, fear</para>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Self-report of pain intensity and characteristics using a standardized scale</para>
<para>Guarding behaviors</para>
<para>Expressive behaviors&mdash;facial grimacing, restlessness</para>
<para>Changes in vital signs (acute pain)</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Pain Level</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Report pain is relieved or controlled.</para>
<para>Appear relaxed and able to sleep and rest appropriately.</para>
<para><emphasis role="strong">Pain Control</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Demonstrate behaviors to manage pain.</para>
</note>
<note role="none" id="ch0007s0239note0608"><table frame="top" id="ch0007s0239ta0344"><title/>
<tgroup colsep="0" rowsep="0" cols="3">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<colspec colnum="3" colname="3" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom" spanname="1-2">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Pain Management: Acute/Chronic</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Identify contributing factors (i.e., diagnosed lymphoma of one or body systems, late-stage disease, side effects of cancer therapies).</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Pain associated with lymphomas is often twofold: (1) primary pain is caused by the cancer itself. Many NHL patients experience bone and/or nerve pain. And, since the disease may develop in many parts of the body&mdash;such as the neck, groin, breastbone, and underarm&mdash;pain varies for each individual. (2) Secondary pain may result from common cancer treatments such as chemotherapy, radiation therapy, and surgery. For example, chemotherapy may lead to peripheral neuropathy, a condition that causes tingling, numbness, and weakness in the hands and arms or legs and feet.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Investigate reports of pain. Note changes in intensity, character, and location of pain.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Pain with lymphomas may be (1) acute (depending on stage of disease and organs involved), (2) chronic (and acute superimposed upon chronic), and (3) breakthrough (triggered by a particular activity or change in medications) in a client already on pain management measures.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Monitor vital signs, noting changes in blood pressure, heart rate, and breathing pattern. Note nonverbal cues, such as facial mask of pain, grimacing, crying, withdrawal, muscle tension, and restlessness.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Indicators of acute pain that can corroborate verbal reports or may be only indicators in client unable or unwilling to verbalize pain. Client with long-term condition may have acute pain superimposed on chronic pain issues and be reluctant to report new symptoms. Older client may or may not report pain but may have more pain behaviors.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Determine client&rsquo;s acceptable level of pain and help client achieve pain control.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Pain is a subjective experience and needs to be fully addressed by care providers to promote the best possible quality of life. Client may report having a level of discomfort that is manageable (e.g., can do desired activities when pain level is reduced from a 10 to a 3). Another client may need to be pain-free in order to function.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Provide quiet environment and reduce stressful stimuli: noise, lighting, and constant interruptions.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Promotes rest and enhances coping abilities.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Provide comfort measures, such as massage, cool packs, and psychological support, including encouragement and presence, as appropriate.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Nonpharmacologic measures can enhance effects of medication.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Review and promote client&rsquo;s own comfort interventions&mdash;position and physical activity or nonactivity.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Successful management of pain requires client involvement. Use of effective techniques provides positive reinforcement, promotes sense of control, and prepares client for interventions to be used after discharge.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Evaluate and support client&rsquo;s coping mechanisms.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Using own learned perceptions and behaviors to manage pain can help client cope more effectively.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Encourage use of stress management techniques, such as deep-breathing exercises, guided imagery, visualization, and Therapeutic Touch.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Facilitates relaxation, augments pharmacological therapy, and enhances coping abilities.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Assist with or provide diversional activities and relaxation techniques.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Helps with pain management by redirecting attention.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Collaborative</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Collaborate in treatment of underlying condition(s) and protocols for management of treatment side effects.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>***<emphasis>Note:</emphasis> There is no one-size-fits-all treatment plan for lymphomas, because while there are similarities in lymphomas, they are also unique to the individual and subtype of the disease. Therefore, treatments are highly individualized. Thus, nurse is referred to physician treatment plan for each individual and pharmacologic/medical resources for information regarding treatment types and related concerns for each one.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer other medications, as indicated, for example:</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Analgesics, such as acetaminophen (Tylenol), and NSAIDs (<emphasis>including and not limited to</emphasis>) motrin (Advil), naproxen (Naprosyn), and ketorolac (Toradol)</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Given for mild to moderate acute and chronic pain not relieved by comfort measures. <emphasis>Note:</emphasis> Avoid aspirin-containing products because they may potentiate hemorrhage.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Opioids (<emphasis>including and not limited to</emphasis>) (1) codeine, morphine, and hydromorphone (Dilaudid) and (2) fentanyl (Duragesic), hydrocodone (Vicodin), and oxycodone (Oxycontin)</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Opioids may be used for acute and chronic pain. Typically, those in list 1 are used to manage disease-related organ pain and breakthrough pain. Drugs in list 2 are often needed to manage the chronic pain syndromes often associated with lymphomas.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Antianxiety agents, such as diazepam (Valium) and lorazepam (Ativan)</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>May be given to enhance the action of analgesics and opioids.</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0239note0609">
<title><emphasis role="strong">NURSING DIAGNOSIS:</emphasis>&nbsp;<emphasis role="strong">Nausea</emphasis></title>
<para><emphasis role="strong">May Be Related To</emphasis></para>
<para>Treatment regimen [chemotherapeutic agents; radiation therapy]</para>
<para>Gastrointestinal irritation</para>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Gagging sensation</para>
<para>Aversion toward food</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Nausea &amp; Vomiting Severity</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Be free of nausea.</para>
<para><emphasis role="strong">Nausea &amp; Vomiting Disruptive Effects</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Manage nausea as evidenced by acceptable level of dietary intake.</para>
</note>
<note role="none" id="ch0007s0239note0610"><table frame="top" id="ch0007s0239ta0345"><title/>
<tgroup colsep="0" rowsep="0" cols="3">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<colspec colnum="3" colname="3" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom" spanname="1-2">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Nausea Management</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Identify client at risk for nausea and vomiting (e.g., receiving chemotherapy treating, presence of localized GI disease, pain).</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Nausea is associated with both the lymphoma condition and treatment, which can result in severe discomfort, malnutrition, and fluid deficits. <emphasis>Note:</emphasis> Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared side effects of chemotherapy. With the correct use of antiemetics, CINV can be prevented in 70% to 80% of patients (Jordan et al, 2014; NCI, 2017a).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Assess/document the presence and severity of nausea ongoing.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Helps identify therapy needs and response to interventions.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Control environmental factors, such as strong or noxious odors or noise. Avoid overly sweet, fatty, or spicy foods.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Can trigger nausea and vomiting response.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Encourage use of relaxation techniques, such as visualization, guided imagery, and moderate exercise before meals.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May prevent onset or reduce severity of nausea, decrease anorexia, and enable client to increase oral intake.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Provide or encourage frequent oral hygiene.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Prevents drying of mucosa, promotes comfort, and reduces sour taste sometimes associated with cancer therapies.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Evaluate effectiveness of antiemetic agents.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Individuals respond differently to all medications. First-line antiemetics may not work, requiring alteration in or use of combination drug therapy.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Identify client who experiences anticipatory nausea or vomiting and take appropriate measures.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Psychogenic nausea and vomiting occurring before chemotherapy generally does not respond to antiemetic drugs. Change of treatment environment or client routine on treatment day may be effective.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Encourage open communication regarding anorexia.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Often a source of emotional distress, especially for SO who wants to feed client frequently. When client refuses, SO may feel rejected or frustrated.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Adjust diet before and immediately after treatment (such as providing clear, cool liquids; light or bland foods; dry crackers; toast), as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>The effectiveness of diet adjustment is individualized in relief of posttherapy nausea. Clients must experiment to find best solution.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Collaborative</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Refer to other healthcare providers and services as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Assistance may be needed over time from various experienced providers (e.g., nutritionist/dietary services, oncology physician, nurse, and pharmacist) who provide advice and a comprehensive coordinated approach to treating cancer-associated nausea.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Administer medications, as indicated, for example:</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Antiemetics may be given prophylactically or on a regular schedule during and after treatments. <emphasis>Note:</emphasis> Relieving nausea and vomiting can reduce fluid deficits, enhance oral intake, and greatly improve client&rsquo;s quality of life.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Antiemetics: such as ondansetron (Zofran), inapsine (Droperidol), aprepitant (Emend), and dronabinol (Marinol)</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Most antiemetics act to interfere with stimulation of the vomiting center in the brain, and chemoreceptor trigger zone agents also act peripherally to inhibit reverse peristalsis.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Antacids and proton pump inhibitors, such as esomeprazole (Nexium), lansoprazole (Prevacid), and pantoprazole (Protonix)</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Minimizes gastric irritation, decreases nausea, and reduces risk of mucosal ulceration. <emphasis>Note:</emphasis> Client with <emphasis>H. pylori</emphasis> gastritis is at increased risk for lymphoma; therefore, it is conceivable that client with lymphoma may have gastritis or ulcers associated with <emphasis>H. pylori</emphasis>.</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0239note0611">
<title><emphasis role="strong">NURSING DIAGNOSIS:</emphasis>&nbsp;<emphasis role="strong">Sexual Dysfunction</emphasis></title>
<para><emphasis role="strong">May Be Related To</emphasis></para>
<para>Altered body structure or function (e.g., disease process, surgery, chemotherapy, radiation)</para>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Alteration in sexual activity/satisfaction</para>
<para>Actual or perceived limitations</para>
<para>Insufficient knowledge/misinformation about sexual function</para>
<para>[Change in relationship with SO]</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Sexual Functioning</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Verbalize understanding of individual reasons for sexual problems.</para>
<para>Identify stressors in lifestyle that may contribute to the dysfunction.</para>
<para>Discuss concerns about body image, sex role, and desirability as a sexual partner with partner or SO.</para>
</note>
<note role="none" id="ch0007s0239note0612"><table frame="top" id="ch0007s0239ta0346"><title/>
<tgroup colsep="0" rowsep="0" cols="2">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="strong">Sexual Counseling</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Assess knowledge of client and SO regarding sexual function and effects of current situation.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Lymphomas often affect the relatively young in their reproductive years, who may be less knowledgeable about the possibilities of change.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Collaborate with other healthcare team members in informing client and partner of potential sexual side effects of treatment plans and provide opportunity to consider options. Discuss sperm banking and pregnancy issues, when appropriate, before beginning treatment.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Some lymphomas and the treatments used for them can affect male and female sexual development, libido, fertility, and the success of pregnancy. In males, impotence and permanent sterility can occur as a result of radiation when combined with certain chemotherapeutic agents. In females, menstruation may cease during the active phase of treatment, and infertility may occur. The woman&rsquo;s age during treatment and certain chemotherapy regimens (e.g., type and dose of alkylating agent) are more likely than others to impact fertility. In addition, side effects of treatment can impact sexual enjoyment (e.g., vaginal dryness and atrophy of vaginal tissues) but can be managed when client and partner are given information and resources (Harel et al, 2010; Recklitis et al, 2010).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Identify preexisting and current stress factors that may be affecting the relationship.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Client may be concerned about other issues, such as job, financial, and illness-related problems.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Determine specific pathophysiology involved and impact on, or perception of, individual.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Client&rsquo;s perception of the individual effects of this illness is crucial to planning interventions that will be appropriate to those affected.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Assist with treatment of underlying condition.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>As illness is treated and client can see improvement, hope is restored and client can begin to look to the future.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Provide factual information.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Promotes trust in caregivers.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Encourage and accept expressions of concern, anger, grief, and fear.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Helps client identify feelings and begin to deal with them.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Encourage client to share thoughts and concerns with partner and to clarify values and impact of condition on relationship.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Helps couple begin to deal with issues that can strengthen or weaken relationship.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para><emphasis role="bi">Collaborative</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Refer to appropriate community resources or support groups for sexual dysfunction, such as the American Cancer Society.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Provides information about resources that are available to help with individual needs. Meeting with others who are dealing with the effects of devastating illness can help client and family.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Provide written material, informational websites such as Fertile Hope, and other resources appropriate to age and situation.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Reinforces information client has received regarding sexual and fertility issues.</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Refer to psychiatric clinical nurse specialist or professional sexual therapist, as indicated.</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>May need additional in-depth assistance to resolve existing problems.</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0239note0613">
<title><emphasis role="strong">NURSING DIAGNOSIS:</emphasis>&nbsp;<emphasis role="strong">deficient Knowledge regarding disease process, prognosis, treatment regimen, self-care, and discharge needs</emphasis></title>
<para><emphasis role="strong">May Be Related To</emphasis></para>
<para>Lack of exposure, recall</para>
<para>Insufficient information; misinformation presented by others</para>
<para>Insufficient knowledge of resources</para>
<para>Alteration in cognitive functioning</para>
<para><emphasis role="strong">Possibly Evidenced By</emphasis></para>
<para>Insufficient knowledge</para>
<para>Inaccurate follow-through of instruction</para>
<para><emphasis role="strong">Desired Outcomes/Evaluation Criteria&mdash;Client Will</emphasis></para>
<para><emphasis role="strong">Knowledge: Cancer Management</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnoc.jpg"/></imageobject></inlinemediaobject></para>
<para>Verbalize understanding of condition, prognosis, and potential complications.</para>
<para>Identify relationship of signs and symptoms to disease process.</para>
<para>Initiate necessary lifestyle changes.</para>
</note>
<note role="none" id="ch0007s0239note0614"><table frame="top" id="ch0007s0239ta0347"><title/>
<tgroup colsep="0" rowsep="0" cols="3">
<colspec colnum="1" colname="1" align="left" colsep="0"/>
<colspec colnum="2" colname="2" align="left" colsep="0"/>
<colspec colnum="3" colname="3" align="left" colsep="0"/>
<spanspec spanname="1-2" namest="1" nameend="2"/>
<thead>
<row rowsep="1" valign="bottom">
<entry rowsep="1" morerows="0" colsep="0" valign="bottom" spanname="1-2">
<para><emphasis role="strong">ACTIONS/INTERVENTIONS</emphasis></para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="bottom">
<para><emphasis role="strong">RATIONALE</emphasis></para>
</entry></row></thead>
<tbody>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="strong">Teaching: Disease Process</emphasis>&nbsp;<inlinemediaobject><imageobject><imagedata fileref="pnic.jpg"/></imageobject></inlinemediaobject></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para><emphasis role="bi">Independent</emphasis></para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Review with client and SO their understanding of client&rsquo;s diagnosis and outlook.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Although lymphomas are complex and have intensive treatment regimens, the outlook has improved in recent years. The 5-year survival rate after treatment in both categories of lymphomas has improved significantly, and many people live with lymphoma in remission.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Review potential treatments client may be considering.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>May assist client and SO in making informed choices. <emphasis>Note:</emphasis> In general, the goal of therapy is remission of the lymphoma, and treatments vary according to the disease process and stage.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Various combinations of chemotherapy agents and/or radiation therapy</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Chemotherapy and radiation therapy are the most commonly used treatments and may be used alone or combined. Chemotherapy is a systemic treatment that uses a combination of several drugs, given by IV injection or by mouth, typically given in cycles, based on the duration of the drug&rsquo;s effect and other factors. Radiation therapy targets and kills cancer cells in a specific area, using an external beam (EBRT) or radioisotope-targeted therapy (see below). Since lymphoma cells are likely to be present in widespread areas, radiation therapy is not commonly used alone.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Interferon-alpha (INF-&alpha;) and monoclonal antibodies, such as rituximab (Rituxan) and alemtuzumab (Campath)</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Biological therapies may be used to treat HL or NHL.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Targeted therapies such as:</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top">
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Radioimmunotherapy (RIT) such as ibritumomab tiuxetan (Zevalin)</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>In this therapy, radioisotopes are attached to monoclonal antibodies and delivered intravenously to target and destroy specific cancer cells. By delivering the radiation directly to the tumor cells, this treatment helps limit toxic effects on normal tissues.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Stem cell transplantation</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Stem cell transplant from bone marrow is now standard therapy for selected clients with NHL. May be combined with high-dose chemotherapy for clients with HL who have relapsed or who have experienced a failed primary chemotherapy regimen.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Discuss potential complications relative to specific therapeutic regimen.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Receiving radiation or chemotherapy increases the risk of contracting another type of lymphoma or another type of cancer, so client will continue to need monitoring after treatment. After 5 disease-free years, however, risk becomes close to normal.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Emphasize need for ongoing medical follow-up, posttreatment surveillance, and testing.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>After completion of primary therapy, appropriate tests will be repeated to determine efficacy of therapy. Also, monitoring for certain late or long-term side effects of HL treatment (e.g., fertility issues, infections, thyroid dysfunction) are continued (ACS, 2017c).</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Identify signs and symptoms requiring further evaluation, such as cough, fever, chills, malaise, dyspnea, weight gain, slow pulse, decreased energy level, intolerance to cold; moderate fever, chest pain, dry cough, dyspnea, rapid pulse (pericarditis [rare]); or dyspnea, fatigue, chest pain, dizziness, or syncope (cardiomyopathy [rare]).</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Prompt intervention can identify recurrence or perhaps limit progression of complications, thereby reducing further debilitating effects.</para>
</entry></row>
<row rowsep="0" valign="top">
<entry rowsep="0" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Recommend regular exercise in moderation, with adequate rest. Discuss energy conservation techniques. Refer for physical therapy or cancer exercise program, as indicated.</para>
</entry>
<entry rowsep="0" morerows="0" colsep="0" valign="top">
<para>Promotes general well-being. <emphasis>Note:</emphasis> Fatigue is associated with disease process and treatment regimen as well as developing complications. Therefore, balancing activity with rest enhances client&rsquo;s ability to perform activities of daily living (ADLs).</para>
</entry></row>
<row rowsep="1" valign="top">
<entry rowsep="1" morerows="0" colsep="0" valign="top" spanname="1-2">
<para>Recommend or refer to appropriate community resources&mdash;support groups, social worker, counselor, pastor; home health assistance, medical equipment and supplies; hospice; and Lymphoma Research Foundation and American Cancer Society.</para>
</entry>
<entry rowsep="1" morerows="0" colsep="0" valign="top">
<para>Client and SO can benefit from many available resources and networks for such help as care assistance, transportation to treatments, sources of financial resources, and long-term support or counseling.</para>
</entry></row></tbody></tgroup></table></note>
<note id="ch0007s0239note0615">
<para><emphasis role="strong">POTENTIAL CONSIDERATIONS</emphasis> following acute hospitalization (dependent on client&rsquo;s age, physical condition and presence of complications, personal resources, and life responsibilities)</para>
<itemizedlist mark="&bull;">
<listitem><para><emphasis role="bi">ineffective Health Management</emphasis>&mdash;complexity of therapeutic regimen, decisional conflicts, economic difficulties, excessive demands made on individual or family, perceived benefits, powerlessness</para></listitem>
<listitem><para><emphasis role="bi">risk for Infection</emphasis>&mdash;inadequate secondary defenses: alterations in mature WBCs (low granulocyte and abnormal lymphocyte count), increased number of immature lymphocytes, immunosuppression, bone marrow suppression (effects of therapy/transplant)</para></listitem>
<listitem><para><emphasis role="bi">ineffective Role Performance</emphasis>&mdash;situational crisis, physical illness, fatigue, stress</para></listitem>
<listitem><para><emphasis role="bi">interrupted Family Processes</emphasis>&mdash;situational crisis (illness, disabling and expensive treatments); shift in health status of a family member, shift in family roles</para></listitem></itemizedlist>
</note>
</sect2></sect1></chapter>
